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Currently, cardiovascular diseases are the leading cause of mortality 
worldwide, accounting for about 17 million global deaths every year, with 
about 7.3 million deaths caused by coronary heart disease or acute myocardial 
infarction (AMI), and 6.2 million deaths due to stroke 1-4. This number is 
expected to increase further in the next decades 4-6. The acute clinical 
manifestations of cardiovascular diseases (i.e. AMI and stroke) are mainly 
caused by rupture of advanced atherosclerotic plaques, rendering 
atherosclerosis the major cause for cardiovascular disease 3.  
Atherosclerosis is a progressive vascular disease, characterized by 
accumulation of lipids and cellular and fibrous constituents in the arterial tree 
(Figure 1). The onset of atherosclerosis in humans can be as early as childhood, 
when lesions called fatty streaks develop at sites of disturbed blood flow 7-10. 
At these sites, e.g. the coronary arteries, the aortic arch, and the bifurcation of 
the carotid artery, the endothelial layer is susceptible for the entry of lipids, 
allowing influx of low density lipoprotein (LDL) into the subendothelial space, 
where it subsequently undergoes modifications like oxidation (oxLDL). As a 
response to this lipid influx, immune cells will be recruited to remove these 
lipids. This is facilitated by an increase in adhesion molecules on the 
endothelium and a rise in local cytokines and chemokines at the site of 
inflammation 11, allowing recruitment of inflammatory cells to the 
subendothelial space. Primarily monocytes will be attracted, which, in the 
subendothelial layer, differentiate into macrophages. After lipid uptake, these 
macrophages develop into foam cells and are rendered immobile, giving rise to 
a gradual accumulation of macrophages in the subendothelial layer, and a 
subsequent chronic inflammatory response, involving recruitment of more 
inflammatory cell types (e.g. T cells, B cells, neutrophils, dendritic cells (DCs)) 
towards the atherosclerotic lesion reviewed in 12-15.  
With time, the inflammatory milieu and local inflammatory stimuli will 
induce local apoptosis and necrosis of local inflammatory cells. Lack of 
efferocytosis, i.e. the clearance of apoptotic cells, as well as the increased 
necrosis and continued accumulation of lipids and inflammatory cells, will 
cause plaque progression towards a more advanced plaque phenotype 16-18. In 
these advanced lesions, vascular smooth muscle cells (VSMCs) are recruited 
from the medial layer in response to chemotactic signals and form a collagen-
rich fibrous cap, maintaining vascular integrity and plasticity by preventing the 
plaque from rupturing and releasing the necrotic and lipid-rich plaque material  
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Figure 1. Schematic representation of atherosclerosis development with time. Lesion formation 
is initiated by accumulation of lipids in the subendothelial space (between the EC layer and the 
medial layer) at sites of disturbed flow. After local modification of the lipids in the subendothelial 
space, e.g. oxidation of LDL (oxLDL), an immune response is elicited to clear these lipids. 
Monocytes enter from the blood, differentiate into macrophages and take up the modified lipids, 
giving rise to foam cell formation. Additional inflammatory cells (e.g. T cells, B cells and DCs) are 
recruited, potentiating the chronic inflammatory response. With time, an advanced lesions 
consisting of a lipid-rich necrotic core (light purple) and a fibrous, collagen- and VSMC-rich cap is 
formed. Production of proteases can destabilize the fibrous cap, potentially causing plaque 
rupture and consequent thrombotic events. During the progression of lesion formation, an 
expansion of adventitial vasa vasorum and lymph capillaries has been recorded, accompanied by 
ingress of both vessel types into the lesion. Expansion of blood and lymph vessels has been 
associated with a more advanced plaque stage. Figure based on Sanz et al 19.    
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into the circulation. This lesion type is considered to be a stable advanced 
lesion. However, production of several types of proteases, e.g. matrix-
degrading metalloproteases (MMPs), by inflammatory cells, will destabilize the 
fibrous cap, allowing the plaque to evolve to an unstable, vulnerable plaque 
phenotype 20. Upon rupture, the necrotic core with its pro-thrombotic 
components will come into contact with the blood, causing thrombus 
formation, potentially causing occlusion of coronary arteries (acute myocardial 
infarction) or occlusion of cerebral arteries (stroke). Two main focus points of 
atherosclerosis research have been lipid metabolism and uptake, and 
inflammation in the atherosclerotic lesion. Although these processes are of key 
importance, other processes have been gaining more and more interest, 
including plaque hypoxia which gives rise to expansion of local 
microcirculation, and involvement of the lymphatic system 21, 22. Definitely, 
vulnerable plaques are not merely characterized by the presence of a large 
lipid-laden necrotic core underlying a thin fibrous cap, and abundant 
inflammatory cell deposits in the adventitia and the shoulder regions of the 
plaque 23. Atherosclerotic plaques are to a large extent hypoxic 24, providing a 
basis for an angiogenic response. Indeed, multiple human studies have shown 
that more advanced lesions are generally heavily vascularized, and the extent 
of vascularization has been shown to correlate with progression stage, 
inflammatory content of the plaque, and plaque stability 25, reviewed in 26. More 
recently, evidence has been presented showing an increase in lymphatic 
capillaries in both early and advanced lesions 21, 27, as will be discussed in more 
detail later.  
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Atherosclerosis and angiogenesis 
 
The concept of an angiogenic response occurring during plaque development is 
not new. It was already in 1876 that Köster suggested that (advanced) 
atherosclerotic lesions are associated with an increased density in vasa 
vasorum 28. The vasa vasorum is the adventitial plexus of microvessels 
surrounding the larger arteries (>0.5 mm in diameter 29) that provides the 
medial and adventitial layer of arteries with oxygen and nutrients and removes 
waste products. However, it was not until three decades ago that plaque 
neovascularization regained interest, which led to a better understanding of its 
involvement in atherosclerosis 26.  
 
 General background  
Angiogenesis is defined as the sprouting of new blood vessels from pre-existing 
blood vessels, and is not to be confused with arteriogenesis (functional 
dilatation and maturation of pre-formed collaterals) or vasculogenesis (de 
novo formation of blood vessels from progenitor cells). This process of 
angiogenesis is of great physiological importance during embryogenesis, 
development, and wound healing, but is involved in a plethora of pathological 
conditions as well, such as oncology, rheumatoid arthritis, vascular 
complications in diabetes like retinopathies, endometriosis, and 
atherosclerosis. The normal, physiological angiogenic process can be divided in 
several stages, as was reviewed extensively 30-33.  
Shortly, in a hypoxic or inflammatory environment in which angiogenic 
mediators are secreted, nearby endothelial cells (ECs) are activated (Figure 2). 
This is followed by (i) detachment of pericytes from the vessel wall by 
angiopoietin-2 (Ang-2) and MMPs and (ii) loosening of the endothelial 
junctions by vascular endothelial growth factors (VEGFs) and other vascular 
growth factors, causing vessel dilatation and increasing vascular  
permeability 33, 34. Due to this increased permeability, plasma proteins can 
enter the extravascular space, and provide a basis for the second step, the 
proliferation and migration of ECs. To this end, two types of ECs can be 
distinguished, namely the tip cell and the stalk cell. Tip cells are equipped with 
filopodia, which they use to sense gradients of angiogenic (guidance) 
molecules like VEGF and ephrins to migrate towards the site of hypoxia or 
inflammation. The stalk cells follow the lead of the tip cells, and are the cells 
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which elongate the newly forming vessel by repeated cellular division 35 (under 
control of e.g. NOTCH , WNT and several growth factors), and allow formation 
of a lumen 36 (requiring amongst others VE-cadherin, VEGFs and their 
receptors (VEGFRs), CD105, CD34, junctional adhesion molecule-A (JAM-A) 37). 
From here, an immature vessel is formed and the surrounding extracellular 
matrix (ECM) is reorganized to support this immature vessel, and form a new 
basement membrane (stimulated by protease inhibitors like tissue inhibitors of 
metalloproteinases (TIMPs)). The final step in the angiogenic process is vessel 
maturation, in which pericytes are recruited to cover the immature vessels. 
This step, which is also described as the “quiescent phalanx resolution” 34, is 
highly dependent on angiopoietin-1 (Ang-1), transforming growth factor-β 
(TGF-β) and platelet-derived growth factor B (PDGF-B). In addition, the new 
blood vessel may undergo an additional step of arterio-venous differentiation, 
governed by ephrins and NOTCH signaling 30, 34. Arterio-venous differentiation 
allows local adaptation and will influence, e.g. permeability, by changing the 
intra-endothelial junctions or pericyte coverage rate.   
During pathological angiogenesis, the development of new 
(micro)vessels is aberrant. Two major types of abnormalities can be 
distinguished. The first comprises of aberrations in guidance and proliferation, 
causing an unorganized growth of the newly formed vessels with excessive 
branching and enlarged luminal diameters. The second type of aberrations 
involves atypical maturation, characterized by e.g. basement membrane 
detachment, lack of pericyte coverage, junctional abnormalities, causing 
functional defects and a ‘leaky’ phenotype. Both types of aberrations are well-
known from tumor angiogenesis, but are also present in other pathologies, 
including atherosclerosis 32, 38, 39. 
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Figure 2. Schematic representation of the angiogenic process. Upon a hypoxic stimulus, the 
quiescent vessel (A) is activated, inducing degradation of the basement membrane, detachment 
of pericytes from the vessel wall, vessel dilatation, and loosening of the endothelial junctions 
causing increased in vascular permeability (B). Plasma proteins enter the extravascular space, 
facilitating proliferation and migration of endothelial cells. Initially, tip cells (red), equipped with 
filopodia, sense gradients of angiogenic (guidance) molecules to migrate towards the site of 
hypoxia or inflammation. The stalk cells follow the lead of the tip cells and elongate the newly 
forming vessel by repeated cellular division (C). The surrounding extracellular matrix (ECM) is 
reorganized to support the immature vessel, and a new basement membrane is formed. Finally, 
pericytes are recruited to cover and stabilize the immature vessel, forming a stable, mature 
vessel (D). Figure based on Carmeliet et al 34. 
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Angiogenesis in atherosclerosis 
As described earlier, the first description of adventitial microvasculature being 
present in atherosclerotic lesions dates back to the late 1800s, when Köster 
noted an increased vasa vasorum density in humans. In the 1930s, Paterson 
described intimal vascularization of human atherosclerotic coronary arteries 40. 
After that, it was not until the 1980s that plaque vascularization regained 
interest 41, 42. Kamat et al were among the first to study localization of plaque 
neovascularization and performed the first actual quantitative histological 
analysis on human coronary arteries, and could confirm extensive vasa 
vasorum expansion, although intraplaque vascularization was undetectable 43. 
Later studies led to further classification and quantification of plaque 
neovascularization during atherosclerosis progression 44-48. Overall, there is a 
clear association between expansion of microvessels and plaque progression, 
both in the adventitia and the intima 26. 
Not only the expansion of plaque microvessels points towards a role of 
angiogenesis in atherosclerotic lesions. Others have focused on the angiogenic 
response, and were able to show that human plaque material exhibits 
angiogenic properties 49. Since then, it has been established that well-known 
angiogenic factors are present in atherosclerotic lesions, including members  
of the VEGF and VEGFR family 50-52, placental growth factor (PlGF) 53, 54, and 
Ang-1 and Ang-2 55 , as well as factors associated with the angiogenic process, 
e.g. MMPs 56, 57. Furthermore, several cell types within the atherosclerotic 
plaque may express these pro-angiogenic factors, like mast cells 58-60 and 
macrophages 22, 61, 62. More importantly, it was shown that atherosclerotic 
lesions are hypoxic due to an increased physical distance to the lumen or the 
vasa vasorum – greater than the diffusion distance of oxygen and nutrients 
(approximately 100-250 μm) 63 – and an increased metabolic activity of 
inflammatory cells inside the lesion 24, 26. Hypoxia would be the logical trigger 
for the angiogenic process. 
 
The important question that arises is whether angiogenesis in human 
atherosclerosis is a beneficial or detrimental event. Over the years, 
atherosclerotic plaque neovascularization has been attributed a dual role, as 
also described by Moreno et al 22. On the one hand, it has been suggested that 
(initial) angiogenesis would be a means to resolve the atherosclerotic lesion. 
Not only would it resolve plaque hypoxia, but formation of new microvessels in 
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atherosclerosis may guide efflux of macrophages and T cells, or alternatively 
allow ingress of anti-inflammatory cell types, as Moreno et al suggest from 
their data 22. Also, plaque angiogenesis may be involved in removal of intimal  
LDL when the systemic LDL concentration is lower than intimal LDL 
concentrations 64. This could be the case during statin treatment, which e.g. in 
the SATURN study was shown to induce plaque regression 65. Though some 
experimental studies in larger animal models are in support of a beneficial 
function of plaque neovascularization 66-70, this point of view is still debated, 
and should be substantiated in vivo.  
On the other hand, a more substantial amount of evidence suggests 
that plaque angiogenesis is detrimental. As mentioned earlier, there is a strong 
association between enhanced vascularization and the progression from initial 
towards advanced, vulnerable lesions in human atherosclerosis 26. The current 
general hypothesis is that local hypoxia would induce release of angiogenic 
factors inside the lesion, inducing ingrowth of microvessels into the lesion, 
after initial expansion of the vasa vasorum 71-73. A part of the intraplaque 
microvessels may however derive from sprouting from the luminal 
endothelium 74-76. Due to the inflammatory environment, the endothelium of 
the plaque microvessels is likely to attain a leaky phenotype, characterized by 
impaired functionality and leakiness, i.e. open intra-endothelial junctions, 
basement membrane detachment and absent pericyte coverage, as was 
described after ultrastructural analysis using electron microscopy (EM) 77. Such 
leaky microvessels would in turn favor the influx of circulating erythrocytes, 
leukocytes, and blood platelets into the plaque 72, 78-80. In fact, plaque 
microvessels have already been associated with accumulation of a myriad of 
inflammatory cells, as well as lipoproteins and albumin, as reviewed by Sluimer 
et al 26 and may thus promote further plaque expansion, destabilization, and 
thrombogenicity. Alternatively, intraplaque microvessels may weaken the 
biomechanical integrity of the plaque, particularly at the rupture prone plaque 
shoulder region, where the shear stress on the vessel wall is highest 81, 82. Yet, 
direct evidence hereof is still lacking. 
Taken together, it is likely to assume that functional aberrations of 
plaque microvasculature could indeed cause exacerbation of the 
atherosclerotic process. The human studies however show nothing more than 
guilt-by-association, and cannot confirm whether functional aberrations of 
plaque microvasculature could be causative. Experimental models of 
CHAPTER 1 
18 
1 
atherosclerosis however also provide ample evidence supporting an adverse 
role of plaque angiogenesis. Pro-angiogenic factors have been implicated in 
lesion formation 54, 83-86, while anti-angiogenic factors show the opposite effect, 
and reduce lesion formation 74, 87-92. One of the most elegant studies in this 
field by Moulton et al actually could show an increase in adventitial and intimal 
plaque vascularization in apolipoprotein-E (ApoE)/Collagen type XVIII (Col18) 
double-knockout mice, in concurrence with augmented plaque growth upon 
enhanced vascularization 90. In general however, just few of these studies 
could show an actual causative effect on plaque vascularization, and 
angiogenesis-independent effects cannot be ruled out. Moreover, in small 
animal models, presence of plaque vascularization seems to be a rather 
infrequent phenomenon. Adventitial microvessels are seen frequently, and 
make up the majority of plaque vasculature studied. Yet, intraplaque 
vascularization seems to be a rare occurrence in mouse models, and only has 
been shown in a few models, e.g. the p22phox model 93, and some studies in 
apolipoprotein-E deficient (ApoE-/-) and low density lipoprotein receptor 
deficient (LDLr-/-) mice 74, 84, 89, 94.  Of note, actual functionality of the described 
intraplaque vessels is debatable, since the intraplaque vessels at least in part 
appear to be invaginations derived from luminal endothelium 74.  
This addresses the important point of not only establishing the 
presence of plaque vascularization, but also gaining more insight into its 
localization and function in vivo, and establishing whether plaque 
vascularization in experimental models may be considered representative for 
human plaque vascularization. New imaging modalities, both microscopic and 
non-microscopic like magnetic resonance imaging (MRI), micro- or nano-
computed tomography (CT) 95-97, will be of importance in studying this by 
examining whole (living) tissue. 
The latter would also allow functional study of plaque vascularization, 
and could function as a platform for examining the effect of interventions. 
Assuming that plaque neovascularization indeed is negatively contributing to 
plaque development, two intervention strategies would come to mind: (i) anti-
angiogenic therapy or (ii) therapy focused on normalizing the leaky 
microvascular phenotype. Anti-angiogenic therapy would seem an attractive 
option, and showed a reduction in plaque burden in experimental models of 
atherosclerosis, but some important considerations should be made. One of 
the considerations is that anti-angiogenic therapy can, at this moment, not be 
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applied locally. As such, sustained therapy as would be needed in 
atherosclerosis would induce overall inhibition of angiogenesis, also in natural 
processes like wound healing. More importantly, and as discussed previously, 
it cannot be excluded that plaque angiogenesis does exert some beneficial 
effects. These would include the before mentioned efflux of cholesterol, but 
also a decreased necrosis upon sustained plaque hypoxia. 
Normalization of plaque microvessels would then be a sound 
alternative, as has been reviewed extensively over the last years 33, 38, 39, 50, 98, 99. 
The beneficial effects of plaque neovascularization, alleviating local hypoxia 
and potential cholesterol efflux, would still be accommodated, yet without the 
leakage of erythrocytes, lipids and inflammatory cells into the plaque. This 
concept has received a lot of attention in other diseases involving pathologic 
angiogenesis, like tumorigenesis or certain hereditary disorders, and could 
consist of restoring endothelial barrier function or pericyte coverage 39, 100. A 
key example proving the potential of vessel normalization is a study by Lebrin 
et al showing that pharmacological intervention using thalidomide stimulated 
vessel maturation in patients with hereditary hemorrhagic telangiectasia, 
mostly by increasing pericyte coverage 100. Recently, more targeted 
approaches of vessel normalization, like blocking of PlGF, neutralization of 
Ang-2, or inhibiting the angiogenic αVβ3 integrin activity are proving relatively 
successful in cancer treatment, and may be potential future targets for 
microvessel normalization in atherosclerosis 38, 39, 50, 98. 
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Atherosclerosis and lymphangiogenesis 
 
In contrast to the early discovery of vasa vasorum expansion, the possible 
involvement of the lymphatic system in atherosclerosis has only very recently 
gained more interest. This is quite surprising, taking into account that the 
lymphatic system already has been implicated in regulation of lipid efflux and 
inflammation decades ago.  
 
General background  
The lymphatic system for some time had been an underappreciated system 
with regard to its function. Initially, it was regarded as a simple return system 
for fluid buildup in tissues due to fluid loss via the arterial system caused by 
pressure and osmotic gradients. The current view is more refined, suggesting 
an important role in regulation of lipid transport, especially in the intestine and 
regulation of inflammation 101-103. 
Lymph vessels are more irregularly shaped vessels, which are 
characterized by interendothelial valve-like openings 104-107. Additionally, all 
lymph vessels with the exception of the lymph capillaries contain intraluminal 
valves to prevent backflow of lymph fluid. Lymph vessels, and in conjunction 
lymph nodes, have been implicated in edema formation, cancer, asthma, and 
several inflammatory diseases 108-110. 
Lymphangiogenesis is mostly present during embryogenesis, and its 
molecular regulation has been described elegantly by Adams and Alitalo 30. 
During embryogenesis, the first lymphatic endothelial cells (LECs) are derived 
from the embryonic cardinal vein. A few ECs of the cardinal vein induce 
expression of the transcription factor prospero-related homeobox-1 (Prox-1) 
and migrate away from the cardinal vein. Under the influence of additional 
factors like the tyrosine kinase SYK, the LECs phenotypically completely 
separate from blood vessels and form the so-called lymphatic sac. In adults, 
Prox-1 is also a required factor for induction of lymphangiogenesis. Following 
formation of the lymphatic sac, sprouting and formation of the first lymphatic 
plexus is induced by VEGF-C and VEGFR-3 (Figure 3), in combination with the 
guidance receptor neuropilin-2 (NRP-2) 111, 112. After formation of the lymphatic 
network, the lymph vessels undergo a maturation step, including valve 
formation, under influence of Ang-2, podoplanin, ephrin-B2 and forkhead box 
protein C2 (Fox-C2). 
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Figure 3. Both angiogenesis and lymphangiogenesis are regulated by the VEGF and VEGFR-
family. In angiogenesis, VEGFR-1 and predominantly VEGFR-2 on the endothelial cells is 
stimulated by PlGF and VEGF-A, -B and -E, and facilitate processes involved in angiogenesis, e.g. 
proliferation and migration. Homologously, lymphatic endothelial cells express VEGFR-3, which 
upon activation by VEGF-C and VEGF-D elicits a lymphangiogenic response, but have also been 
described to elicit an angiogenic response (asterisks). Accessory neuropilin (NRP) receptors are 
required to potentiate the (lymph)angiogenic response and are additionally involved as guidance 
molecules. Figure based on 50, 113. 
 
Lymphangiogenesis in adults follows the same principle and has been 
studied mainly in oncology and inflammatory bowel disease. There is a great 
homology between the pathways involved in lymphangiogenesis and 
angiogenesis, and the processes do share a similar pattern 30, 102, 113. 
Additionally, recent reports also indicate towards a VEGF-independent 
lymphangiogenesis, i.e. mechano-induced lymphangiogenesis (dependent on 
integrin activation of VEGFR-3), suggesting a mechanism which responds 
directly to pressure buildup (Figure 4) 114. Next to Prox-1, podoplanin and 
VEGFR-3, lymphatic vessel endothelial hyaluronan receptor (LYVE-1), present 
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on lymphatic capillaries, is regarded as one of the key markers for lymph 
vessels. 
Evidence suggests that lymphangiogenesis under pathologic conditions 
occurs similarly to its physiological equivalent, although the mechanisms do 
differ slightly between intranodal and extranodal lymphangiogenesis 102. 
Intranodal lymphangiogenesis is characterized by a response to increased 
lymph flow and antigen presentation, while extranodal lymphangiogenesis is 
responsive to inflammatory stimuli and local fluid buildup 102.  
 
Lymphangiogenesis in atherosclerosis 
The lymphatic system was first described in human arteries by Johnson in the 
late 1960s 115. Its function was regarded to be fluid resorption from the 
extravascular tissue. With time, increasing evidence gathered that the 
lymphatic system could also be involved in lipid transport and inflammation, in 
the adventitia of healthy larger blood vessels 116, as well as under pathologic 
conditions like atherosclerosis 21, 117-121.  
The first record of lymph vessels in atherosclerosis dates back to 1970, 
where lymphatics were studied in a rat model of atherosclerosis, where it was 
linked to increased edema formation 118. Around the 1980s, Sims described 
increases in atherosclerotic disease in patients with obstructed lymphatics due 
to carcinomas, as well as an increase in edema formation in patients suffering 
from coronary atherosclerosis 122, 123. Around the same period, Wollinsky 
suggested that upon a dysbalance in the influx and efflux of lipids and 
inflammatory cells, as is the case in atherosclerosis, the lymphatic system 
might be implicated 124. It took until the early 1990s before Miller et al 
suggested a potential causative role for lymphatics and lymphangiogenesis in 
(coronary) atherosclerosis 119. Nakano et al described the presence of 
lymphangiogenic factors like VEGF-C and -D in human plaques in the coronary 
artery 52, and a study from 2011 by Wong et al confirmed these findings 125. 
Just recently, the first study was published which actually showed lymphatic 
(micro)vasculature in human atherosclerotic lesions using specific markers for 
lymph vessels 27. Syväranta et al and Drozdz et al furthermore showed a 
positive correlation between the number of lymph vessels and the severity of 
atherosclerosis, comparable to microvessel expansion 21, 120. 
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Figure 4. Lymphangiogenesis can be induced classically and non-classically. Lymphangiogenesis 
is classically induced by activation of VEGFR-3 by VEGF-C and VEGF-D (A). Binding of the ligands 
to their receptor phosphorylates the intracellular domains, subsequently inducing an 
upregulation of e.g. Fox-C2 and Prox-1 expression via phosphoinositide 3-kinase (PI3K) and 
mitogen-activated protein kinase (MAPK). Nuclear factor κB (NF-κB) signaling can enhance this 
response. Alternatively, lymphangiogenesis can be induced independent of VEGFR-3 activation by 
VEGF-C and VEGF-D. Recently, a stretch-induced mechanism of lymphangiogenesis has been  
described 114. Stretch of lymphatic endothelial cells by e.g. edema formation will activate β1-
integrins, allowing direct phosphorylation of the intracellular domain of VEGFR-3 (B). Both 
mechanisms increase expression of VEGFR-3 on the lymphendothelial cell surface, and induce 
proliferation and migration of lymphatic endothelial cells.  
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Besides the histological evidence presented above, other evidence also 
supported a contribution of lymphangiogenesis to atherosclerosis. The 
involvement of draining lymph nodes of atherosclerotic arteries, and thus 
conceivably the lymph vessels facilitating transport of inflammatory cells like T 
cells and dendritic cells (DCs) away from the plaque towards draining lymph 
nodes, has been described 101, 126, 127. Several studies have even described 
formation of tertiary lymphoid organs (TLOs) or vascular associated lymphoid 
tissue (VALT) in the adventitia of atherosclerotic arteries, in which an 
abundance of microvessels and lymphatic capillaries is present 128, 129. In 
addition, it is known that lymphangiogenesis is stimulated by inflammation, as 
a result of expression of lymphangiogenic molecules by macrophages, B cells 
and T cells 102, 130, 131. Of note, inflammatory cells are also able to express anti-
lymphangiogenic molecules like transforming growth factor-β (TGF-β) and 
interferon-γ (IFN-γ) 130, 132.  
However, there is still a lot to clarify on the interactions of the 
different types of inflammatory cells and the lymphatic vessels. Moreover, also 
the role of lymph vessels in (experimental) atherosclerosis is to a large extent 
unresolved, as reflected by the absence of papers published on this subject, 
and will require more study. An improved understanding of the role of 
lymphangiogenesis in disease will potentially lead to new targeted  
therapies.  
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Hypothesis and outline of this thesis 
 
It is clear that both angiogenesis and lymphangiogenesis play a role in 
atherosclerotic plaque progression, although their contributions are 
incompletely understood. The hypothesis of this thesis is that both 
angiogenesis and lymphangiogenesis are of key importance to atherosclerosis, 
and that the aberrant function of blood vessels and lymph vessels under 
inflammatory conditions promote atherosclerosis progression. To investigate 
the role of angiogenesis and lymphangiogenesis in atherosclerosis, we 
performed several studies in both human atherosclerosis and experimental 
models of atherosclerosis.  
Our first approach was focused on establishing functional imaging of 
atherosclerotic plaque vascularization. To this end, we used an in vivo 
multiphoton laser scanning microscopy (MPLSM) approach. Chapter 2 reviews 
the current state of in vivo cardiovascular imaging using MPLSM, and discusses 
the benefits and shortcomings of the technique. In chapter 3, we applied this 
technique to study plaque neovascularization in a murine model for 
atherosclerosis (ApoE-/- mice). We could establish not only the occurrence of 
adventitial plaque neovascularization in these murine models, but also the 
dysfunctional, leakier phenotype of plaque-associated vasa vasorum.  
In order to further explore possible mediators of this leaky phenotype, 
we investigated the function of two important endothelial junction molecules, 
JAM-A and VE-cadherin. In chapter 4, we focused on the role of the adhesion 
molecule JAM-A on endothelial permeability and leukocyte adhesion. It was 
shown that in the large arteries, JAM-A was critical for leukocyte adhesion and 
transmigration, and that distortion of physiological endothelial JAM-A 
distribution induced increased leukocyte recruitment. Another endothelial 
junction molecule involved in endothelial barrier function, VE-cadherin, was 
studied in chapter 5. Here, we studied the effect of acute deterioration of the 
endothelial barrier function in plaque microvessels. We could show that 
specific blocking of VE-cadherin could induce increased microvascular 
permeability in control microvessels, but not in plaque microvessels, 
suggesting that either VE-cadherin may already be dysfunctional in plaque-
associated vasa vasorum or alternatively is not involved in microvascular 
permeability in plaque-associated microvessels at all.   
CHAPTER 1 
26 
1 
Next, we went from studies in murine models to a genomics-based study in 
human atherosclerotic lesions samples, to identify novel targets involved in 
plaque angiogenesis and lymphangiogenesis. In chapter 6, we correlated 
microarray data from stable and ruptured atherosclerotic lesions to 
(lymphatic) vascularization state, and we were able to establish a set of genes 
and five miRNAs which may be involved in regulation of angiogenesis in 
atherosclerosis. For regulation of lymphangiogenesis in atherosclerosis, we 
found a low correlation between the detected genes and the lymphatic marker 
D2-40, and thus will require more detailed study in the future.   
In order to gain a better understanding of the role of the lymphatic 
system in atherosclerosis, we performed several intervention studies in 
atherosclerotic ApoE-/- mice. In chapter 7, it was shown that removal of the 
lymph node draining the carotid artery, as well as after inhibition of 
lymphangiogenesis, had an adverse effect on plaque progression, 
characterized by an increased plaque size and a more inflammatory phenotype 
with significantly increased T cell numbers. This enhanced inflammatory 
phenotype was also observed after inhibition of lymphangiogenesis, suggesting 
a beneficial role of the lymphatic system during plaque progression. 
Lastly, in chapter 8, the results described in this thesis and potential 
implications hereof were discussed and put in perspective. Also, future 
directions were given for further study of angiogenesis and lymphangiogenesis 
in atherosclerosis. 
 
 
  
GENERAL INTRODUCTION 
27 
1 
References 
 
1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke 
statistics--2009 update: A report from the american heart association 
statistics committee and stroke statistics subcommittee. Circulation. 
2009;119:e21-181 
2. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World 
Neurosurg. 2011;76:S85-90 
3. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular 
disease prevention in clinical practice (version 2012): The fifth joint task force 
of the european society of cardiology and other societies on cardiovascular 
disease prevention in clinical practice (constituted by representatives of nine 
societies and by invited experts). Atherosclerosis. 2012;223:1-68 
4. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 
2012;60:932-942 
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease 
from 2002 to 2030. PLoS Med. 2006;3:e442 
6. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--
2011 update: A report from the american heart association. Circulation. 
2011;123:e18-e209 
7. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: 
A comprehensive morphological classification scheme for atherosclerotic 
lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275 
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N 
Engl J Med. 2005;352:1685-1695 
9. Libby P. Atherosclerosis: The new view. Sci Am. 2002;286:46-55 
10. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241 
11. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of 
atherosclerosis. Cardiovasc Res. 2010;86:192-201 
12. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat 
Immunol. 2011;12:204-212 
13. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 
2012;32:2045-2051 
14. Soehnlein O, Lindbom L, Weber C. Mechanisms underlying neutrophil-
mediated monocyte recruitment. Blood. 2009;114:4613-4623 
15. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte 
subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol. 
2008;8:802-815 
16. Businaro R, Tagliani A, Buttari B, et al. Cellular and molecular players in the 
atherosclerotic plaque progression. Ann N Y Acad Sci. 2012;1262:134-141 
17. Schrijvers DM, De Meyer GR, Martinet W. Autophagy in atherosclerosis: A 
potential drug target for plaque stabilization. Arterioscler Thromb Vasc Biol. 
2011;31:2787-2791 
CHAPTER 1 
28 
1 
18. Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells 
in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol. 
2011;41:2515-2518 
19. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 
2008;451:953-957 
20. Ketelhuth DF, Back M. The role of matrix metalloproteinases in 
atherothrombosis. Curr Atheroscler Rep. 2011;13:162-169 
21. Drozdz K, Janczak D, Dziegiel P, et al. Adventitial lymphatics and 
atherosclerosis. Lymphology. 2012;45:26-33 
22. Moreno PR, Purushothaman M, Purushothaman KR. Plaque 
neovascularization: Defense mechanisms, betrayal, or a war in progress. Ann 
N Y Acad Sci. 2012;1254:7-17 
23. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable 
patient: A call for new definitions and risk assessment strategies: Part i. 
Circulation. 2003;108:1664-1672 
24. Sluimer JC, Gasc JM, van Wanroij JL, et al. Hypoxia, hypoxia-inducible 
transcription factor, and macrophages in human atherosclerotic plaques are 
correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51:1258-
1265 
25. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is 
increased in ruptured atherosclerotic lesions of human aorta: Implications for 
plaque vulnerability. Circulation. 2004;110:2032-2038 
26. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: Angiogenesis and 
hypoxia in atherosclerosis. J Pathol. 2009;218:7-29 
27. Kholova I, Dragneva G, Cermakova P, et al. Lymphatic vasculature is increased 
in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and 
calcified atherosclerotic lesions. Eur J Clin Invest. 2011;41:487-497 
28. Köster W. Endarteritis and arteritis. Berl Klin Wochenschr. 1876;13:343-345 
29. Wolinsky H, Glagov S. Nature of species differences in the medial distribution 
of aortic vasa vasorum in mammals. Circ Res. 1967;20:409-421 
30. Adams RH, Alitalo K. Molecular regulation of angiogenesis and 
lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464-478 
31. Carmeliet P. Blood vessels and nerves: Common signals, pathways and 
diseases. Nat Rev Genet. 2003;4:710-720 
32. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660 
33. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of 
angiogenesis. Cell. 2011;146:873-887 
34. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of 
angiogenesis. Nature. 2011;473:298-307 
35. Eilken HM, Adams RH. Dynamics of endothelial cell behavior in sprouting 
angiogenesis. Curr Opin Cell Biol. 2010;22:617-625 
36. Iruela-Arispe ML, Davis GE. Cellular and molecular mechanisms of vascular 
lumen formation. Dev Cell. 2009;16:222-231 
37. Naik MU, Stalker TJ, Brass LF, et al. Jam-a protects from thrombosis by 
suppressing integrin alphaiibbeta3-dependent outside-in signaling in 
platelets. Blood. 2012;119:3352-3360 
GENERAL INTRODUCTION 
29 
1 
38. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for 
cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417-427 
39. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of 
cancer and other diseases. Physiol Rev. 2011;91:1071-1121 
40. Paterson JC. Vascularization and hemorrhage of the intima of arteriosclerotic 
coronary arteries. Arch Path. 1936;22:313-324 
41. Grundy SM. Atherosclerosis: Pathology, pathogenesis, and role of risk factors. 
Dis Mon. 1983;29:1-58 
42. Schwartz SM. Cellular proliferation in atherosclerosis and hypertension. Proc 
Soc Exp Biol Med. 1983;173:1-13 
43. Kamat BR, Galli SJ, Barger AC, et al. Neovascularization and coronary 
atherosclerotic plaque: Cinematographic localization and quantitative 
histologic analysis. Hum Pathol. 1987;18:1036-1042 
44. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression 
and vulnerability to rupture: Angiogenesis as a source of intraplaque 
hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-2061 
45. Jeziorska M, Woolley DE. Neovascularization in early atherosclerotic lesions of 
human carotid arteries: Its potential contribution to plaque development. 
Hum Pathol. 1999;30:919-925 
46. Cliff WJ, Heathcote CR, Moss NS, et al. The coronary arteries in cases of 
cardiac and noncardiac sudden death. Am J Pathol. 1988;132:319-329 
47. McCarthy MJ, Loftus IM, Thompson MM, et al. Angiogenesis and the 
atherosclerotic carotid plaque: An association between symptomatology and 
plaque morphology. J Vasc Surg. 1999;30:261-268 
48. Mofidi R, Crotty TB, McCarthy P, et al. Association between plaque instability, 
angiogenesis and symptomatic carotid occlusive disease. Br J Surg. 
2001;88:945-950 
49. Alpern-Elran H, Morog N, Robert F, et al. Angiogenic activity of the 
atherosclerotic carotid artery plaque. J Neurosurg. 1989;70:942-945 
50. Vuorio T, Jauhiainen S, Yla-Herttuala S. Pro- and anti-angiogenic therapy and 
atherosclerosis with special emphasis on vascular endothelial growth factors. 
Expert Opin Biol Ther. 2012;12:79-92 
51. Chen YX, Nakashima Y, Tanaka K, et al. Immunohistochemical expression of 
vascular endothelial growth factor/vascular permeability factor in 
atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc 
Biol. 1999;19:131-139 
52. Nakano T, Nakashima Y, Yonemitsu Y, et al. Angiogenesis and 
lymphangiogenesis and expression of lymphangiogenic factors in the 
atherosclerotic intima of human coronary arteries. Hum Pathol. 2005;36:330-
340 
53. Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, et al. Expression of the 
angiogenic protein, platelet-derived endothelial cell growth factor, in 
coronary atherosclerotic plaques: In vivo correlation of lesional microvessel 
density and constrictive vascular remodeling. Arterioscler Thromb Vasc Biol. 
1999;19:2340-2347 
CHAPTER 1 
30 
1 
54. Pilarczyk K, Sattler KJ, Galili O, et al. Placenta growth factor expression in 
human atherosclerotic carotid plaques is related to plaque destabilization. 
Atherosclerosis. 2008;196:333-340 
55. Post S, Peeters W, Busser E, et al. Balance between angiopoietin-1 and 
angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with 
high microvessel density. J Vasc Res. 2008;45:244-250 
56. Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (mmp-1) 
expression in human carotid atherosclerosis. Circulation. 1995;92:1393-1398 
57. Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial 
remodeling and the localization of macrophages and matrix metalloproteases 
1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000;150:245-253 
58. Bot I, Biessen EA. Mast cells in atherosclerosis. Thromb Haemost. 
2011;106:820-826 
59. Kaartinen M, Penttila A, Kovanen PT. Mast cells accompany microvessels in 
human coronary atheromas: Implications for intimal neovascularization and 
hemorrhage. Atherosclerosis. 1996;123:123-131 
60. Lappalainen H, Laine P, Pentikainen MO, et al. Mast cells in neovascularized 
human coronary plaques store and secrete basic fibroblast growth factor, a 
potent angiogenic mediator. Arterioscler Thromb Vasc Biol. 2004;24:1880-
1885 
61. Hao NB, Lu MH, Fan YH, et al. Macrophages in tumor microenvironments and 
the progression of tumors. Clin Dev Immunol. 2012;2012:948098 
62. Mapp PI, Walsh DA. Mechanisms and targets of angiogenesis and nerve 
growth in osteoarthritis. Nat Rev Rheumatol. 2012;8:390-398 
63. Torres Filho IP, Leunig M, Yuan F, et al. Noninvasive measurement of 
microvascular and interstitial oxygen profiles in a human tumor in scid mice. 
Proc Natl Acad Sci U S A. 1994;91:2081-2085 
64. Moreno PR, Purushothaman KR, Sirol M, et al. Neovascularization in human 
atherosclerosis. Circulation. 2006;113:2245-2252 
65. Nicholls SJ, Borgman M, Nissen SE, et al. Impact of statins on progression of 
atherosclerosis: Rationale and design of saturn (study of coronary atheroma 
by intravascular ultrasound: Effect of rosuvastatin versus atorvastatin). Curr 
Med Res Opin. 2011;27:1119-1129 
66. Barker SG, Talbert A, Cottam S, et al. Arterial intimal hyperplasia after 
occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thromb. 
1993;13:70-77 
67. Booth RF, Martin JF, Honey AC, et al. Rapid development of atherosclerotic 
lesions in the rabbit carotid artery induced by perivascular manipulation. 
Atherosclerosis. 1989;76:257-268 
68. Nakata Y, Kamiya K. An experimental study on the vascular lesions caused by 
obstruction of the vaso vasorum. Ii. Special consideration on the deposition of 
fat into vascular wall. Jpn Circ J. 1970;34:1029-1034 
69. Nakata Y, Shionoya S. Vascular lesions due to obstruction of the vasa 
vasorum. Nature. 1966;212:1258-1259 
70. Nakata Y, Shionoya S, Matsubara J, et al. An experimental study on the 
vascular lesions caused by disturbance of the vasa vasorum. 3. Influence of 
GENERAL INTRODUCTION 
31 
1 
obstruction of the venous side of the vasa vasorum and the periaortic vein. 
Jpn Circ J. 1972;36:945-951 
71. de Boer OJ, van der Wal AC, Teeling P, et al. Leucocyte recruitment in rupture 
prone regions of lipid-rich plaques: A prominent role for neovascularization? 
Cardiovasc Res. 1999;41:443-449 
72. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for 
atherosclerosis. J Am Coll Cardiol. 2007;49:2073-2080 
73. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in 
atherogenesis--a double-edged sword. Ann Med. 2008;40:606-621 
74. Hauer AD, van Puijvelde GH, Peterse N, et al. Vaccination against vegfr2 
attenuates initiation and progression of atherosclerosis. Arterioscler Thromb 
Vasc Biol. 2007;27:2050-2057 
75. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human 
coronary atherosclerosis: Its origin and pathophysiological significance. Hum 
Pathol. 1995;26:450-456 
76. Depre C, Havaux X, Wijns W. Neovascularization in human coronary 
atherosclerotic lesions. Cathet Cardiovasc Diagn. 1996;39:215-220 
77. Sluimer JC, Kolodgie FD, Bijnens AP, et al. Thin-walled microvessels in human 
coronary atherosclerotic plaques show incomplete endothelial junctions 
relevance of compromised structural integrity for intraplaque microvascular 
leakage. J Am Coll Cardiol. 2009;53:1517-1527 
78. de Boer OJ, van der Wal AC, Teeling P, et al. Leucocyte recruitment in rupture 
prone regions of lipid-rich plaques: A prominent role for neovascularization? 
Cardiovasc Res. 1999;41:443-449 
79. Jeziorska M, Woolley DE. Local neovascularization and cellular composition 
within vulnerable regions of atherosclerotic plaques of human carotid 
arteries. J Pathol. 1999;188:189-196 
80. Moos MP, John N, Grabner R, et al. The lamina adventitia is the major site of 
immune cell accumulation in standard chow-fed apolipoprotein e-deficient 
mice. Arterioscler Thromb Vasc Biol. 2005;25:2386-2391 
81. Gijsen FJ, Wentzel JJ, Thury A, et al. Strain distribution over plaques in human 
coronary arteries relates to shear stress. Am J Physiol Heart Circ Physiol. 
2008;295:H1608-1614 
82. Jeziorska M, Woolley DE. Local neovascularization and cellular composition 
within vulnerable regions of atherosclerotic plaques of human carotid 
arteries. J Pathol. 1999;188:189-196 
83. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor 
enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-429 
84. Lucerna M, Zernecke A, de Nooijer R, et al. Vascular endothelial growth 
factor-a induces plaque expansion in apoe knock-out mice by promoting de 
novo leukocyte recruitment. Blood. 2007;109:122-129 
85. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (plgf) and its receptor 
flt-1 (vegfr-1): Novel therapeutic targets for angiogenic disorders. Ann N Y 
Acad Sci. 2002;979:80-93 
CHAPTER 1 
32 
1 
86. Tanaka K, Nagata D, Hirata Y, et al. Augmented angiogenesis in adventitia 
promotes growth of atherosclerotic plaque in apolipoprotein e-deficient mice. 
Atherosclerosis. 2011;215:366-373 
87. Kolodgie FD, Narula J, Yuan C, et al. Elimination of neoangiogenesis for plaque 
stabilization: Is there a role for local drug therapy? J Am Coll Cardiol. 
2007;49:2093-2101 
88. Luttun A, Brusselmans K, Fukao H, et al. Loss of placental growth factor 
protects mice against vascular permeability in pathological conditions. 
Biochem Biophys Res Commun. 2002;295:428-434 
89. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin 
or tnp-470 reduce intimal neovascularization and plaque growth in 
apolipoprotein e-deficient mice. Circulation. 1999;99:1726-1732 
90. Moulton KS, Olsen BR, Sonn S, et al. Loss of collagen xviii enhances 
neovascularization and vascular permeability in atherosclerosis. Circulation. 
2004;110:1330-1336 
91. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque 
neovascularization reduces macrophage accumulation and progression of 
advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003;100:4736-4741 
92. Petrovan RJ, Kaplan CD, Reisfeld RA, et al. DNA vaccination against vegf 
receptor 2 reduces atherosclerosis in ldl receptor-deficient mice. Arterioscler 
Thromb Vasc Biol. 2007;27:1095-1100 
93. Khatri JJ, Johnson C, Magid R, et al. Vascular oxidant stress enhances 
progression and angiogenesis of experimental atheroma. Circulation. 
2004;109:520-525 
94. de Nooijer R, Verkleij CJ, von der Thusen JH, et al. Lesional overexpression of 
matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced 
lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc 
Biol. 2006;26:340-346 
95. Calcagno C, Cornily JC, Hyafil F, et al. Detection of neovessels in 
atherosclerotic plaques of rabbits using dynamic contrast enhanced mri and 
18f-fdg pet. Arterioscler Thromb Vasc Biol. 2008;28:1311-1317 
96. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of 
angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-
targeted nanoparticles. Circulation. 2003;108:2270-2274 
97. Langheinrich AC, Michniewicz A, Sedding DG, et al. Correlation of vasa 
vasorum neovascularization and plaque progression in aortas of 
apolipoprotein e(-/-)/low-density lipoprotein(-/-) double knockout mice. 
Arterioscler Thromb Vasc Biol. 2006;26:347-352 
98. De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: Another 
hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr 
Opin Genet Dev. 2011;21:73-79 
99. Yla-Herttuala S, Bentzon JF, Daemen M, et al. Stabilisation of atherosclerotic 
plaques. Position paper of the european society of cardiology (esc) working 
group on atherosclerosis and vascular biology. Thromb Haemost. 2011;106:1-
19 
GENERAL INTRODUCTION 
33 
1 
100. Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation 
and reduces epistaxis in individuals with hereditary hemorrhagic 
telangiectasia. Nat Med. 2010;16:420-428 
101. Forster R, Braun A, Worbs T. Lymph node homing of t cells and dendritic cells 
via afferent lymphatics. Trends Immunol. 2012;33:271-280 
102. Kim H, Kataru RP, Koh GY. Regulation and implications of inflammatory 
lymphangiogenesis. Trends Immunol. 2012;33:350-356 
103. Rovenska E, Rovensky J. Lymphatic vessels: Structure and function. Isr Med 
Assoc J. 2011;13:762-768 
104. Casley-Smith JR. The fine structure and functioning of tissue channels and 
lymphatics. Lymphology. 1980;13:177-183 
105. Leak LV. Electron microscopic observations on lymphatic capillaries and the 
structural components of the connective tissue-lymph interface. Microvasc 
Res. 1970;2:361-391 
106. Leak LV, Burke JF. Fine structure of the lymphatic capillary and the adjoining 
connective tissue area. Am J Anat. 1966;118:785-809 
107. Oh SJ, Jeltsch MM, Birkenhager R, et al. Vegf and vegf-c: Specific induction of 
angiogenesis and lymphangiogenesis in the differentiated avian 
chorioallantoic membrane. Dev Biol. 1997;188:96-109 
108. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and 
human disease. Nature. 2005;438:946-953 
109. Nagahashi M, Ramachandran S, Rashid OM, et al. Lymphangiogenesis: A new 
player in cancer progression. World J Gastroenterol. 2010;16:4003-4012 
110. Flister MJ, Wilber A, Hall KL, et al. Inflammation induces lymphangiogenesis 
through up-regulation of vegfr-3 mediated by nf-kappab and prox1. Blood. 
2010;115:418-429 
111. Saharinen P, Petrova TV. Molecular regulation of lymphangiogenesis. Ann N Y 
Acad Sci. 2004;1014:76-87 
112. Takahashi H, Shibuya M. The vascular endothelial growth factor (vegf)/vegf 
receptor system and its role under physiological and pathological conditions. 
Clin Sci (Lond). 2005;109:227-241 
113. Lohela M, Saaristo A, Veikkola T, et al. Lymphangiogenic growth factors, 
receptors and therapies. Thromb Haemost. 2003;90:167-184 
114. Planas-Paz L, Strilic B, Goedecke A, et al. Mechanoinduction of lymph vessel 
expansion. Embo J. 2012;31:788-804 
115. Johnson RA. Lymphatics of blood vessels. Lymphology. 1969;2:44-56 
116. Sacchi G, Weber E, Comparini L. Histological framework of lymphatic vasa 
vasorum of major arteries: An experimental study. Lymphology. 1990;23:135-
139 
117. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health 
and disease. Cancer Cell. 2002;1:219-227 
118. Jellinek H, Veress B, Balint A, et al. Lymph vessels of rat aorta and their 
changes in experimental atherosclerosis: An electron microscopic study. Exp 
Mol Pathol. 1970;13:370-376 
119. Miller AJ, DeBoer A, Palmer A. The role of the lymphatic system in coronary 
atherosclerosis. Med Hypotheses. 1992;37:31-36 
CHAPTER 1 
34 
1 
120. Syvaranta S, Helske S, Lappalainen J, et al. Lymphangiogenesis in aortic valve 
stenosis--novel regulatory roles for valvular myofibroblasts and mast cells. 
Atherosclerosis. 2012;221:366-374 
121. Xu X, Lin H, Lv H, et al. Adventitial lymphatic vessels -- an important role in 
atherosclerosis. Med Hypotheses. 2007;69:1238-1241 
122. Sims FH. The arterial wall in malignant disease. Atherosclerosis. 1979;32:445-
450 
123. Sims FH. A comparison of coronary and internal mammary arteries and 
implications of the results in the etiology of arteriosclerosis. Am Heart J. 
1983;105:560-566 
124. Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue 
metabolic activity as a basis for understanding atherogenesis. Circ Res. 
1980;47:301-311 
125. Wong BW, Wong D, Luo H, et al. Vascular endothelial growth factor-d is 
overexpressed in human cardiac allograft vasculopathy and diabetic 
atherosclerosis and induces endothelial permeability to low-density 
lipoproteins in vitro. J Heart Lung Transplant. 2011;30:955-962 
126. Packard RR, Shi GP. Atherosclerosis progression and monocyte emigration 
from plaque. Future Cardiol. 2006;2:415-418 
127. Randolph GJ. Emigration of monocyte-derived cells to lymph nodes during 
resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol. 
2008;19:462-468 
128. Grabner R, Lotzer K, Dopping S, et al. Lymphotoxin beta receptor signaling 
promotes tertiary lymphoid organogenesis in the aorta adventitia of aged 
apoe-/- mice. J Exp Med. 2009;206:233-248 
129. Weih F, Grabner R, Hu D, et al. Control of dichotomic innate and adaptive 
immune responses by artery tertiary lymphoid organs in atherosclerosis. 
Front Physiol. 2012;3:226 
130. Zampell JC, Avraham T, Yoder N, et al. Lymphatic function is regulated by a 
coordinated expression of lymphangiogenic and anti-lymphangiogenic 
cytokines. Am J Physiol Cell Physiol. 2012;302:C392-404 
131. Kim KE, Koh YJ, Jeon BH, et al. Role of cd11b+ macrophages in intraperitoneal 
lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic 
function in the diaphragm. Am J Pathol. 2009;175:1733-1745 
132. Kataru RP, Kim H, Jang C, et al. T lymphocytes negatively regulate lymph node 
lymphatic vessel formation. Immunity. 2011;34:96-107 
 
 
  
GENERAL INTRODUCTION 
35 
1 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER
 2 
 
 
 
 
Multiphoton Laser  
Scanning Microscopy in  
Atherosclerosis Research 
 
 
 
 
 
 
 
Zhuojun Wu, Timo Rademakers, Adelina Curaj, Mitrajit Ghosh,  
Fabian Kiessling, Michael Vogt, Remco T.A. Megens, Marc A.M.J. van Zandvoort 
 
 
 
Submitted
CHAPTER 2 
38 
2 
Abstract 
 
In the last decades, there have been great advances in the understanding of 
the atherosclerotic process. This has been achieved due to extensive 
histological research of human atherosclerotic samples, and a vast number of 
studies in experimental atherosclerosis models, which resulted in insight into 
structural and functional characteristics of plaque constituents. A great hiatus 
has been caused by the lack of (in vivo) whole tissue imaging techniques, 
allowing characterization of the dynamic processes involved in atherosclerotic 
plaque development and progression. Over the last decade, advances have 
been made in non-invasive imaging of atherosclerosis, although the techniques 
used, for example ultrasound, MRI, or SPECT lack the spatial resolution to 
examine the dynamic processes on a cellular level. Multiphoton laser scanning 
microscopy is an optical imaging technique allowing, albeit invasive, 
(sub)cellular imaging of whole tissue.   
In this review, the background of multiphoton laser scanning 
microscopy is addressed, and advances in imaging in the light of 
atherosclerosis research are discussed. 
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Introduction 
 
Despite technological and diagnostic advances, the complex molecular 
mechanisms underlying the pathogenesis of atherosclerosis are still not fully 
elucidated. Although death rates from cardiovascular diseases (CVD) have 
been declining in recent years, it still remains one of the leading causes of 
morbidity and mortality in Western societies 1. The majority of life-threatening 
cardiovascular events, including myocardial infarction and stroke, are triggered 
by atherosclerosis, which is characterized by a chronic inflammation of the 
blood vessel wall, accumulation of modified lipoproteins, macrophages, and  
T cells, and leading to remodeling of the blood vessel walls to form 
atherosclerotic plaques. These ultimately may cause blockage of blood flow by 
thrombosis and embolization upon plaque rupture 2. Thrombotic events are 
the major cause for atherosclerosis-related complications 3. 
The goal of atherosclerosis-related (vital) imaging in animals is to 
further unravel the complex morphological, functional, and molecular 
mechanisms associated with disease progression that would improve the 
understanding of atherogenesis and ultimately lead to novel clinical 
prevention, detection, and intervention strategies. Continuous innovations in 
noninvasive clinical imaging technologies, including magnetic resonance 
imaging (MRI), computed tomography (CT), nuclear imaging, fluorescence 
imaging, and ultrasound, provide high-resolution anatomical and functional 
information of the human cardiovascular system. However, in case of animal 
models these modalities can only define anatomical and physiological 
parameters. At the same time, these modalities lack the ability to provide 
insight on disease-related cellular and molecular processes, as each of these 
imaging modalities are associated with drawbacks such as, low sensitivity, low 
spatial resolution, and low signal-to-noise ratio 4. Optical imaging techniques 
offer a spatial resolution superior to the conventional clinical modalities and 
allow not only the detailed assessment of vessel morphology, but can also 
provide insights on tissue composition and cellular marker expression on a 
molecular level. Currently, multiple optical imaging techniques such as optical 
coherence tomography (OCT) 5, and photoacoustic tomography (PAT) 6, 7 are 
being used for imaging in human atherosclerosis. Yet, both techniques have 
their limitations regarding sensitivity, resolution, and penetration depth. 
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Application of OCT and PAT imaging in cardiovascular tissues are well 
described in several other reviews 8, 9. 
The optical imaging techniques multiphoton laser scanning microscopy 
(MPLSM), near-infrared (NIR) microscopic imaging, and fluorescence life time 
imaging (FLIM) are being applied to assess cardiovascular disease in vivo in 
animals and ex vivo on human tissue 10-14. MPLSM has favorable properties that 
overcome many of the limitations of conventional single-photon imaging 
modalities, such as lack of out-of-focus fluorescence, better penetration depth, 
and reduced photo-toxicity, photo-activation, and photobleaching 15, 16. The 
combination of high spatial 3D resolution and superior penetration depth (up 
to 1 mm, dependent on tissue type) has been frequently used to study intact 
tissue and provide information on a cellular and subcellular level 17. More 
importantly, MPLSM allows the acquisition of functional, structural, and 
molecular information simultaneously in intact tissue and organs, which offers 
the opportunity to study processes in their physiological environment. This is 
particularly important for atherosclerosis, a disease associated with both 
structural and functional alterations18. Besides classical MPLSM systems, a 
variety of MPLSM systems are currently being developed as the basis for 
image-guided diagnostics and therapies such as photodynamic therapy (PDT) 
and photothermal therapy (PTT).  
This review will describe the principles of MPLSM and address both the 
advantages and limitations for its use in cardiovascular research, and will focus 
especially on imaging of atherosclerosis in animals and humans. Furthermore, 
it will highlight how its application can benefit from the development of novel 
imaging probes for clinical use.  
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Principles of multiphoton laser scanning microscopy 
 
Nonlinear optical imaging has many facets. Besides the usage of conventional 
dyes for tissue staining, nonlinear imaging allows the visualization of tissue 
with intrinsic properties by exploiting second and third harmonic generation. 
 
Multiphoton excitation 
Multiphoton microscopy is based on the localized nonlinear excitation of 
fluorescence, which is the emission of a photon by a fluorophore activated by 
the absorption of multiple photons. During the absorption process, the 
fluorophore reaches the excited state from which it returns to the ground 
state by photon emission. While in conventional wide-field fluorescence or 
confocal laser scanning microscopy, the fluorophore-excitation is achieved 
with a single photon using a continuous laser, multiphoton excitation, two-
photon excitation in this example (Figure 1), only occurs when a fluorophore 
absorbs two photons each with half the energy necessary for excitation, nearly 
simultaneously (within 10-18 s) 19. For example, a fluorophore can be excited by 
two photons from the near-infrared (NIR) range (800-1000nm), each having 
half the energy of a single photon with a wavelength of 400 nm. As the 
probability of such a nonlinear excitation event is rather low, a high photon 
density is required, which is provided by a powerful femtosecond pulse laser.  
While the photon output and peak power is very high during the pulse 
(80-100 femtoseconds), the average energy output is relatively low when 
compared with a continuous laser. In addition, the photon density is highest in 
the focal spot of the objective and deteriorates rapidly outside the focal spot, 
reducing out-of-focus excitation and subsequent fluorescence, without the use 
of an emission pinhole as in confocal microscopy. Furthermore, multiphoton 
excitation can generate multiple color fluorescence using the same excitation 
wavelength 20, which subsequently can be spectrally separated into multiple 
channels using band pass filters. In contrast, confocal imaging requires the use 
of multiple laser lines for simultaneous imaging of more than one fluorophore. 
This causes an increase in acquisition time proportional to the numbers of 
wavelengths/probes, or inefficient detection of fluorophores due to exclusion 
of excitation laser light from the emitted fluorescence.  
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Figure 1. Principle of two-photon excitation represented in a simplified Jablonski diagram. 
When a fluorophore absorbs two photons with each half the energy necessary for excitation, 
within 10-18 s, two-photon excitation is elicited and fluorescent light will be emitted. 
 
 
As a result of the MPLSM layout, multiple advantages over 
conventional and confocal laser microscopy are evident. Firstly, the 
multiphoton excitation is achieved using low-energy photons in the NIR 
spectrum, which decreases tissue absorption and scattering and greatly 
increases the penetration depth. Secondly, the probability of multiphoton 
excitation is the highest at the focal point of the laser. Fluorophore excitation, 
photo-damage, photo-toxicity, and photo-bleaching are confined only to the 
focal point, whereas the rest of the specimen is only exposed to harmless NIR 
light. Thirdly, the lack of a pinhole allows the detection of scattered and 
unscattered emitted fluorescence for image formation, resulting in higher 
sensitivity, reduced excitation laser power/tissue damage and a better signal-
to-noise ratio. Lastly, although a high photon density is needed for 
multiphoton excitation, the high-energy output is only maintained for 80-100 
femtoseconds. The average energy output of the multiphoton laser is much 
lower than continuous lasers, which reduces photodamage. One of the most 
prominent applications of MPLSM is deep tissue 3D imaging, during which a 
series of sequential images is acquired repeatedly at increasing depth to form 
3-dimensional image stacks (z-stack).  
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All these features are important for long-term vital deep tissue imaging, for 
example imaging of tumor angiogenesis 21, cell tracking studies 22, 23, embryo-
development 24 or the progression of atherosclerosis. 
 
Second harmonic generation 
Many biological tissues contain endogenous fluorophores, which can be 
exploited to provide additional information on cellular activity and tissue 
composition, such as nicotinamide adenine dinucleotide phosphate (NAD(P)H), 
flavin adenine dinucleotide (FAD) and extracellular matrix components  25, 26. A 
different phenomenon in optical imaging, referred to as second harmonic 
generation (SHG), is frequently used for label-free imaging 27. Contradictory to 
the multiphoton excitation process, in SHG two photons interact 
simultaneously with a non-centrosymmetric target, e.g. collagen fibrils leading 
to the emission of a single photon with exactly twice the energy (frequency 
doubling). Consequently, with an excitation wavelength of 800 nm, the SHG 
signal is 400 nm (blue) 28. As SHG is not dependent on the ground/excited 
states of molecules, i.e., SHG is a scattering process, it provides photon 
emission without photo-bleaching, which is of great advantage for ex vivo and 
in vivo imaging. 
 
Third harmonic generation 
Similar to SHG, third harmonic generation (THG) is also a nonlinear process, 
which requires the simultaneous interaction of three photons for the emission 
of a single photon with one third of the excitation wavelength. As a result, an 
excitation wavelength of 1200 nm is required for THG imaging at 400 nm. The 
major difference to SHG is that THG does not require a non-centrosymmetric 
environment for photon emission. Refraction index change within the focal 
spot induces THG. However, standard multiphoton microscopes have a limited 
wavelength spectrum and do not allow THG, unless equipped with an Optical 
Parametric Oscillator (OPO). Since it is at current not used in atherosclerosis 
imaging, THG will not be further discussed in this review.  
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Imaging of atherosclerosis 
 
The application of MPLSM for atherosclerosis imaging offers a unique 
perspective. Superior tissue penetration combined with molecular, structural 
and functional imaging on a subcellular resolution enables the visualization of 
biomarkers, morphological changes, and signal molecules. All these 
characteristics are essential for the understanding of disease progression and 
the development of adequate intervention and prevention strategies. 
 
Ex vivo MPLSM imaging 
In the last few years MPLSM has been applied successfully on variety of viable 
tissues ex vivo, such as brain 29-31, kidney 32-36, lymphoid tissue 37-41, 
tumors 21, 42, 43, and heart tissue 44, 45. The imaging of viable blood vessels ex 
vivo is frequently done using perfusion chambers, in which intact isolated 
vessels are mounted on glass pipettes, pressurized, and corrected for 
longitudinal tension 46. In the absence of these environmental factors, the 
blood vessel collapses and contracts, often leading to the loss of functionality 
and structural integrity 47, 48. The application of transluminal pressure, 
longitudinal tension and physiological buffer preserves vessel wall integrity and 
mimics the intact blood vessel in its physiological environment, in which not 
only 3D sectioning of the vascular wall and structural and functional vessel 
characteristics can be determined up to several hours 46. Moreover, 
applications of specific labeling agents can be performed extraluminal, 
intraluminal, or both for improved labeling specificity. Together with the 
enhanced uptake of agents (which is especially of importance for the 
endothelium monolayer), mounting of arteries enhances the labeling 
characteristics. As such, mounting of arteries is an elegant and well 
controllable method for investigating the binding and uptake kinetics of multi-
modal probes and contrast-agents under flow and shear stress conditions, such 
as fluorescent microbubbles 49, magneto-optical nanoparticles 50, and contrast 
agents 51.  
 
Imaging of second harmonic generation signal 
In biological tissue, the extracellular matrix mainly contributes to SHG due to 
the high content of non-centrosymmetric structures such as collagen fibers. 
Typical for blood vessel walls, most of the extracellular material between the 
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smooth muscle and in the adventitia is collagen, which is responsible for 
vascular integrity and stability 52, 53. Moreover, collagen plays an important role 
in the progression of atherosclerotic plaques and other cardiovascular diseases 
such as hypertension and age-related arterial stiffness 54-56. Its extensive 
contribution to and impact on vascular remodeling and plaque development 
has been reviewed by Adiguzel et al in 2009 57.  
Collagen has been the focus of many cardiovascular-related studies 
using MPLSM 58-61. The complex mechanisms and dysfunctional balance of 
collagen synthesis and degradation during atherogenesis has a major impact 
on disease progression. While collagen content can spike up to 60% of total 
plaque proteins, therefore contributing significantly to plaque growth and 
arterial narrowing in fibrous lesions. Alternatively, collagen degradation in the 
fibrous cap makes the plaque vulnerable and prone to rupture. It should be 
noted, however, that only specific types of collagen such as collagen I, III, IV, V, 
and VIII along the subendothelial layer are actively involved in plaque 
development and rupture 57, 62. 
 
Imaging of disease-specific markers 
In addition to SHG and THG, the combination of high-resolution and -sensitivity 
imaging and deep tissue penetration of MPLSM has yielded insights into the 
structural, functional, and molecular alterations in the arterial wall prior to 
lesion development and the composition of atherosclerotic plaques in the later 
stages of disease progression. 
The detection of molecular disease markers such as inflammatory 
receptors requires a method with high sensitivity, as their concentration is 
expected to be in the nanomolar range. This is especially true for markers in 
the subendothelial space, as probes will only limitedly penetrate the intima. 
Commonly used imaging modalities such as molecular ultrasound 63-65,  
PET 66, 67, CT 68, and MRI 69, 70 all lack the capability for the visualization of 
(sub)cellular structures. Multiphoton imaging using fluorescence and NIR 
excitation, has shown its potential as a high-resolution and highly sensitive 
imaging method for atherosclerosis in preclinical studies in small animals, both 
ex vivo and in vivo 11, 12, 15, 18, 51.  
One of the targets for imaging of early stages of atherosclerosis 
development is endothelial dysfunction, which is considered one of the key 
events in the onset of atherogenesis. The dysfunction of both barrier and 
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secretory functions is accompanied by the luminal presence and release of 
chemokines and cytokines 71, and overexpression of cell adhesion molecules, 
such as intercellular adhesion molecule (ICAM), vascular cell adhesion 
molecule (VCAM), platelet endothelial cell adhesion molecule (PECAM/CD31), 
and selectins 72, 73. These processes cause an increased accumulation of 
inflammatory cells, such as monocytes, neutrophils, and T cells, as well as lipids 
in the vessel wall. Both cell adhesion molecules and chemokines/cytokines can 
potentially be used as molecular markers for early stages of lesion 
development using optical imaging techniques as demonstrated in multiple 
studies with fluorescent labeled multimodal probes, i.e. VCAM-1 labeled 
nanoparticles or P-selectin labeled microbubbles 74-78.  
Prominent molecular markers for the later stages of lesion 
development are inflammatory- and angiogenesis-related receptors such as 
CD13 79 or αvβ3 integrin 80 for studying plaque neovascularization. Furthermore, 
extracellular matrix (ECM)-related proteins such as collagen and endothelial 
fibrin 58, 81, 82 could serve as markers for studying cap formation and cap 
thinning, and thrombus-related factors like activated platelets 83, 84 may serve 
as markers for intraplaque hemorrhage (IPH) or plaque rupture. In addition to 
the disease-related molecular markers, MPLSM allows the visualization of 
functional alteration in the murine vascular wall typical for atherogenesis such 
as NO production (Ghosh et al, submitted), structural changes in the vascular 
wall typical for atherogenesis such as angiogenesis 15, endothelial glycocalyx 
thickness and structure 10, 85, collagen levels 58, and morphological changes 
such as the vessel diameter and vessel wall thickness 86.  
Functional imaging of atherosclerosis using MPLSM has only recently 
been explored by visualizing NO production within diseased tissue ex vivo 
(Ghosh et al, submitted). The altered NO production as a consequence of  
endothelial dysfunction results in a number of cardiovascular symptoms such 
as hypertension and atherosclerosis 87. The combination of an NO-sensitive 
fluorescence probe and MPLSM has provided valuable information regarding 
the structural-functional relationship of NO production in the vessel wall with 
direct visualization of the structures producing NO, shedding light onto the role 
of NO during vascular dysfunction.  
In addition to the molecular and functional imaging possibilities, the 
strong tissue penetration of MPLSM allows structural imaging of the 
components of the (intact) vessel wall. The media consists mostly of layers of 
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smooth muscle cells separated by elastin fibers, while the major component of 
the most outer adventitia layer is collagen 88. During lesion progression, the 
vessel wall undergoes structural remodeling steps, such as the increase of the 
intima-media thickness (IMT), alteration of the endothelial glycocalyx  
thickness 10, 85, increased smooth muscle cell proliferation, and collagen 
synthesis. As demonstrated in a study by Megens et al in 2007, the collagen-
marker CNA35 was characterized and established using MPLSM, as a molecular 
marker for atherosclerotic plaques in ApoE-/- mice, mainly based on the 
endothelial uptake and distribution of the collagen-marker. Due to 
characteristic increase of endothelial permeability and elevated collagen 
content in the lesion areas, CNA35 showed significantly higher binding 
compared to healthy tissue.  
The characterization of novel molecular probes using MPLSM imaging 
provides both functional and structural information on a cellular and 
subcellular level and may contribute to the development of multi-modal 
agents for noninvasive clinical imaging modalities with shortcomings in spatial 
resolution or sensitivity, such as molecular ultrasound, MRI, CT, and 
PET/SPECT. 
 
In vivo MPLSM imaging  
Despite significant improvements of in vitro and ex vivo models for 
atherosclerosis, preclinical animal experiments are still crucial for 
understanding disease processes, effects of new drugs, and contrast agents. So 
far, in vivo multiphoton laser scanning microscopic imaging has been mostly 
performed in relatively motionless/fixed tissue, and has been applied for 
studying renal (patho)physiology 89-92, tumor biology 93, 94, and angiogenesis 95. 
Other fields implementing in vivo MPLSM techniques are ophthalmology 96, 
dermatology 97, pulmonary research 98, and neurosciences 99-102. The field of 
immunology has also greatly profited from in vivo MPLSM, where it has led to 
new insights in e.g. haematopoietic stem cells and their trafficking 103, immune 
cell recruitment 104-107, immune cell trafficking 108, 109, and infection in  
general 110. Most in vivo MPLSM of the vasculature has been focusing on 
imaging of microvasculature in various tissue beds and organs and is mainly 
utilized for determining e.g. flow in the brain 111 or in tumors 112, cell  
trafficking 113, 114, permeability 115 and contractility 116, coagulation 117, or 
structural composition and aberrations (e.g. of the glycocalyx) 10, 118, and the 
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process of angio- and atherogenesis 119. Yet, the macrovasculature, among 
others important for studying atherosclerosis or related processes, has not 
been extensively studied in vivo with MPLSM because of practical difficulties 
concerning image quality.  
Initial studies of the microvasculature focused mainly on coping with 
motion artifacts and were used for structural imaging of the vessel wall 120 and 
to study interactions of leukocyte subsets with the endothelium 11, 12. The in 
vivo motion artifacts are mainly caused by both the cardiac and respiratory 
cycle of living specimen which results in movement of tissue beds with a 
certain frequency. In case of mice, the heart frequency is roughly 5-6 Hz and 
the respiratory cycle 2-4 Hz (dependent on applied anesthesia). Consequently, 
the thoracic area, the myocardium, and the larger arteries will display a 
rhythmic motion with similar frequencies. As a result, imaging of these tissue 
beds in vivo with a laser scanning microscope, strongly suffers from two types 
of artifacts: intra-frame and inter-frame motion artifacts. The intra-frame 
motion artifacts are a result of the laser scanning properties of MPLSM, where 
there is a gradient in time difference between the first scanned pixel in the left 
top corner of the image matrix and the last scanned pixel at the right bottom 
corner. As such, the tissue in the 2-3 µm thin focal plane varies within the 
single image and the motion of the tissue causes a deterioration of the image 
due to the actual motion and loss of focus (Figure 2) 18. In an imaging sequence 
(either in depth or over time), the motion of tissue also causes a difference of 
the tissue in focus between subsequent images. As a result, (three 
dimensional) reconstructions of cellular processes or structures are almost 
impossible to perform without adapting the current imaging methods in order 
to limit or overcome motion artifacts. 
Besides the sometimes rather non-physiological procedures of physical 
suppression of the tissue motion either by adapting the surgical preparation 
method 121, or temporary reduction of the heart rate or respiration 122, there 
are three strategies to (partially) overcome both artifacts: 1) utilize the cardiac 
and respiratory cycle to guide the imaging by timing of the MPLSM acquisition 
in a time window where the motion will be limited; 2) trigger the acquisition by 
using the cardiac and respiratory signals (triggered acquisition); 3) record the 
moving tissue randomly, and apply extensive post-processing of the images 
series to detect comparable tissue representations over time.  
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Figure 2. Motion artifacts and loss of focus in untriggered in vivo MPLSM imaging 18. Three 
subsequent optical sections (A-C) of a left carotid artery of a C57Bl6/J mouse obtained in vivo 
without application of external triggering. Frame rate was 2.3 Hz (1200 lps; line scan rate 1x, 
matrix size 512 x 512 pixels). Drawing indicates the position of the optical sections in the vessel 
wall; bars indicate 20 μm. Cell nuclei (SYTO13, green) and collagen (SHG, blue/purple) are 
visible. All sections are disturbed by motional artifacts which cause the arterial wall (blue arrow) 
to appear as a curved-like structure. Moreover, every optical section contains different parts of 
the (moving) vessel wall. The VSMC nuclei (green), with their typical morphology and 
orientation, are hardly recognizable; the position of the lumen is unclear. 
 
Respiratory timing 
In order to (partially) overcome in vivo motion artifacts, timing of the image 
acquisition between the tissue movements is a logical step. When the image 
acquisition frequency is higher than the movement frequencies, in principle 
one can record a single image without intra-image artifacts. Timing of image 
acquisition has been performed for imaging of the lung using intravital and 
laser scanning microscopy 123. By mechanically controlling the respiration, a 
stable respiration motion frequency is obtained that allows image acquisition 
in between the respiration frequency without intra-image artifacts (only when 
acquisition frequency is higher than motion frequency). Additionally, when the 
motion frequency is very stable and acquisition frequency is high enough, it 
will be possible to overcome inter-image artifacts and as a result potentiate 
studying of structures and or processes in 3D over time.  
 
Respiratory triggering 
When motion artifacts are caused by more than one determinant or the 
motion frequencies are less stable and consequentially difficult to predict, it is 
virtually impossible to avoid motion artifacts by simple timing of acquisition. In 
such tissue beds, image acquisition can be timed by gating / triggering on the 
main determinants of the sample motion, a technique applied for other 
imaging modalities such as MRI 124. Gating, or triggered acquisition, makes it 
feasible to overcome a combination of motion artifacts when using a triggering 
CHAPTER 2 
50 
2 
tool that enables generation of trigger pulses based on more than one signal. 
Moreover, it offers the advantage that smaller motional irregularities can be 
blocked using appropriate trigger thresholds or trigger delays and as such do 
not contribute to the resultant data set.  
In case of studying cardiovascular samples such as the large arteries, 
the motion disturbances are a consequence of the cardiac (5-6 Hz) and 
respiratory (2-4 Hz) cycle, from which the cardiac cycle is the most prominent 
motion disturbance 18. In this study, utilization of a gating- or triggerbox (Rapid 
biomedical, Würzburg, Germany), originally developed for MRI systems, 
combined with image acquisition at a rate of 5-6 Hz resulted in more stable 
image series of murine carotid and renal arteries without large intra- and inter-
image artifacts caused by motion. However, in order to achieve the required 
acquisition rates and the detection sensitivity, the number of pixels had to be 
lowered and the scan speed increased. As a result, the image quality suffered 
due to a degraded signal-to-noise ratio. Moreover, the resolution is reduced 
since the Nyquist sampling criterion is not met due to the reduced number of 
voxels (a consequence of the mismatch between digital and optical resolution: 
optical resolution / pixel size ≤ 2.3).  
In the latest generation of commercially available MPLSM systems, 
overall sensitivity has drastically improved due to strongly enhanced optics 
(apochromatic objectives with high numerical aperture and low magnification) 
and acquisition rates of >30 Hz using resonance scanning (8000-12000 Hz, 125) 
or multiplication of the excitation laser beam (1-64 beams 126, 127), improving 
time resolution. The latter enables recording at video rates without a negative 
impact on the overall image quality, size of the field of view, or the image 
resolution. Moreover, novel fluorophores with improved quantum yields and 
stokes-shift contribute to improvement of image quality 128. As a consequence, 
the intra- and inter-image artifacts can be strongly reduced, allowing more 
accurate gating with strict thresholds, and ultimately, enable recording of >1 
optical slice within the time window of tissue stability. Due to the real-time 
nature of motion depression by gated image acquisition, this technique holds 
potential for obtaining three dimensional datasets over time in strongly 
motional tissues since subsequent images may be obtained at exactly the same 
starting point within the motion cycle(s). By controlling the tissue in focus 
(preferably by a piezo- or galvo- controlled z-drive for fast focusing), accurate 
three-dimensional datasets may be obtained.  
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Fast scanning imaging 
Besides timed or gated imaging, one can record the moving tissue over time at 
a 10-30Hz acquisition rate without triggering or other hardware aids. The 
resultant dataset consists of optical slices where motional artifacts are 
captured with a frequency that matches or exceeds the frequency of the heart 
respiration rate (Figure 3). Such datasets can be subjected to extensive post-
processing of the images series in order to detect comparable tissue 
representations over time. In most cases, the (partially) stable images have a 
rhythmic appearance (dependent on motion and acquisition frequency) within 
the data set which is beneficial for the selection process. Secondly, non-moving 
structures or cells within the selected images may be compared using overlays, 
edge detection, or co-localization protocols; The matching images may then be 
used for analyses of biological structures 12 or cell recruitment 11, 129. Post 
processing of the acquired data may be further optimized by making use of the 
signal recordings of the motion disturbances (e.g. electrocardiography or 
respiratory signals). Moreover, while the post-processing method can be 
performed manually, a more automated (structure recognition based) image 
processing is preferential since the process is extremely time consuming and 
has an unclear outcome (are there enough stable images within the dataset? Is 
the quality good enough to trace cells or study structures over time?).  
Another point of attention is the vulnerability of manual post 
processing for intra-observer artifacts. Finally, in order to make post 
processing corrected in vivo imaging more mainstream, there is a need for 
(development of) automatic processing protocols to analyze non-gated in vivo 
datasets that make use of pattern recognition algorithms and incorporate 
(real-time) knowledge of the motion frequency (i.e. heart and respiration 
rates). Besides improved quality, automatic in vivo post processing will enable 
more researchers to apply laser scanning microscopy in strongly motional 
samples and eventually, may generate novel data on the behavior of structures 
under in vivo motion (for example arterial wall deformation as a result of the 
blood pressure).  
As is evident, all three techniques (respiratory timing, respiratory 
triggering and fast scanning imaging) have their advantages and disadvantages, 
and the choice for one of the three will also depend on the research question 
at hand. Studies focused on e.g. tissue structure would greatly profit from the 
most stable imaging, requiring triggering whereas fast processes may benefit 
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more from continuous imaging, e.g. tracking of cells in the arterial system, 
since triggering-based techniques would result in too slow acquisition for 
proper assessment of real-time dynamics. In general, the quality of the in vivo 
image series is strongly dependent on the stability of the sample preparation 
(i.e. tissue drifts or loss of immersion water may cause a shift of the in-focus 
tissue) and the stability of the subject under investigation (method of 
anesthesia, heart rate, blood pressure, body temperature). Independent of the 
technique used, in vivo multiphoton imaging has become an important imaging 
tool over the years, and has given new insight in different fields of research.  
 
 
 
 
Figure 3. Fast scanning imaging allows stable imaging of moving tissue. Nine consecutive 
optical sections (A-I) from a murine carotid artery are shown with vascular endothelial marker 
CD31 (red) and elastin autofluorescence (green). A rhythmic appearance can be appreciated. 
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Heart imaging 
In vivo multiphoton imaging of the heart has been gaining interest since many 
fields of research, also atherosclerosis research, would benefit greatly from 
subcellular imaging of the heart in vivo. Yet, the heart is being more affected 
by severe motion artifacts than any other organ, and as such it is one of the 
most challenging organs to apply in vivo multiphoton microscopy on. Only 
recently, a first attempt has been made to visualize a beating mouse heart at a 
subcellular resolution. Li et al were able to perform in vivo MPLSM imaging on 
a beating heart using a system involving heterotopic transplants and an 
imaging chamber 130. In vivo imaging of the heart has been further refined by  
Lee et al 131, who elegantly combined existing triggering methods with a heart 
stabilizing tool that suppresses part of the motion of the beating heart inside 
the pericardial cavity. The impressive result is high resolution imaging of the 
intact in vivo mouse heart for studies with a duration of >4 hours. It can be 
expected that especially the latter method will prove to be a powerful tool for 
in vivo studies of the heart and will strongly contribute to our understanding of 
its morphology, physiology, and pathophysiology, especially when combined 
with systems allowing even faster acquisition rates and more sensitive 
detection. 
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Novel imaging agents 
 
New advances in imaging agents are very important factors in successful in 
vivo imaging. In general, high quantum yields are favorable, especially when 
studying fast processes. In vivo MPLSM imaging has therefore significantly 
benefited from the introduction of new nanoparticles, as has been reviewed 
extensively 128, 132. Aside from the traditional probes, especially quantum dots 
have been widely studied for in vivo MPLSM imaging. Their stability, high 
quantum yield and narrow emission spectra have made them excellent 
candidates for achieving a high signal-to-noise ratio in tissues suffering from 
intra-frame and inter-frame motion artifacts, while at the same time allowing 
multicolor imaging. For long-term studies, quantum dots are still debated due 
to the lack of clearance and concomitant degradation and release of toxic 
constituents inside the organism. Novel methods which are focused on 
lowering the toxicity of quantum dots will prove helpful in future studies 133, 134. 
Yet, (in vivo) MPLSM imaging has profited as well from development of 
more advanced probes, e.g. multimodal probes or photo-activatable,  
photo-convertible or photo-switchable probes. Multimodal probes are imaging 
agents designed to be detectable by two or more imaging modalities, like 
combinations of MPLSM with MRI 50, 51, 135, 136, OCT (reviewed by Tang et al 137), 
Fluorescence Molecular Tomography (FMT) 138, and Contrast-Enhanced 
Ultrasound (CEUS) 49. Such probes have made it possible to examine 
biodistribution and gross anatomy using (non-invasive) imaging techniques, 
and afterwards using MPLSM imaging to determine localization of the probe at 
(sub-)micron resolutions. The most prominent problem with multimodal 
imaging, however, still encompasses the integration of the different 
techniques. Further integration, as reviewed for MPLSM and OCT 137, is 
needed, but will, in the future, facilitate actual multimodal imaging in vivo.  
 
Photo-activatable, -convertible or -switchable probes have been 
developed over the last decade and are very suitable for studying protein 
dynamics in live-cell imaging 139-142. Dependent on the exact type of probe, it is 
non-fluorescent and can become fluorescent (photoactivation), is fluorescent 
and irreversibly shifts fluorescence emission (photoconversion) or is 
fluorescent and reversibly shifts fluorescence emission (photoswitching). The 
transition is traditionally accomplished by ultraviolet (UV) illumination, 
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changing the molecular structure of the fluorescent molecule, but can also be 
achieved by multiphoton excitation, where the activation wavelength and 
excitation wavelength for imaging obviously need to be separated. More 
recently, these probes have been applied as a cell tracking tool for 
immunologic responses in microvasculature 143-145, and are bound to be applied 
in the microvasculature in the near future. 
An additional novel development in probes and probe detection is the 
use of wavelength mixing. It is especially for lineage tracking and cell tracking, 
and allows imaging of multiple probes simultaneously, taking into account the 
relative expression of the probes. Mahou et al described the use of a MPLSM 
setup equipped with an OPO unit, to enable even higher near infrared 
excitation wavelengths (700-1350nm), in combination with a Brainbow 
transgene approach 146. Although this technique is not available for live 
imaging yet, it holds promise for future in vivo tracking studies.   
 
Pros and cons of MPLSM 
 
Imaging of viable tissue using MPLSM offers great advantages. It reduces the 
probability of artifacts that accompany the various steps of tissue processing 
required for histology and immunohistochemistry (cutting, fixation,  
staining) 147 since penetration depth of MPLSM allows imaging of structures 
and function in intact large arteries or organs. The penetration depth of light is 
strongly dependent on tissue type, as each tissue composition shows unique 
absorption and scattering profiles 148, 149, which make conventional 
fluorescence imaging methods less effective in deeper tissue layers. In 
atherosclerotic lesion areas, penetration depth is heavily restricted due to 
calcification and the accumulation of tissue components with high scattering 
coefficients such as cholesterol esters. Both scattering and absorption are 
wavelength-dependent and decrease with longer excitation wavelength. Yet, 
the emitted fluorescence still is in the range of normal fluorescence 
microscopy and thus suffers equally from scattering and absorption. The 
wavelengths used in TP imaging are within the limits of the NIR transparency 
window (700-1100 nm) of biological tissues, showing reduced absorption and 
thereby maximizing tissue penetration. Moreover, the lack of pinholes 
positively influences the detected emission, which is beneficial for sensitivity 
and imaging at depth. 
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In general, MPLSM is favored over conventional wide field and confocal 
microscopy due to its ability to penetrate deeper into biological tissues with 
reduced deterioration of spatial resolution. Nevertheless, MPLSM has some 
drawbacks. Firstly, the use of NIR excitation results in a larger resolution spot 
for MPLSM, therefore the spatial resolution of confocal microscopy supersedes 
that of MPLSM at shallow depths 150. Secondly, although photo-toxicity is 
confined to the focal spot and reduced, TP excitation can still have a negative 
impact on tissue viability. High photon density and laser power during the 
excitation period of the femtosecond laser can cause photo- damage to the 
specimen, potentially leading to oxidative stress and ultimately cell death 151. 
Thirdly, contradictory to conventional brightfield-fluorescence intravital 
microscopes, which use CCD cameras for acquisition, MPLSM image acquisition 
is based on point-to-point scanning of the field of view. As a result, imaging 
rate in classical MPLSM systems (±20 fps) is still reduced and can lead to 
motion artifacts in in vivo imaging studies. This can be compensated by using 
timing, triggering systems or fast, resonance or multi-beam based MPLSM 
imaging systems. However, it is important to note that the signal-to-noise ratio 
decreases with the scanning frequency, emphasizing the need for highly-
sensitive detectors. Fourthly, the ability to provide multiphoton excitation and 
subcellular resolution is associated with usage of high numerical aperture 
objectives and therefore often has a relatively small field of view. The latter is 
limiting the potential of imaging whole animals. Finally, one of the major 
drawbacks and the reason why MPLSM has not been fully integrated into 
laboratory routine is its high price and the requirement for specialized 
personnel to run the system 152.  
 
Conclusion  
 
MPLSM is a still rapidly evolving tool that has already shown its feasibility for 
various research fields. Its main strength to maintain resolution within various 
tissue types permits the visualization of cellular structures with high resolution 
(±1 µm), which has helped to characterize and establish novel imaging agents 
for atherosclerosis, as well as shed light into the molecular mechanisms of 
vascular remodeling and atherosclerotic lesion development. Furthermore, low 
photo-toxicity of MPLSM imaging supports long-term in vivo studies in the 
same animals, which is essential for the characterization of a slow-progressing 
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disease such as atherosclerosis. Advances in triggering-systems and high-
frequency optical scanners will further improve imaging-rate and image quality 
of MPLSM, allowing precise structural, functional, and molecular analysis in 
vivo.  
 
Future directions 
 
In many cases, the ultimate goal of exploratory work in multiphoton imaging is 
to translate those insights towards the development of in vivo and clinical 
diagnostic and therapeutic tools. Although the feasibility of in vivo applications 
for cardiovascular research has been demonstrated in animals, to our 
knowledge there have been no reports on its application on human subjects. 
Until now, clinical multiphoton imaging has almost exclusively been used on 
human skin both ex vivo and in vivo 153-155. Due to limited light penetration 
through the skin, in vivo cardiovascular MPLSM imaging requires procedures to 
expose the tissue of interest and create a surgically embedded optical window 
or the application of an endoscope. 
As already developed and established a decade ago, the combination 
of fluorescence imaging and endoscopy offers the possibility of non- or 
minimal invasive imaging in humans 156. Contradictory to the high numbers of 
single-photon confocal mircoendoscopy studies in humans and increased 
usage in clinical routine 157-160, there has been only one MPLSM study in 
humans 161. The major challenges are the efficient delivery of femtosecond 
excitation light without major degradation, the wide-field collection of the 
multiphoton fluorescence, miniaturization of objective lenses and the 
endoscope itself. Recent technological innovations in photonic crystal fibers 162 
and imaging lenses (fiber-coupled gradient-index – GRIN lenses) 163 have 
partially overcome these limitations. New multiphoton microendoscopes have 
been developed and tested in animal studies 164-166 and will mostly likely 
contribute to the development of clinical multiphoton microendoscope 
prototypes and clinical studies outside of the dermatological field in the next 
years.  
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Abstract 
 
Neovascularization of human atherosclerotic plaques is implicated in plaque 
progression and destabilization, although its functional implications are yet 
unresolved. Here, we aimed to elucidate functional and morphological 
properties of plaque microvessels in mice in vivo.  
Atherosclerotic carotid arteries from aged (>40wks) ApoE-/- mice 
(n=51) were imaged in vivo using multiphoton laser scanning microscopy. Two 
distinct groups of vasa vasorum microvessels were observed at sites of 
atherosclerosis development (median diameters of 18.5 and 5.9 μm, 
respectively), while microvessels within the plaque could only rarely be found. 
In vivo imaging showed ongoing angiogenic activity and injection of FITC-
dextran confirmed active perfusion. Plaque vasa vasorum showed increased 
microvascular leakage, combined with a loss of endothelial glycocalyx. Mean 
blood flow velocity in plaque-associated vasa vasorum was reduced by ±50% 
compared to diameter-matched control capillaries, while mean blood flow was 
reduced 8-fold. Leukocyte adhesion and extravasation were increased 6-fold in 
vasa vasorum versus control capillaries.  
Using a novel in vivo functional imaging strategy, we showed that 
plaque-associated vasa vasorum were angiogenically active and, albeit poorly, 
perfused. Moreover, plaque-associated vasa vasorum showed increased 
permeability, reduced blood flow, and increased leukocyte adhesion and 
extravasation, i.e. characteristics that could contribute to plaque progression 
and destabilization. 
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Introduction 
 
Human atherosclerotic plaques are characterized by local expansion of the 
vasa vasorum and development of intraplaque microvasculature. The extent of 
vascularization has been shown to correlate with progression stage, 
inflammatory content of the plaque and plaque instability 1, 2. Ever since Köster 
suggested that advanced atherosclerotic lesions are associated with an 
increased density in vasa vasorum 3, a growing number of studies has shown 
that both intraplaque microvasculature and vasa vasorum expansion enhance 
human atherosclerotic plaque progression 1, 4, 5. Intraplaque microvessels are 
thought to be derived mainly from the vasa vasorum by angiogenic sprouting, 
followed by ingrowth into the lesion 6-8. The angiogenic response itself is 
considered to arise from the gradual development of lesional hypoxia due to (I) 
increased physical distance to the lumen, exceeding the diffusion distance of 
oxygen, and (II) increased local metabolic activity of the plaque’s inflammatory 
content 1, 9. Additionally, the endothelium of the newly formed microvessels is 
prone to continuous exposure to inflammatory mediators, which could lead to 
impaired functionality and increased permeability, caused by deteriorated 
inter-endothelial junctions and basement membrane detachment 10. 
Dysfunctional microvessels would favor influx of circulating erythrocytes, 
leukocytes and blood platelets into the plaque 6, 7, 11, thereby promoting plaque 
expansion, destabilization and thrombogenicity.  
Despite the clinical relevance of plaque neovascularization, 
experimental animal studies on functionality of plaque microvessels have been 
hampered by their low incidence, or even lack thereof, in mouse models of 
atherosclerosis. Pro-angiogenic interventions in murine models have shown to 
increase plaque development and disease burden 12-16, whereas anti-
angiogenic therapy decreases atherosclerosis development 17-20, implicating a 
potent role for angiogenesis in experimental atherosclerosis models. However, 
the interventions also influenced the inflammatory response, thereby affecting 
lesion development independent of plaque neovascularization. In general, 
animal studies have failed to show a direct causal relation between plaque 
vascularization on the one hand, and plaque progression and destabilization on 
the other. 
Lack of adequate detection tools also hampered functional studies of 
plaque microvessels. Several methods like magnetic resonance imaging 21, 22 or 
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micro- and nano-computed tomography 23 have been applied to investigate 
plaque vascularization in murine models of atherosclerosis. These methods 
lack the spatial and/or temporal resolution to detect functional and structural 
properties of individual microvessels, or to distinguish between the artery and 
microvessels. Also, these techniques lack the ability to detect multiple imaging 
probes simultaneously. Multiphoton Laser Scanning Microscopy (MPLSM) can 
overcome these shortcomings and has previously been used for in situ imaging 
of healthy and atherosclerotic arteries at subcellular resolution 24, 25, as well as 
for quantifying angiogenic activity in models of tumor vascularization and 
myocardial infarction 26, 27. In addition, MPLSM has been used to image large 
blood vessels in vivo, triggered on heart rate and respiration to reduce motion 
artifacts 28, 29. More recently, MPLSM was used to quantify blood flow and 
haematocrit in blood vessels 30, substantiating MPLSM as a valuable tool for 
functional studies of the (micro)vasculature. 
Here, we studied plaque microvessels to elucidate their structural and 
functional characteristics. Using MPLSM imaging in a novel in vivo imaging 
strategy, plaque microvessels could be visualized in aged ApoE-/- mice. More 
importantly, angiogenic activity could be visualized and functional 
characteristics, including blood flow, adhesion and extravasation of leukocytes, 
and microvascular permeability could be quantified and were found to differ 
significantly from control microvascular beds.  
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Methods 
 
Animals 
For ex vivo and in vivo experiments aged ApoE-/- mice (40-50 wks of age; n=51) 
with advanced atherosclerotic plaques, were used. Young ApoE-/- mice (12-16 
wks of age; n=8), without or with only initial atherosclerotic plaques, and age-
matched wild-type C57Bl/6 mice (n=20) served as controls. Mice were supplied 
by the institutional animal facility and were housed in conventional cages and 
received a normal chow diet. Experiments were approved by the local animal 
ethics committee and performed according to institutional guidelines.  
For ex vivo MPLSM, mice were anaesthetized by a dorsal subcutaneous 
injection with ketamine (100mg/kg body weight, Nematek) and xylazine (10 
mg/kg body weight, Sedamun). Hereafter, animals were injected with the 
fluorescently labeled ligands via the tail vein and after 10 minutes of 
circulation of the ligands the animals were sacrificed. The lumen of the 
vasculature was flushed with 0.9% NaCl by injecting the heart, and carotid 
arteries (including the bifurcation), abdominal aorta, as well as heart, liver, 
spleen and kidney were excised and kept in cold Hanks Balanced Saline 
Solution (HBSS, pH 7.4, Invitrogen). Connective tissue and surrounding fat 
tissue was removed and carotid arteries were mounted in a home-built 
perfusion chamber, after which a transmural pressure of approximately 80 
mmHg was applied to mimic physiological conditions 24, 25. Abdominal aorta 
and organs were embedded in 2 weight/volume percentage (w/v%)  agarose 
gel (Invitrogen). Disposables were purchased from Greiner Bio One. 
For in vivo MPLSM, mice were anaesthetized using a dorsal 
subcutaneous injection with ketamine (100 mg/kg body weight, Nematek) and 
xylazine (10 mg/kg body weight, Sedamun) through a catheter made from a 
28mm polyethylene tube fitted with a 30G needle. Body temperature was kept 
at 37°C by means of a heating pad. Every 30 minutes an additional dose of 
anaesthetics was administered to maintain anaesthesia. The carotid artery was 
exposed, fluorescently labelled cells and ligands were administered via tail vein 
injection, and mice were imaged in vivo. After in vivo imaging, mice were 
sacrificed and in situ imaging was used for further examination. The number of 
mice used for the various experiments are indicated in Supplemental Table I.  
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Fluorescent probes  
A biotinylated anti-CD31 antibody (BD Pharmingen) was used to detect 
vascular endothelial cells (ECs). The anti-CD31 antibody was conjugated to 
either streptavidin-quantum dots (QD) 525 (Invitrogen) or streptavidin-QD585 
(Invitrogen), depending on the emission spectrum of the co-staining used. Co-
stainings were performed with different probes. Biotinylated cyclic Asn-Gly-Arg 
(cNGR) was synthesized as described previously 26 and was used to target 
CD13, a marker of angiogenic activity of vascular endothelium. Biotinylated 
anti-CD105 (R&D Systems) was used as an alternative marker for activated, 
angiogenic endothelium 31, 32. Expression of these markers was scored as being 
absent/low or present. Biotinylated Ephrin-B2 and EphB4 (R&D systems) 
antibodies were used to assess the arterial or venous origin of the microvessels 
in vivo, respectively. Biotinylated antibodies were conjugated with either 
streptavidin-QD525 or streptavidin-QD585 as indicated. 
To examine fluid phase perfusion of vessels as well as microvascular 
leakage, 100-150 µl of 70 kDa or 150 kDa fluorescein isothiocyanate (FITC) 
labelled dextran (1 mg/ml; Sigma) was injected into the tail vein to label blood 
plasma. Imaging was started directly after injection of FITC-dextran and was 
performed up to 60 minutes. In relation to measuring microvascular leakage, 
100µl FITC-labelled wheat germ agglutinin (WGA, 1mg/ml; Sigma) was injected 
to assess the status of the glycocalyx in microvessels. 
For studying blood flow and blood flow velocity, platelets were isolated 
from donor C57Bl/6 mice and labelled with carboxyfluorescein N-succinimidyl 
ester (CFSE, Invitrogen; 5 µg/ml) as described previously 33. Briefly, blood from 
a donor mouse was collected on 0.5 volume parts 5mM Hepes buffer pH 7.14 
containing 20 U/ml heparin, and platelet rich plasma (PRP) was prepared by 
centrifugation at 2,000g for 10 minutes PRP was incubated for 15 minutes at 
room temperature with CFSE. Platelets were then washed and the pellet was 
resuspended in phosphate-buffered saline (PBS) and platelet concentration 
was adjusted to the final concentration. In total, 200 μl of 5.0 x 107 
platelets/ml was injected in the tail vein.  
Additionally, bone marrow derived cells were isolated from the tibia 
and femur from C57Bl/6 control mice, incubated with 1 μM cell tracker red 
(CMTPX, Invitrogen) for 30 min at room temperature, washed and 1.0 x 107 
cells were injected into the tail vein. 
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For in vivo labeling of leukocytes, 20μl of a Rhodamine 6G solution (Sigma,  
1 mg/ml in 0.9% NaCl solution) was injected into the tail vein as described 
previously 34. Imaging was performed directly after injection of Rhodamine 6G 
up to 60 minutes to reduce visualization of non-specific binding of Rhodamine 
6G to e.g. endothelial cells. 
To better assess intraplaque microvascular structures in ex vivo 
experiments, vessels were excised and mounted as described above, before 
incubation with Nile Red (500 μg/mL in HBSS buffer) to stain lipids within the 
plaque. Additionally, nuclear staining was performed in vivo and ex vivo using  
2 μM Syto41 (Invitrogen) for both ex vivo and in vivo imaging. 
 
Multiphoton laser scanning microscopy  
MPLSM imaging was performed on a Leica SP5 imaging platform (Leica 
Microsystems, Germany) that integrates multiphoton microscopy with fast 
resonant scanning, and uses a Compact Ultrafast Ti:Sapphire Laser 
(Chameleon, Coherent, USA). An excitation wavelength of 880nm was used in 
all experiments. Tissues were observed using a 20x 1.0 water immersion 
objective (HCX PL APO L, Leica Microsystems, Germany) with a numerical 
aperture of 1.00 and integrated optical zoom allowing magnification up to 60x. 
Photo-multiplier tubes were used to detect three spectral regions: 420-470 nm 
(Syto41, Second Harmonic Generation (SHG)), 515-560 nm (FITC, CFSE, QD525) 
and 570-600 nm (QD585, CMTPX, Rhodamin 6G, Nile Red).  
Ex vivo image acquisition was performed at a frame size of 512 x 512 
pixels (pixel size: 1.44 x 1.44 μm), scanning at 100Hz and a frame average filter 
of 2 was used to reduce noise. In-depth scans were performed at 200Hz with a 
frame average of 2. Consecutive images had an interplanar distance of  
1.00 μm. 
In vivo MPLSM imaging was performed at a frame size of 400x400 
pixels (pixel size: 1.0882 x 1.0882 μm), scanning at 8000Hz for fast recording 
(20 frames/sec) and using a line average of 2 (10 frames/sec) for more detailed 
scans. Per time series, a total of 500 frames was recorded. After in vivo 
imaging, the animal was sacrificed and additional in situ imaging was 
performed to examine the vessel at higher resolution and an increased signal-
to-noise ratio without motion artifacts. In situ imaging was performed at a 
frame size of 512 x 512 pixels (pixel size 0.847 x 0.847 μm), scanning at 250Hz 
and an interplanar distance of 0.50 μm.  
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Data analysis 
All data analyses, except for microvascular permeability analysis, were 
performed using Image Pro 6.3 (MediaCybernetics). Prior to analysis, all data 
were deconvolved using AutoQuant X2-AutoDeblur (MediaCybernetics) in 3D 
blind deconvolution mode. Microvascular permeability was assessed using 
ImageJ (http://imagej.nih.gov/ij/). 3D rendering was performed using an 
ImageJ plugin for high level 3D visualization 35. The analyzed data sets are 
specified in Supplemental Table II. 
Microvessel diameter was assessed by measuring the maximum 
distance between the opposite sides of the microvessel wall at minimally ten 
separate points per microvessel, from which the median diameter per 
microvessel was calculated. Microvessel diameter was determined for 
intraplaque and adventitial vessels.  
Microvascular permeability was determined by calculating the ratio of 
the extraluminal/intraluminal fluorescence intensity of the FITC-dextrans, and 
corrected for extra- and intraluminal baseline autofluorescence present before 
dextran injection. Extraluminal tissue was defined as the area within 1.5x 
vessel diameter’s distance of the microvessel wall. The mean ratio was 
calculated per time point and plotted. 
 Adhesion of leukocytes to the vessel wall was assessed by tracking ex 
vivo (CMTPX) or in vivo (Rhodamin 6G) labeled cells that remained at the same 
point within the vessels for at least 250 frames (i.e. approximately 30 sec; 
Supplemental Figure I). Adhesion rates were normalized to the microvessel 
surface, which was derived from the microvessel length and microvessel 
diameter. The adjacent sternohyoid muscle capillaries and cremaster muscle 
capillaries served as control microvessels.  
Blood flow velocity was derived from in vivo measurements using both 
ex vivo and in vivo labeled platelets and leukocytes. Movement of single 
platelets or leukocytes was tracked in microvessels during multiple frames and 
average travelled distance per 6 frames (Δt = 0.357 sec) was calculated 
(Supplemental Figure II). Adherent leukocytes were excluded for blood flow 
velocity measurements. Flow speed was then compared to control capillaries 
(sternohyoid muscle capillaries) of similar diameter. Additionally, blood flow 
velocity was determined in the carotid artery, proximal to the plaque, to 
validate the blood flow velocity measurements in the microvessels. For 
determining blood flow velocity in the carotid artery, we used the 
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displacement i.e. track length of single platelets and leukocytes within a single 
frame (Supplemental Figure II-A). Briefly, velocities in both x and y direction 
were determined separately by measuring the displacement in both directions 
in relation to the respective scanning time interval to calculate the total 
velocity of the platelet/leukocyte. Velocities were corrected for the angle 
between the vessel and the imaging plane (Supplemental Figure II-B). 
 
Histology, immunohistochemistry and electron microscopy 
After MPLSM, tissue was harvested, fixed in 1% paraformaldehyde (PFA) and 
embedded in paraffin. From all tissues, 4 μm sections were cut and stained 
with haematoxylin-eosin (HE) to assess general morphology and plaque stage. 
Immunohistochemical stainings for CD31 (Invitrogen) and von Willebrand 
factor (vWf; DAKO) were performed to stain microvessels in the adventitia 
surrounding the atherosclerotic lesion.  
 Also, carotid artery samples were collected on 2.5% glutaraldehyde 
(GTA; Ted Pella, Redding, CA, USA) in 0.1M phosphate buffer (pH=7.6). After 
several washes, tissue fragments were post fixed in 1% osmium tetroxide 
solution, and routinely dehydrated through 100% ethanol, cleared with 
propylene oxide, and embedded in epoxy resin. Ultra-thin sections (70-90 nm) 
were cut on an ultra-microtome, mounted on Formvar (1595 E, Merck)-coated 
75mesh copper grids, and counterstained with uranyl acetate and lead citrate 
before analysis on a Philips CM100 transmission electron microscope. In total, 
lesions from 6 aged ApoE-/- mice were evaluated, with 2-5 microvessels 
examined per lesion. 
 
Statistics 
Data are presented as mean ± SEM, unless stated otherwise. Statistics were 
performed using Graphpad Prism 5.0 or PASW Statistics 18. The non-
parametric Mann-Whitney U-test was applied to adhesion, extravasation and 
blood flow velocity data. Microvascular permeability data were analyzed using 
curve fitting regression analysis. Fisher’s exact test was used for examining 
differences between groups for presence of plaque-associated 
microvasculature. Results were considered statistically different when p < 0.05.
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Results 
 
Vasa vasorum were visualized and morphologically characterized in vivo 
The vasa vasorum were studied in detail using in vivo and in situ MPLSM after 
labeling with anti-CD31, allowing characterization of microvessel morphology 
throughout the adventitia. Characteristics like microvessel diameter were 
similar in the adventitia of the carotid artery and abdominal aorta (Table 1). 
Based on size and orientation, two types of plaque-specific microvessels could 
be discriminated. The larger vasa vasorum microvessels (median diameter: 
18.5 μm) generally ran in parallel to the artery, whereas smaller microvessels 
(median diameter: 5.9 μm) mostly covered the artery radially. The adventitia 
surrounding the atherosclerotic plaque showed several microvessels (Figure 1A 
and 1B, Supplemental Video I and II), which was confirmed by 
immunohistochemistry for CD31 and von Willebrand factor (vWf) 
(Supplemental Figure III). Microvessels in peri-adventitial fat were excluded 
from analysis based on collagen imaging of the adventitia using second 
harmonic generation (SHG) and imaging of autofluorescence of the peri-
adventitial fat. Microvessels were mostly situated within 40-80 μm from the 
outer elastic lamina, but occasionally – at sites of large advanced plaques – 
microvessels would be situated within 15-20 μm from the outer elastic lamina.  
 
 
Table 1. Quantification of microvessel diameter from plaque-associated microvessels in the 
carotid artery and abdominal aorta; ND: not determined 
 Location Median (μm) Range (μm) # of microvessels 
(# mice) 
Carotid artery Intraplaque 6.65 4.42 - 9.02 6 (20) 
 Adventitial (large; >10 µm) 18.5 10.5 - 21.2 71 (39) 
 Adventitial (small; <10 µm) 5.9 5.56 - 6.23 56 (39) 
Abdominal aorta Intraplaque ND ND ND 
 Adventitial (large; >10 µm) 22.7 16.6 - 43.8 8 (8) 
 Adventitial (small; <10 µm) 6.0 2.1 - 16.5 5 (8) 
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Vasa vasorum were exclusively located at atherosclerotic foci around the 
carotid bifurcation, and were neither observed further upstream at the non-
diseased common carotid artery, nor in younger ApoE-/- mice or age-matched 
C57Bl/6 controls (Table 2). Individual ECs (Figure 1C, arrowheads) of the vasa 
vasorum and their nuclei (Figure 1C, arrows) could be delineated. 
 
 
Figure 1. Plaque-associated vasa vasorum of atherosclerotic plaques at the carotid artery 
bifurcation in aged ApoE-/- mice could be detected using MPLSM. 3D rendering of the carotid 
artery directly proximal from the bifurcation and viewed from the luminal side depicts vasa 
vasorum (green, arrows) embedded in adventitial collagen (blue). Plaque autofluorescence in 
green (P) is also visible (A, Supplemental Video 1). Also, when focusing merely on the adventitia, 
the vasa vasorum is clearly detectable (B, green; Supplemental Video 2). In C, single CD31+ (red, 
arrowheads) endothelial cells including nuclei (green, arrow) were detected. When assessing 
arterial/venous lineage of the vasa vasorum, microvessels were found to be predominantly 
arterial in origin as shown by Ephrin-B2 staining (D, red), while the venous marker EphB4 (green) 
was not detectable. Using a cNGR probe (red, inset figure E) to detect angiogenic endothelium, 
angiogenic sprouting from a pre-existing vasa vasorum vessel (green) was detected. CD31+ vasa 
vasorum vessels (red, arrows), as well as new sprouts (CD31low, arrowhead), are actively perfused 
as determined by a FITC-labeled (green) 70 kDa dextran (F). Leakage of dextran into tissue 
surrounding the vasa vasorum could be detected (F, *). Dotted lines indicate the outline of the 
carotid artery, which is situated below the vasa vasorum. Bars indicate 100 μm (A and B) or  
25 μm (C-F). 
CHAPTER 3 
80 
3 
Table 2. Prevalence of vasa vasorum in the carotid artery in the various experimental groups 
 
 Adventitial microvessels 
Genotype Number of mice No Yes % present 
C57Bl/6 20 20 0 0*** 
ApoE-/- (<16 wks) 8 7 1 12.5*** 
ApoE-/- (>40 wks) 51 6 45 88.2 * 
***p < 0.005; Fisher’s exact test; vs. aged ApoE-/- 
 
In vivo measurements displayed a predominantly arterial phenotype of 
the vasa vasorum (Figure 1D), as observed by Ephrin-B2 and EphB4 staining. 
Moreover, upon local or bilateral ligation of the jugular vein for up to 30 
minutes, functional parameters, e.g. microvessel diameter, remained 
unaltered (Supplemental Figure IV), arguing a marginal role of the venous 
system in controlling the vasa vasorum. 
 
Plaque-associated vasa vasorum showed angiogenic activity in vivo  
The particular localization of the microvasculature at sites of plaque formation 
and absence of microvasculature in young atherosclerotic mice, suggests 
angiogenesis to underlie the development of these microvessels. Therefore, a 
cNGR probe targeting the angiogenic marker CD13 and specific for angiogenic 
endothelium upon in vivo injection 26 was used to investigate whether ongoing 
angiogenesis was present. The vasa vasorum showed CD31+/CD13– 
microvessels accompanied by occasional CD31low/CD13+ sprouts (Figure 1E). At 
the site of sprouting, part of the endothelium expressed both CD31 and CD13 
(Figure 1E, inset).  
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Plaque-associated vasa vasorum were actively perfused and hyperpermeable 
As the normal physiology and perfusion of vasa vasorum microvessels were 
unknown, this was assessed by injection of 70 kDa and 150 kDa FITC-dextrans, 
which indicated active perfusion (Figure 1F, green) of the vasa vasorum (red: 
CD31) in vivo. Also, sprouting of new microvessels was observed (Figure 1F, 
arrowhead), with new sprouts displaying low CD31 expression. Additionally, a 
rise in fluorescence intensity, i.e. dextran concentration, in the adventitia was 
observed (Figure 1F, asterisk). 
 
 
Figure 2. Microvascular permeability was calculated from the ratio of the 
extraluminal/intraluminal fluorescence intensity of 70 kDa FITC-dextran. Extraluminal 
fluorescence intensity increased over time, as depicted for t=3 and t=35 minutes after injection 
(A-1 and B-1, respectively) for vasa vasorum, while only a limited increase in fluorescence 
intensity was observed for the control sternohyoid muscle at the same time points (A-2 and B-2, 
respectively). The ratio extraluminal/intraluminal fluorescence intensity was calculated for 
different time points, as shown in a representative plot (C). Over time, the extraluminal presence 
of 70 kDa FITC-dextran increased significantly in the vasa vasorum (black line), but not in control 
microvessels (dotted line). No significant microvascular leakage was observed for 150 kDa 
dextrans in either vessel types (not shown). In plaque-associated vasa vasorum (D), the 
glycocalyx (green: WGA) was present in only a small part of the microvessel (arrow; red: CD31). 
In contrast, the glycocalyx was consistently present in control microvessels in the sternohyoid 
muscle (E). Inter-endothelial junctions in plaque-associated vasa vasorum were however intact 
(F, higher magnification in G; arrows), though the endothelial cells did show signs of membrane 
blebbing (*). Pericytes (P) surrounding the endothelial cells were also found. Dotted line indicates 
the outline of the carotid artery, which is situated below the vasa vasorum; bars indicate 25 μm 
(A-E), 2 μm (F), and 1 μm (G).  
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Concurrently, dextran injection allowed measurement of microvascular 
permeability by calculating the time-dependent rise in extraluminal 
fluorescence intensity compared to intraluminal fluorescence intensity. While 
intraluminal dextran levels remained constant for over 60 minutes, the 
extraluminal content of 70 kDa dextran increased with time to an 
extraluminal/intraluminal ratio of approximately 0.46 after 35 minutes in 
plaque-associated vasa vasorum (Figure 2A-1 and 2B-1). Since vasa vasorum, in 
accordance with literature 19, 36, was not observed in non-diseased arteries, we 
used the similar sized microvasculature of the nearby sternohyoid muscle as a 
control. In the sternohyoid muscle, only a limited increase in extravascular 
dextran concentration was observed (Figure 2A-2 and 2B-2). Upon 
quantification, extravascular dextran concentration (Figure 2C, black line, 
p<0.05) was significantly increased only in vasa vasorum, but not in control 
microvessels (Figure 2C, dotted line), indicative of enhanced microvascular 
permeability in the vasa vasorum. Additionally, extravasation of 70 kDa 
dextran occurred earlier in vasa vasorum compared to control microvessels 
(Figure 2C). Due to myocyte autofluorescence, baseline extra-/intraluminal 
fluorescence ratios varied slightly, however all experiments showed an 
identical pattern of significantly increased microvascular permeability of the 
vasa vasorum (p < 0.05). Of note, microvascular extravasation of 150 kDa 
dextran did not significantly increase over time, neither in the vasa vasorum 
nor in control microvessels (not shown). 
A size-dependent increase in permeability could be caused by several 
mechanisms. It is known that reduction or absence of endothelial glycocalyx in 
microvessels can, independently from the inter-endothelial junctions, lead to 
increased permeability and leukocyte adhesion37. In addition, disruption of the 
endothelial barrier may cause hyperpermeability. To determine what caused 
the increased permeability, we examined glycocalyx integrity by Wheat Germ 
Agglutinin (WGA) staining and analyzed the integrity of the inter-endothelial 
junctions by electron microscopy. Staining for WGA in vivo showed an irregular 
staining pattern in the vasa vasorum (Figure 2D), contrary to an evenly 
distributed expression of glycocalyx throughout control microvessels in the 
sternohyoid muscle (Figure 2E; Supplemental Figure V).  
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Figure 3. Cellular perfusion of vasa vasorum in aged ApoE-/- mice. In A, vascular endothelium 
(red), cellular perfusion (green; arrow) and elastin autofluorescence (green) of the carotid artery 
is also visible. Leukocytes (B; red) adhered to (yellow arrow) or extravasated from (white arrow) 
the vasa vasorum (B; green). Dotted lines indicate the outline of the carotid artery, situated 
below the vasa vasorum; bars indicate 25 μm. Leukocyte velocity in vasa vasorum (black bars, C) 
is significantly reduced compared to control microvessels (white bars, C). Blood flow in vasa 
vasorum is also significantly lower than in control microvessels (D).  
 
The inter-endothelial junctions were intact as shown by EM (Figure 2F 
and 2G; arrows), and occasionally, pericytes (P) were found covering the 
microvascular endothelium. The ECs did however show initial signs of 
membrane blebbing, indicative of early endothelial dysfunction. 
 
Plaque-associated vasa vasorum showed decreased blood flow, yet an 
increased adhesion and extravasation of leukocytes 
Leukocytes were observed within the vasa vasorum after in vitro (Figure 3A) 
and in vivo (Figure 3B) labeling. Using labeled leukocytes and platelets, blood 
flow velocity and blood flow were assessed in the carotid artery, vasa vasorum 
and control microvessels. Both blood flow velocity (2.1 fold decrease,  
p < 0.001; Figure 3C, Supplemental Table I) and blood flow (7.6-9.8 fold 
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decrease, p < 0.001; Figure 3D) were significantly reduced in vasa vasorum 
compared to control microvessels. Changes in blood flow and flow velocity 
were independent of microvessel diameter. Blood flow direction was identical 
to the main artery.  
 
 
Figure 4. In aged ApoE-/- mice, adhesion and extravasation was significantly increased in vasa 
vasorum compared to control microvessels of similar diameters (A and B). This is accompanied 
by decreased blood flow (see Figure 3C and 3D). 3D reconstruction (C and D) of in situ z-scan 
showed adhering (yellow arrow) and transmigrated cells (white arrows), as well as cells in the 
progress of transmigration through the microvessel wall (yellow arrowheads). MPLSM allowed 
differentiation of morphologically distinct cell types, e.g. pseudopodia-rich cells resembling a 
dendritic morphology (white arrowheads). Dotted line indicates arterial vessel wall at the site of 
the plaque, bars indicate 25 μm. 
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Additionally, adhesion and transmigration of ex vivo and in vivo labeled 
leukocytes were significantly increased compared to control microvessels 
(Figure 4). Increased adhesion (Figure 4A, 1.3x10-2 ± 0.3x10-2 vs. 0.2x10-2 ± 
0.1x10-2 cells/mm2/min, p < 0.05) and extravasation (Figure 4B, 1.8x10-2 ± 
0.4x10-2 vs. 0.3x10-2 ± 0.2x10-2 cells/mm2/min, p < 0.05) of leukocytes was 
observed in plaque-associated vasa vasorum and control microvessels, 
respectively. Leukocyte adhesion and extravasation was examined in more 
detail ex vivo, using 3D image analysis. Cell morphology suggested 
transmigration of different leukocyte subtypes, including pseudopodia-rich 
cells resembling a dendritic cell morphology, from the vasa vasorum towards 
the plaque (Figure 4C and 4D, Supplemental Video III).  
 
Ex vivo MPLSM confirmed presence of vasa vasorum and intraplaque 
microvascular structures 
Plaque-associated vasa vasorum were also imaged ex vivo, allowing imaging at 
higher resolution and signal-to-noise ratio without motion artifacts. For ex vivo 
imaging, the carotid artery or abdominal aorta was excised, mounted in a 
perfusion chamber and imaged under a transmural pressure of 80 mmHg to 
mimic physiological conditions 24. Ex vivo imaging was performed up to 30μm 
from the outer elastic lamina. Vasa vasorum were detected both in the carotid 
artery and abdominal aorta (Table 1).  
Ex vivo imaging clearly visualized intraplaque microvascular structures 
(Supplemental Figure VI-A and VI-B), yet intraplaque microvessels were only 
found in 6 out of 20 plaques (Supplemental Table III). Surprisingly, none of 
these microvessels derived from the vasa vasorum. Rather, data suggested 
that these microvessels originated from endothelial sprouting from the luminal 
endothelial layer (3 out of 6 plaques; Supplemental Figure VI-C). No functional 
characteristics could be determined for intraplaque vessels, arguing a limited 
role for intraplaque microvessels in this model. Also, occurrence of intraplaque 
hemorrhage (IPH) was determined in aged ApoE-/-, and was found in 4 out of 
20 (20%) mice examined. Although all mice which showed IPH, also showed 
vasa vasorum, only a minor fraction of vasa vasorum containing plaques 
showed features of IPH. Occurrence of IPH could not be linked to occurrence of 
luminal microvascular structures. 
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Discussion  
 
The presence and role of plaque-associated microvessels in murine plaques 
has been extensively debated in literature. Previous attempts to detect these 
microvessels yielded varying results, in part depending on the animal model 
and visualization techniques used. Here, we used in vivo MPLSM to show that 
plaque-associated vasa vasorum (I) are present in ApoE-/- mice; (II) show 
angiogenic activity; (III) are actively perfused and hyperpermeable; (IV) have 
significantly reduced blood flow and blood flow velocity compared to control 
microvessels with similar diameter, and (V) show enhanced leukocyte adhesion 
and transmigration at the site of the atherosclerotic plaque. Taken together, 
we show that plaque-associated microvessels exhibit functional features which 
could facilitate plaque development and progression. 
The increased adhesion of leukocytes may, in part, be a consequence 
of the reduction in blood flow velocity, since this would cause a reduction in 
local shear stress at the microvascular wall. Consequently, low shear stress is 
deemed to cause endothelial cell dysfunction and upregulation of adhesion 
molecules like VCAM-1 and ICAM-1 38-40. The increased leukocyte adhesion was 
accompanied by augmented transmigration to the adventitial tissue, 
facilitating a second site of ingress of leukocytes, besides migration through 
the luminal endothelium. These cells may contribute to further plaque 
development, either by functioning in the adventitia itself, or by infiltration 
into the plaque after migrating through the media. As such, the vasa vasorum 
could contribute to exacerbation of atherosclerosis, by infiltration of new 
inflammatory cells 41.  
Additionally, vasa vasorum hyperpermeability may be another 
important contributor to plaque progression, as it favors extravasation of lipids 
and plasma proteins at sites of plaque development 42. Increased permeability 
may be attributed to disruption of the endothelial barrier function 10. Our 
finding of augmented microvascular extravasation in the vasa vasorum, at least 
for molecules with a molecular weight of up to 70 kDa suggests that abundant 
plasma proteins, such as albumin, can leak into the adventitia. Indeed, 
extravascular albumin has been detected in both human and mouse 
atherosclerotic lesions 43, 44. Here, we extend these findings, demonstrating an 
apparent size limit for endothelial leakage in vasa vasorum of 70-150 kDa in 
vivo in aged ApoE-/- mice. The origin of the microvascular hyperpermeability 
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remains to be further elucidated. EM did not show any aberrations in 
endothelial cell junctions, concordant with a recent study from Eriksson 36. 
However, the endothelial glycocalyx of plaque-associated vasa vasorum was 
disrupted, indicating a possible cause for the increase in vascular permeability, 
and more specifically, permeability for smaller molecules. Both the increased 
leukocyte extravasation and hyperpermeability will affect plaque development 
and progression, especially when plaques become more advanced and vasa 
vasorum has expanded by increasing adventitial inflammation. As such, these 
processes could enhance plaque progression independent of microvascular 
disruption and hemorrhage.  
Vasa vasorum were abundantly present at sites of atherosclerotic 
plaques, sites at which we also observed an increase in vessel wall thickness 
(not shown). Thickening of the vessel wall may infer an increase in 
vascularization, since oxygenation of the entire tissue is hindered by vessel 
wall thickening, potentially increasing local hypoxia. Remarkably, although the 
entire carotid artery was examined, we did not observe any vascularization of 
non-atherosclerotic segments, neither in control animals nor in the young or 
aged ApoE-/- mice. This is consistent with reports by e.g. Gräbner et al 45 and  
Eriksson 36. Given the fact that vasa vasorum was absent in non-atherosclerotic 
segments, we chose the sternohyoid microvasculature as a substitute model 
for general microvascular blood flow. Taken together, development of vasa 
vasorum in ApoE-/- mice appears to be an adaptive response to pathological, 
atherosclerosis-induced vessel wall changes. 
Many studies have suggested a role for angiogenesis in atherosclerosis. 
Pro-atherogenic effects of increased angiogenesis and anti-atherogenic effects 
upon decreased angiogenesis have been described in models of 
pharmacological stimulation or inhibition of angiogenesis 18, 19, 46, as well as in 
certain animal models, e.g. the collagen-XVIII/ApoE double knock-out  
mouse 15. Here, presence of CD13+/CD31low sprouts in the adventitia 
substantiates the presence of ongoing angiogenesis. The reduced expression of 
CD31 is in accordance with studies which have shown that both embryonic 
stem cells and mature ECs show reduced expression of CD31 during 
endothelial differentiation, migration and proliferation 47, 48. It is however 
surprising that the plaque-associated vasa vasorum showed an almost 
exclusively arterial phenotype, which is in contrast to the model suggested by 
Eriksson 36. Possibly, this is attributable to differences in experimental setup, as 
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the current study was performed on mice without a diet and at a younger age 
than the mice used by Eriksson, resulting in a less developed vasa vasorum. On 
the other hand, it should be noted that Ephrin-B2 is known to be expressed on 
angiogenic endothelium, and therefore could account for the increased Ephrin-
B2 staining. However, since there was no response to venous ligation, it is 
conceivable that the vasa vasorum in fact may drain on the carotid artery, 
acting comparable to an arterial shunt. This would explain the low flow, which 
could be a consequence of a small pressure gradient over the vasa vasorum, 
although the latter may also be influenced by pulsation caused by systolic and 
diastolic phases of the cardiac cycle.  
 Whereas plaque-associated microvessels were primarily located in the 
adventitia surrounding the atherosclerotic lesion, vessel-like structures were 
sporadically detected within the plaque itself (Supplemental Table II). 
Surprisingly, these structures did not originate from the vasa vasorum, since 
microvessels did not traverse the media. These findings oppose observations in 
human plaques 8. Of note, incidental sprouting from the luminal endothelium 
was observed, yet these intraplaque vascular structures did not seem to be 
functionally perfused in vivo. Lucerna et al showed that overexpression of 
vascular endothelial growth factor (VEGF) in mice led to more luminal 
invaginations, accompanied by an increased leukocyte influx into the plaque 13. 
Therefore, intraplaque microvascular structures, even when originating from 
the lumen, may contribute to the progression of atherosclerotic plaques in 
mice. Additionally, intimal microvessels are suggested to be causal for IPH, 
although no causal link between IPH and plaque vascularization could be 
discerned. The observed occurrence of IPH was within the range described in 
e.g. the studies from Rosenfeld 49, Calara 50, and Johnson 51, which however 
show a large variation in the occurrence of IPH (3.6-75%). Generally, proof of a 
causal relationship between vascularization and intraplaque hemorrhage is 
lacking in murine models, which is substantiated by our current study. The 
data however are suggestive for a contribution of vasa vasorum to IPH, or 
plaque instability in general, although vasa vasorum presence does not infer 
occurrence of IPH.  
Even though this murine model does not completely mimic human 
atherosclerosis, as it only shows a limited, yet consistent occurrence of 
(intraplaque) vascularization, it provides new insights into the potential role of 
vasa vasorum in human atherosclerosis. Importantly, a number of features 
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found in our study are consistent with previous studies in human 
atherosclerosis. For example, human plaque microvessels have been 
associated with ingress of leukocytes and erythrocytes and with leakage of 
albumin 2. In this study, we established increased leukocyte adhesion and 
extravasation from adventitial microvessels, as well as an increased 
permeability of microvessels for 70 kDa dextrans, resembling albumin leakage 
in human atherosclerosis. Interestingly, and in contrast to our model, human 
plaque microvessels generally seem to have a more instable microvascular 
phenotype and show disrupted inter-endothelial junctions 10, especially in 
intraplaque microvessels. Hence, it would be interesting to investigate 
functional features of plaque neovascularization in other murine models, 
which have already described intraplaque microvessels or more extensive vasa 
vasorum expansion 15, 52.  
In summary, using a novel in vivo imaging strategy we were able to 
study plaque-associated microvessels in mice and quantify its functional 
characteristics. The plaque-associated vasa vasorum demonstrated a 
significantly reduced blood flow, blood flow velocity, as well as an increase in 
leukocyte adhesion, leukocyte transmigration and endothelial permeability as 
compared to control microvasculature. In conjunction with the ongoing 
angiogenic activity, these features would support progression of 
atherosclerotic lesions. Further studies will help to unravel by which means 
microvascular function in the vasa vasorum may be normalized.  
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Supplemental Tables & Figures  
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Supplemental Table II. Prevalence of intraplaque microvessels observed ex vivo in the carotid 
artery in the various experimental groups  
 
P = 0.1412; Fisher’s exact test; young vs. aged ApoE-/- ___         
 
 
 
 
 
Supplemental Table III. Quantification of the average blood flow velocity and accompanying 
average microvessel diameter of vasa vasorum and control microvessels of similar diameter 
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Supplemental Figure I. Occasional adhesion of leukocytes (red), defined as cells showing the 
same localization >30 seconds at identical focal planes, to the vessel wall (green) was observed 
(yellow arrows; A-C, Δt=6 frames). In a different focal plane, extravasated leukocytes could be 
detected (white arrows; D). Bars indicate 25 μm. 
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Supplemental Figure II. High speed imaging at 8000Hz allows recording and calculation of blood 
flow velocity in both larger vessels (A and B) and microvessels (C). In the carotid artery, blood 
flow velocity can be derived from the distance that e.g. leukocytes or platelets travel during 
image acquisition (A), taking into account differences in delay time in the x- and y-direction 
during imaging (inset) and the angle of imaging compared to the angle of the vessel (B). Dotted 
arrow indicates flow direction. For microvessels, which exhibit lower blood flow velocity, the 
distance travelled can be determined between two frames (C-1 and C-2, Δt=60 ms).  
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Supplemental Figure III. Presence of adventitial microvessels surrounding the plaque was 
confirmed by immunohistochemistry. Both CD31 (A) and vWf (B) were able to detect vasa 
vasorum vessels (arrows). 
 
 
 
 
 
 
Supplemental Figure IV. No changes in microvascular diameter were observed after bilateral 
ligation of the jugular vein (17.56 ± 0.55 μm before, 17.63 ± 0.38 μm after ligation) arguing a lack 
of venous connections of the plaque-associated vasa vasorum. 
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Supplemental Figure V. WGA-FITC staining in sternohyoid muscle showing constitutive 
expression of WGA (A, green) in the microvessels of the muscle (B, red).  
 
 
 
 
 
 
Supplemental Figure VI. Microvascular structures (red) were detected inside plaques (green, 
nuclei (A and B); lipids (C)) of aged ApoE-/- mice. Intraplaque vessels ranged from short sprouts 
(A) to more extensive vascular structures within the plaque (B). The intraplaque vessels were 
present in 6 out of 20 examined plaques, and seemed to originate predominantly from the 
luminal endothelium (C, arrow). Dotted line outlines the outer perimeter of the plaque. Bars 
indicate 25μm, “L” indicates the lumen of the carotid artery. 
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Supplemental Video Files  
 
Supplemental Video 1  
Link at: 
http://atvb.ahajournals.org/content/suppl/2012/12/13/ATVBAHA.112.300087.DC1/ATV201659.Video1.avi 
 
3D rendering showing the carotid artery, directly proximal from the bifurcation. Blue depicts 
collagen as determined by SHG, green depicts CD31 (adventitia), as well as plaque 
autofluorescence (within the artery). Box size: 738 x 738 x 235 μm3.  
 
 
Supplemental Video 2 
Link at: 
http://atvb.ahajournals.org/content/suppl/2012/12/13/ATVBAHA.112.300087.DC1/ATV201659.Video2.avi  
 
In vivo MPLSM imaging of the vasa vasorum network (green) surrounding the carotid artery at 
the atherosclerotic plaque. Vasa vasorum network was located approximately 15-20 µm from 
the outer elastic lamina. Box size: 434 x 434 x 110 μm3.  
 
 
Supplemental Video 3 
Link at: 
http://atvb.ahajournals.org/content/suppl/2012/12/13/ATVBAHA.112.300087.DC1/ATV201659.Video3.avi 
 
3D reconstruction (A and B) of in situ z-scan showing leukocytes (red) adhering to and 
extravasated from the vasa vasorum (green), as well as cells in the process of extravasation. 
MPLSM allowed differentiation of morphologically distinct cell types, e.g. pseudopodia-rich cells 
resembling a dendritic morphology. Box size: 140 x 140 x 130 μm3. 
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Abstract 
 
Junctional adhesion molecule (JAM)-A is an immunoglobulin superfamily 
protein mainly located at endothelial cell junctions. Engaging in homophilic 
and heterophilic interactions, JAM-A plays an important role in regulating 
endothelial permeability, and inflammatory and atherogenic leukocyte 
extravasation. Little is known about the contributions of endothelial JAM-A to 
atherogenesis and the underlying mechanisms.  
Here, we show that impaired JAM-A expression due to genetic deletion 
in endothelial cells reduced atherosclerotic lesion formation, lesional T cell 
content, and macrophage content in Apolipoprotein-E deficient (ApoE-/-) mice. 
Multiphoton laser scanning microscopy of atherosclerotic carotid arteries ex 
vivo revealed a focal concentration and redistribution of endothelial JAM-A to 
the luminal surface in lesion-prone areas or under conditions of disturbed 
flow. Deficiency in endothelial JAM-A furthermore reduced leukocyte 
recruitment in vivo by approximately 50%. Endothelial barrier function as 
measured by permeability to 70 kDa and 150 kDa dextran was unaffected by 
endothelial JAM-A deficiency.  
Our data identified specific and targetable functions of endothelial  
JAM-A in atherosclerosis, which were mediated by its upregulation and 
redistribution under atherogenic conditions, which in turn facilitated enhanced 
leukocyte recruitment. 
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Introduction 
 
Junctional adhesion molecule (JAM)-A, a member of the immunoglobulin (IgG) 
superfamily, displays a wide variety of functions in cell polarity 1 and barrier 
function via homophilic interactions 2, stem cell adhesion and differentiation 3, 
as well as leukocyte trafficking and recruitment 4. JAM-A is located mainly in 
the junctions of endothelial cells (ECs) and epithelial cells, but is also expressed 
by leukocytes and CD34+ cells 5. In particular, JAM-A mediates the adhesion 
and transmigration via heterophilic interactions with the αLβ2 integrin  
LFA-1 6-8. Furthermore, dendritic cell trafficking to the lymph nodes is increased 
in mice with somatic but not endothelial JAM-A deficiency, indicating a specific 
role in dendritic cell migration 9. Additional findings demonstrated a role of 
leukocyte JAM-A in promoting de-adhesion 10. In the absence of JAM-A, the 
directional motility of neutrophils was reduced, leading to incomplete 
transmigration with neutrophils stuck between the endothelial cell layer and 
the basement membrane 11. Whereas endothelial JAM-A has been implicated 
in the sequential steps mediating stimulus-specific neutrophil  
transmigration 12, recent data confirm that JAM-A on neutrophils can promote 
their chemotaxis by controlling integrin internalization and recycling 10. 
Amongst the intracellular interactions of endothelial JAM-A, binding to the PDZ 
domain protein ZO-1 is important in facilitating anchorage to the  
cytoskeleton 13. Upon co-stimulation with cytokines, endothelial JAM-A is 
redistributed to the luminal surface 14, 15 and specifically to the site of 
leukocyte transmigration as part of lateral border recycling compartments 16. 
Convincing evidence has recently emerged from various models to 
indicate that JAM-A-mediated leukocyte transmigration plays an important 
role in inflammatory disease. For example, JAM-A-deficient mice displayed 
reduced leukocyte infiltration in models of peritonitis, as well as in hepatic and 
myocardial ischemia-reperfusion injury in liver 11, 17. In models of vascular 
disease, somatic JAM-A deficiency is shown to protect against neointimal 
hyperplasia after wire-injury of the carotid artery in ApoE-/- mice 18. 
Accordingly, increased levels of JAM-A transcripts and protein have been 
demonstrated in human plaque biopsies and in atherosclerotic aortas of  
mice 19. The expression of JAM-A on inflamed and early atherosclerotic 
endothelium has been implicated in the recruitment of mononuclear cells 
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through an inhibition with soluble JAM-A, suggesting a functional involvement 
in atherogenesis 20. 
However, little is known about the direct influence and effect of JAM-A 
deficiency in atherosclerosis. Given the differential effects of JAM-A deficiency 
on various cell types relevant in atherosclerosis, the cell-specific contributions 
of JAM-A to atherosclerotic lesion formation and inflammatory phenotype is of 
particular interest. In this study, the role of endothelial JAM-A in 
atherosclerosis is  delineated, using ApoE-/- mice with an inducible, endothelial 
cell-specific deficiency in JAM-A. We demonstrate that endothelial JAM-A is 
crucial in promoting atherosclerotic lesion formation. Endothelial JAM-A is 
redistributed as a result of disturbed flow, and facilitates leukocyte migration 
into the plaque. 
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Methods 
 
Atherosclerotic mouse models with endothelial JAM-A depletion  
A genetic reduction of endothelial JAM-A was achieved by crossing JAM-Afl/fl 
ApoE-/- mice with VeCad CreRT2 mice (both C57Bl/6) to obtain VeCad CreRT2 
JAM-Afl/fl ApoE-/- mice (17072878). At an age of 3 weeks, 5 daily i.p. injections 
of the estradiol analog tamoxifen (0.04 mg/g bodyweight) dissolved in miglyol 
(number 812) were administered to Cre+ deletion (eJAM-A-/- ApoE-/-) and to 
Cre- control (eJAM-A+/+ApoE-/-) mice. Genetic depletion of JAM-A was checked 
via flow cytometry analysis after 2 weeks, resulting in a ±30% reduction in 
endothelial JAM-A, but with no difference in leukocytic JAM-A levels in Cre+ 
mice compared to control Cre- mice. At comparable ages, female littermates 
were subjected for 12 weeks to atherogenic diet (21% fat, 0.15% cholesterol, 
Altromin) with subsequent sacrifice for quantification of atherosclerotic lesion 
formation. Animal experiments were approved by local authorities and 
complied with the German animal protection law (Landesamt für Natur, 
Umwelt und Verbraucherschutz Nordrhein-Westfalen, Recklinghausen, 
Germany).  
 
Quantification and immunohistochemical analysis of atherosclerosis  
The extent of atherosclerosis was assessed in aortic roots and on 
thoracoabdominal aortas by staining according to Elastica Van Gieson protocol 
(EVG) and for lipid depositions with oil red O (ORO), respectively, 21 and was 
quantified by computerized image analysis (Diskus Software, Hilgers) and Leica 
Qwin Imaging software. Briefly, atherosclerotic lesions of aortic roots were 
measured in 5μm transverse paraffin sections through the heart and the aortic 
roots. The thoracoabdominal aorta was opened longitudinally and prepared en 
face, and the percentage of lipid deposition was calculated by dividing the 
stained area by the total thoracoabdominal aortic surface. The relative content 
of macrophages and CD3+ T cells 21 in the aortic root lesions was determined by 
mAb staining for MAC-2, CD3 (both AbD Serotec), and detection with FITC and 
Cy3-conjugated antibody (both Jackson ImmunoResearch Laboratories Inc.). 
Nuclei were counterstained by DAPI. Images were recorded with a Leica DMLB 
fluorescence microscope and CCD camera. 
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In vitro and in vivo monocyte transmigration assays 
CD14+ human monocytes and CD115+ mouse monocytes were freshly isolated 
from blood from healthy volunteers or from spleens of mice with desired 
genetic modification, respectively, for every experimental series using the 
Monocyte Isolation Kit II or the CD115 MicroBead Kit mouse (Miltenyi). Human 
monocytes at a concentration of 7.0x105 cells/ml were applied on Human 
Aortic Endothelial Cells (HAoECs) under shear stress (1.5 dyn/cm2) using a 
syringe pump (WPI) in a laminar flow chamber for 5 minutes and flushed with 
assay medium for 30 minutes, while time lapse were recorded (Olympus, CellM 
system and software). Mouse monocytes at a concentration of 2 x 106 cells/ml 
were applied on stimulated mouse ECs under shear stress (0.8 dyn/cm2, 
BioFlux 200) for 10 minutes and flushed with assay medium for 30 minutes, 
while time lapse images were recorded. Monocytes showing complete 
transmigration were counted and related to adherent monocytes. 
Right carotid arteries of eJAM-A-/- and eJAM-A+/+ mice after treatment 
with tamoxifen were challenged 24 hours in vivo with IL-1β (2 µg/ml, 
BioLegend) carried by a periarterial slowly degrading pluronic gel to induce 
enhanced monocyte recruitment. Additionally, Alexa568-coupled anti-CD115 
antibody (5 µg/mouse, eBioscience) was administered intravenously. On the 
next day, anaesthetized mice were injected intravenously with anti-CD31 
antibody (35 µg/mouse total, BD Bioscience) and subsequently prepared for in 
vivo MPLSM by exposing the common carotid artery by dissection.  
 
Multiphoton microscopy of the carotid artery in vitro and in vivo 
MPLSM imaging was performed on a Leica SP5 imaging platform (Leica 
Microsystems) that integrates multiphoton microscopy with fast resonant 
scanning, and uses a Compact Ultrafast Ti:Sapphire Laser (Chameleon, 
Coherent, USA). An excitation wavelength of 810 nm was used in all 
experiments. Tissues were observed using a 20x NA 1.0 water immersion 
objective (HCX PL APO L, Leica Microsystems, Germany) with a numerical 
aperture of 1.00 and an integrated optical zoom mechanism allowing 
magnification up to 60×. Photo-multiplier tubes (PMT) were used to detect 
three spectral regions: PMT1: 400-470 nm for second harmonic generation 
(SHG); PMT2: 500-565 nm (FITC or Alexa488) and PMT3: 565-605 nm (PI, PE 
and Alexa568). In vivo MPLSM imaging was performed at a frame size of 400 x 
400 pixels (pixel size: 1.0882 x 1.0882 μm), scanning at 8000 Hz for fast 
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recording (20 frames/sec) and using a line average of 2 (10 frames/sec) for 
more detailed scans. Per time series, a total of 500 frames was recorded. After 
in vivo imaging, the animal was sacrificed and additional in situ imaging was 
performed to examine the vessel at higher resolution and an increased signal-
to-noise ratio without motion artifacts. In situ imaging was performed at a 
frame size of 512 x 512 pixels (pixel size: 0.847 x 0.847 μm), scanning at 200 
Hz, and an interplanar distance of 1.00 μm. 
Newly dissected plaque-prone and partially ligated 22 carotid arteries 
were carefully mounted in a perfusion chamber and imaged using an Olympus 
FV1000MPE multiphoton system coupled to an Olympus BX61WI microscope. 
Therefore, mounted carotids were flushed and direct conjugated JAM-A-
Alexa488 (10 µg/ml, AbD serotec) and CD31-PE (2 µg/ml, BD) antibodies were 
luminally applied under physiological pressure for 1h. After thorough washing, 
the vessel was pressurized again. Excitation laser (MaiTai HP) was tuned at 800 
nm to visualize the fluorophores and SHG of collagen. An Olympus 20x (NA 
0.95; water immersion) objective was used. An increase in magnification was 
achieved by internal optical zoom. For detection of emitted fluorescent signals, 
3 PMTs were tuned as described above, ensuring minimal bleed-through. 
Separate images of 1,024×1,024 pixels were obtained from each PMT and 
combined into single RGB images. Images were collected in xy directions, and 
series of xy images were obtained at successive 1 μm depth positions (z-stack) 
for reconstruction of 3D images. Image analysis was performed using Image-
Pro Analyzer 7.0 (Media Cybernetics) and MetaMorph (Molecular Devices). 
 
Measurement of vessel wall permeability 
Dissected carotid arteries from C57Bl/6, ApoE-/- on a chow or Western type 
diet, or VeCad CreRT2 JAM-Afl/fl ApoE-/- (eJAM-A-/-ApoE-/-) on a Western type 
diet were mounted in a perfusion chamber and incubated with 70kDa dextran 
coupled to rhodamine-B and 150 kDa dextran coupled to FITC, 0.35 mg/ml 
each, for one hour under exact 60 mmHg pressure. Control carotids were also 
co-incubated with 50 µM histamine. After subsequent defined washing of the 
vessels z-stacks were taken with an Olympus FV1000MPE multiphoton system 
coupled to an Olympus BX61WI microscope. All microscope setting were left 
unaltered throughout all measurements, besides 830 nm wavelength being 
used for rhodamine-B excitation and 800 nm wavelength being used for FITC 
excitation. Evaluation was performed using Image-Pro Analyzer 7.0 (Media 
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Cybernetics), therefore regions of interest comprising the area between 
internal elastic lamina and intermediate elastic lamina and between 
intermediate elastic lamina and external elastic lamina were determined and 
fluorescent intensities were calculated from desired channels 23.   
 
Statistical Analysis 
Statistical analysis was performed using Prism 4.0 (GraphPad Software). Data 
were compared either by paired or unpaired Student’s t-test or by 1-way 
ANOVA with Newman–Keuls post test. Differences with at least  
p < 0.05 were considered as statistically significant. 
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Results  
 
Deficiency in endothelial JAM-A protected mice against atherosclerosis and 
reduced inflammatory cell content in lesions 
The inhibition of mononuclear cell recruitment by soluble JAM-A has 
implicated JAM-A in atherogenesis 20; however, owing to its pleiotropic 
functions the cell-specific functions of JAM-A have remained elusive. Genetic 
deficiency in endothelial JAM-A significantly reduced diet-induced lesion area 
in the thoracoabdominal aorta (Figure 1A) and aortic root (Figure 1B) of 
tamoxifen-treated VeCad-CreRT2JAM-Afl/flApoE-/- (eJAM-A-/- ApoE-/-) mice, as 
compared to their Cre- (eJAM-A+/+ApoE-/-) littermates (Figure 1C, D), 
demonstrating a remarkable role of JAM-A on endothelial cells in promoting 
atherosclerosis.  
As analyzed by immunohistochemistry, deficiency in endothelial JAM-A 
significantly decreased macrophage content, as compared to Cre- controls with 
intact endothelial JAM-A (Figure 1E). As a hallmark for early lesion formation, 
we next analyzed the content of CD3+ T cells. Consistent with the macrophage 
content, mice with endothelial deficiency in JAM-A displayed a reduced 
content of CD3+ T cells (Figure 1F). Taken together, endothelial JAM-A 
deficiency on atherosclerotic lesion formation was associated with 
corresponding changes in inflammatory cell content, which likely give rise to 
lesion extent and composition. 
 
Redistribution and focal concentration of endothelial JAM-A in lesion-prone 
areas 
Previous analysis of murine atherosclerotic arteries and plaque tissue revealed 
an increase in JAM-A expression compared to healthy murine arteries 19, 20. We 
used ex vivo MPLSM in unfixed and intact carotid arteries of ApoE-/- mice to 
specifically label JAM-A and to determine its distribution in plaque-prone 
vessels as an underlying mechanism of atherogenic leukocyte recruitment. 
Non-atherosclerotic tissue in the common part of the carotid artery explanted 
from 1 year old ApoE-/- mice on normal chow showed a mesh-like junctional 
pattern of JAM-A expression in luminal endothelial cells (Figure 2A, left panel). 
Collagen was rendered visible by SHG. In contrast, segments near the 
bifurcation, which are prone to atherosclerotic lesion formation due to  
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Figure 1. Endothelial JAM-A deficiency reduced plaque size and showed a concomitant 
reduction in macrophages and T cells. Representative images of the thoracoabdominal aorta (A) 
and the aortic root (B) of ApoE -/-eJAM-A+/+ and ApoE-/-eJAM-A-/- mice are shown. Atherosclerotic 
lesions of ApoE-/-eJAM-A-/- showed smaller plaques compared to ApoE-/-eJAM-A+/+ mice as 
depicted by quantification of the ORO+ area in the thoracoabdominal aorta (C), and internal EVG- 
area in the aortic root (D). In addition, the percentage of MAC-2+ macrophages (E) and CD3+ T 
cells (F) was reduced in the aortic root lesions of ApoE-/-eJAM-A-/- mice. Data represent mean ± 
SEM of individual data points depicting averaged plaque size of single slices (n=4 and higher).  
 
A B 
C D 
E F 
ApoE-/-eJAM-A+/+
ApoE-/-eJAM-A-/-
ApoE-/-eJAM-A-/- ApoE-/-eJAM-A+/+
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disturbed flow, displayed redistribution and focal concentration of JAM-A away 
from endothelial cell junctions (Figure 2A, right panel). The middle panel shows 
the transition zone between non-atherosclerotic segments with a normal 
junctional JAM-A pattern (left part) and focal accumulations of JAM-A in the 
shoulder region of a lesion (right part). To comparatively assess the early 
propensity of JAM-A to focally redistribute during lesion formation, we 
performed co-staining with PECAM-1 (CD31) as another junctional protein 
expressed in endothelial cells (Figure 2B). In carotid arteries of ApoE-/- mice fed 
a high-fat diet for 6 weeks, typical examples of co-staining for JAM-A and CD31 
in the non-diseased common part and the plaque-prone areas near the 
bifurcation are shown. Using MetaMorph software, percentage of  
JAM-A+/CD31+ junctions in non-diseased areas was determined (Figure 2C). 
The bifurcation prone to nascent atherosclerotic lesion formation revealed a 
significant decrease in junctional co-localization of JAM-A and CD31 (72.8±8.4% 
of control, n=5), implying preferential redistribution of JAM-A compared to 
other junctional proteins, such as CD31.  
To address whether focal accumulations of endothelial JAM-A are 
indeed located at the luminal surface of endothelial cells or between 
endothelial cells and the basement membrane, we created 3D models based 
on z-stacks of non-diseased and plaque-prone tissues (Supplemental Figure I). 
Transversal sections of healthy vessels revealed continuous JAM-A expression 
(green) partly co-localized (yellow) with CD31 (red) stably at the level of 
endothelial cell nuclei (blue, right panel). In contrast, transversal sections of 
plaque-prone segments displayed a dotted pattern of JAM-A (green) located 
luminally of endothelial cell nuclei (left panel).  
 
Disturbed flow caused JAM-A redistribution 
Because the increased susceptibility to lesion formation in areas near the 
bifurcation is related to altered flow conditions, e.g. low or oscillatory flow, we 
tested whether such aberrant flow conditions as induced by partial ligation of 
the carotid artery could affect the localization of JAM-A. Indeed, co-staining for 
JAM-A and CD31 revealed a discontinuous pattern of JAM-A expression and 
redistribution from the junctions to the entire EC surface in the common part 
of partially ligated carotid arteries, similar to the pattern seen in the 
bifurcation of mice with established lesions (Figure 3A). This redistribution of  
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Figure 2. Endothelial JAM-A localized in a focal manner at the luminal site of atherosclerotic 
plaques. Focal dots of endothelial JAM-A (green) can be detected in the shoulder region and in 
the core of an atherosclerotic plaque near the bifurcation (middle and right panel) by 
multiphoton microscopy of ex vivo carotids mounted in a customized mounting chamber (A). A 
junctional JAM-A pattern could be detected in healthy tissue located in the communis of the 
same carotid (left panel); the carotid artery was dissected from an ApoE -/- mouse. Pictures are 
total projections of z-stack pictures. Collagen is visualized by Second Harmonic Generation (SHG). 
A schematic drawing of a carotid artery (lower part) depicts the site where pictures were taken. 
Scale bar equals 20 µm. Via co-staining of carotids with CD31 (red) semi-quantitative data of 
junctional co-localization of JAM-A and CD31 were generated. Representative pictures of the 
healthy area in the communis and the plaque near the bifurcation are shown (B). Scale-bar 
equals 20 µm. Semi-quantitative analysis of JAM-A+/CD31+ junctions was conducted utilizing 
Metamorph software (C). Measurements were conducted with ApoE -/- mice after high-fat diet 
feeding showing comparable plaque deposition in the carotid (n=5). Data represent mean ±SEM.  
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JAM-A was already evident after 2 weeks and was still clearly detectable within 
8 weeks after partial ligation (not shown). In line with these findings, the co-
localization of JAM-A with CD31 was remarkably reduced in carotids 2 and 8 
weeks after partial ligation (Fig. 3B), indicating that JAM-A is preferentially 
redistributed from its junctional expression pattern under conditions of 
disturbed flow. 
 
 
 
 
Figure 3. Altered shear stress caused JAM-A redistribution. Abnormal JAM-A localization 
(green) combined with a normal CD31 localization (red) is detectable in the common carotid 
artery (A, left panel) and bifurcation of ligated carotid arteries without (A, middle panel) and 
with atherosclerotic lesions (A, right panel), showing that abnormal JAM-A localization occurs in 
the whole carotid artery after partial ligation surgery. Carotid arteries were dissected from  
ApoE -/- mice 2 weeks (left and middle panel) and 8 weeks (right panel) after partial ligation of 
the left carotid and high-fat diet. Pictures are total projections of z-stack pictures. Collagen is 
visible due to SHG. Scale bar equals 20 µm. Semi-quantitative analysis of JAM-A+/CD31+ 
junctions was conducted utilizing MetaMorph software (B). Measurements were performed 
with ligated and unligated carotid arteries of ApoE -/- mice with subsequent high-fat diet for 2 or 
8 weeks (n=4 per time point), as indicated. Data represent mean ± SEM.  
 
A 
B 
Common carotid artery Bifurcation Plaque-prone bifurcation 
CHAPTER 4   
116 
4 
Endothelial JAM-A facilitated leukocyte transmigration in vivo and in vitro, 
but was not involved in vessel wall permeability  
By performing in vivo and in vitro transmigration assays we took effort to 
validate the observed role for endothelial JAM-A in atherogenesis and the 
inflammatory cell recruitment into the plaques. Indeed, we found a decreased 
number of CD115+ monocytes in the media and adventitia of carotids of  
eJAM-A-/- mice after treatment with IL-1β, compared to  eJAM-A+/+ and wild 
type controls (Figure 4A, 4B). Representative figures revealed that CD115+ 
monocytes (red) are abundantly present in eJAM-A+/+ controls, but that their 
numbers are reduced in eJAM-A-/- mice as shown in a Z-projection derived 
from in situ measurements (Figure 4C). Adhesion of monocytes was unaltered 
both in vivo and in situ (not shown). 
These results were identical to results observed in in vitro assays 
performed with cultured ECs and primary leukocytes isolated from  
eJAM-A+/+ApoE-/- and eJAM-A-/-ApoE-/- mice. Time lapse experiments were 
performed under shear-stress conditions in which CD115+ monocytes 
transmigrated through an activated EC monolayer. Isolated mouse monocytes 
did not show differences in adhesion to JAM-A-/- endothelial monolayers under 
shear flow conditions (Figure 4D). Less monocytes however were observed 
underneath the JAM-A-/- EC monolayer compared to the JAM-A+/+ ECs (Figure 
4E), indicating a reduced transmigration in vitro.  
To further discern whether JAM-A is involved in active transmigration, 
and is not involved in vascular barrier function, we determined vascular 
permeability in the presence or absence of endothelial JAM-A. Although 
leukocyte transmigration was reduced in endothelial JAM-A-/- mice, 
permeability for 70 kDa (Figure 4F) and 150 kDa dextran (not shown) was 
unaltered in eJAM-A-/-ApoE-/- mice on a Western type diet, indicating that 
ablation of JAM-A expression does not affect vascular barrier function, and 
that the observed transmigration of leukocytes in not a passive process. 
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Figure 4. Deletion of endothelial JAM-A influenced leukocyte transmigration, but not leukocyte 
adhesion or vascular permeability. The number of cells that transmigrated into the media and 
adventitia was assessed after 24h incubation of the common carotid artery of eJAM-A-/- mice 
with IL-1β administration via slowly degrading Pluronic gel. In vivo time lapses were taken 
subsequent to fluorescent anti-CD115 (red) and anti-CD31 (green) antibody injection via MPLSM 
(A), and showed a strong trend towards a decrease in transmigrated monocytes in eJAM-A-/- 
mice. After in vivo imaging, mice were sacrificed and in situ z-stacks were taken directly after 
ventilation stopped (B), and confirmed reduction of monocyte transmigration in the absence of 
eJAM-A. Data in A and B represent mean ± SEM of individual data points depicting transmigrated 
cell numbers (in vivo: eJAM-A+/+ n=3, eJAM-A-/- n=9; in situ:  eJAM-A+/+ n=3, eJAM-A-/- n=7). 
Representative images of the common carotid artery of eJAM-A+/+ and eJAM-A-/- mice are  
shown (C). Endothelial cells deficient for JAM-A were used to determine the contribution of 
endothelial JAM-A to leukocyte adhesion and transmigration in vitro (D and E), and showed 
results comparable to the in vivo and in situ data. Additionally, vascular permeability was 
assessed in vivo by determining fluorescence intensity of the 70 kDa (F) and 150 kDa (not shown) 
in the medial layer. Vascular permeability was not altered by eJAM-A deficiency. Data represent 
mean ± SEM of at least three experiments performed independently.  
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Discussion 
 
Here, we have unraveled the impact of endothelial JAM-A deficiency on diet-
induced atherosclerosis. By genetic reduction of endothelial JAM-A expression, 
we demonstrate that endothelial JAM-A contributed to an increase in 
atherosclerotic lesion formation, which was mediated by luminal redistribution 
of JAM-A, increasing local adhesion and transmigration of leukocytes into the 
atherosclerotic plaque.  
The exacerbation of atherosclerotic lesion formation by endothelial 
JAM-A appears to be due to its redistribution from the intercellular junctions 
to the luminal surface, as well as to an increase in its expression under 
atherogenic conditions, thus increasing the availability of luminal JAM-A. 
Previous work has addressed redistribution of endothelial JAM-A, showing that 
JAM-A is re-localized to the apical surface in a cytokine-dependent manner 
under static and flow conditions in vitro 14, 15, 24. Herein, we were able to extend 
these findings by showing a focal upregulation and clustered redistribution of 
JAM-A expression in endothelial cells in atherosclerotic carotid arteries, as well 
as after partial ligation of the healthy carotid arteries. This increase in luminal 
JAM-A availability likely mediates enhanced recruitment and increased content 
of macrophages and T cells in atherosclerotic plaques of mice, and is absent in 
mice with endothelial JAM-A deficiency.  
Our data challenge the intuitive assumption that knocking-out a 
protein that is important for junctional barrier function, would cause a non-
specific influx of leukocytes and/or an increase in vascular permeability. 
Rather, our data refutes a role of JAM-A in limiting transendothelial migration 
and point towards a specific role of endothelial JAM-A in leukocyte 
recruitment in the context of atherosclerosis, since genetic reduction of eJAM-
A resulted in decreased macrophages and T cells infiltration into plaques and 
luminal monocyte extravasation in carotid arteries in vivo. Additionally, 
permeability assays utilizing fluorescent dextran revealed no difference in 
arterial barrier function in atherosclerotic mice with endothelial JAM-A 
deficiency. This is in contrast to a function of JAM-A that has been described in 
corneal endothelial, epithelial and intestinal permeability following TNF 
stimulation 25-27. These studies however were performed either in vitro in 
contrast to our ex vivo model, or in epithelial cells, not endothelial cells, 
making a direct comparison difficult.  
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The luminal redistribution of JAM-A is facilitated by aberrant flow conditions, 
e.g. after partial ligation or at predilection sites of atherogenesis, whereas 
laminar shear flow appears to exert beneficial effects on JAM-A, limiting the 
susceptibility to atherogenesis. Of note, Kruppel-like factor 2 (KLF2)-
transduced or shear-stress-stimulated HUVECs have been found to be enriched 
in miR-143/145, providing a mechanism for atheroprotective communication 
with neighboring VSMCs via miR-145-containing microvesicles 28. It would be 
interesting to further investigate these mechanisms, as a miR-145-dependent 
targeting of JAM-A has been identified in tumor cells 29. miR-145 was able to 
suppress fascin expression and entailed a more cortical actin distribution and 
reduced actin stress fiber formation 29. As such, it may also be responsible for 
limiting JAM-A redistribution, and would represent a potential target for 
intervention.  
In relation to earlier studies, it would also be of interest to establish 
the role of endothelial JAM-A on microvascular endothelium, e.g. plaque-
associated vasa vasorum, which have a significant role in leukocyte 
recruitment to atherosclerotic plaques 30. Here, we did not assess the role of  
eJAM-A on plaque-associated vasa vasorum. Conceivably, eJAM-A may even (in 
part) explain the high number of transmigrating leukocytes observed for vasa 
vasorum adjacent to the plaque 30, as the low flow in plaque-associated vasa 
vasorum may implicate a redistribution of JAM-A similarly to the redistribution 
found at sites of disturbed flow described in this study.  
Concluding, our study identifies a crucial involvement of eJAM-A in 
atherogenic leukocyte recruitment in response to disturbed flow at 
predilection sites of atherogenesis. Limiting the flow-dependent redistribution 
of endothelial JAM-A, e.g. by miR-145 upregulation or mimetics, may serve as a 
novel therapeutic approach to treat early atherosclerosis. Moreover, the focal 
and apical localization of endothelial JAM-A may be a suitable marker for 
molecular imaging of early stages of lesion formation and may be exploited as 
a modality for targeted delivery of immunotherapies in atherosclerosis. 
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Supplemental Figures  
 
           
Supplemental Figure I. Differential distribution of endothelial JAM-A between the plaque-
burdened and non-diseased vessel wall. In the plaque-burdened vessels wall, JAM-A (green) was 
distributed in a spotted pattern, more luminal from the endothelial cells (red, CD31). In contrast, 
in the non-diseased vessel wall, JAM-A was co-localized with the endothelial lining. Blue indicates  
collagen as determined by SHG, cell nuclei are depicted in cyan. 
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Abstract 
 
Vascular endothelial (VE)-cadherin is important for preventing leakage of 
plasma proteins and egress of inflammatory cells under physiologic conditions. 
Upon inflammation, inter-endothelial VE-cadherin dimers are disrupted, 
leading to a more permeable endothelium. Recently, leaky vasa vasorum (VV) 
were described surrounding plaque-burdened arteries in ApoE-/- mice. To 
elucidate the cause of the leaky plaque-associated VV, we studied whether VE-
cadherin disruption can explain (part of) the leaky phenotype. 
Plaque-associated VV and sternohyoid microvessels (SH) were imaged 
in vivo in LDLr-/- mice with severe carotid atherosclerosis (52wks old, 40wks 
high cholesterol diet) using multiphoton laser scanning microscopy. Younger 
(16wks old, chow diet) LDLr-/- mice served as controls. Leukocyte adhesion, 
transmigration, and leakage of 70 kDa dextran were imaged with or without 
antibody-mediated VE-cadherin disruption. At baseline, plaque-associated VV 
in old LDLr-/- mice showed increased leukocyte adhesion (0.30 ± 0.09 vs. 1.03 ± 
0.15 cells/mm2; p < 0.01) and transmigration (0.38 ± 0.07 vs. 2.65 ± 0.48 
cells/mm2; p < 0.005) compared to SH microvessels. After VE-cadherin 
blocking, SH microvessels of both young and old LDLr-/- mice showed a 2-fold 
increased permeability (p < 0.05), and increased leukocyte transmigration 
(0.38 ± 0.07 vs. 1.56 ± 0.38 cells/mm2; p < 0.05) in old LDLr-/- mice. In contrast, 
no differences in adhesion, transmigration, or microvascular permeability were 
found in plaque-associated VV of old LDLr-/- mice after VE-cadherin blocking.  
Functional testing of a VE-cadherin tandem peptide to stabilize VE-
cadherin in cultured HUVECs showed increased endothelial basal resistance, 
yet failed to prevent TNFα-induced permeability or restoration of thrombin-
induced permeability. As such, the peptide was at current not a viable tool for 
stabilization of VE-cadherin dimerization in vivo. 
While VE-cadherin blockage increased microvascular permeability in 
SH microvessels of both young and old atherosclerotic LDLr-/- mice, vascular 
permeability and leukocyte transmigration in plaque-associated VV were not 
increased beyond baseline. This suggests either lack of involvement of VE-
cadherin in plaque-associated VV, or a pre-existing dysfunction or disruption of 
VE-cadherin. To prove a role of VE-cadherin in the leaky phenotype in plaque-
associated VV, experiments using the VE-cadherin tandem peptide, enhancing 
endothelial barrier function, will be crucial. 
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Introduction 
 
The inflammatory response in atherosclerosis is regarded as a key process in 
plaque development and progression. Endothelial cells (ECs) play an important 
role in this response, since the endothelial barrier regulates the entry of 
inflammatory cells into the atherosclerotic plaque. This is already illustrated at 
the onset of atherosclerosis, where dysfunction of the luminal endothelial cells 
is initiated by altered shear stress, causing circulating lipoproteins to 
accumulate in the intima. In response, luminal ECs upregulate adhesion 
molecules to facilitate leukocyte recruitment to the subendothelial layer. In 
later stages, ECs from newly formed plaque microvessels are also prominently 
involved in leukocyte recruitment, and are regarded to exhibit a leaky 
phenotype 1, 2. Data from human studies have already suggested that these 
microvessels show aberrant morphology, and electron microscopy (EM) and 
immunohistochemical analysis of human pathological specimens of ruptured 
carotid artery lesions revealed that microvascular ECs are not covered by  
pericytes 3. Moreover, EM of microvessels from unstable human 
atherosclerotic lesions revealed disruptions of their inter-endothelial junctions 
and membrane blebbing 3.  
Recently, our group and others have provided in vivo evidence for a 
dysfunctional VV in atherosclerotic ApoE-/- mice 2, 4, in which both an enhanced 
leukocyte adhesion to and transmigration from the microvascular wall were 
shown, as well as an increase in microvascular permeability. This phenotype 
suggests (1) enhanced leukocyte recruitment,  e.g. by upregulation of adhesion 
molecules like P-selectin and lymphocyte function-associated antigen-1  
(LFA-1) 4, and (2) potential loosening of endothelial junctions, which are of key 
importance for leukocyte transmigration and microvascular permeability.  
Endothelial junctions consist of numerous molecules which partly 
share a role as junction molecule, but are simultaneously recognized by 
immune cells for adhesion and transmigration, e.g. junctional adhesion 
molecule A (JAM-A), platelet endothelial cell adhesion molecule  
(PECAM-1/CD31), and vascular endothelial cadherin (VE-cadherin) 5-7. VE-
cadherin is a transmembrane protein, and has a cytoplasmic domain which 
binds to the actin cytoskeleton via α-catenin and other cofactors 8, 9. Binding to 
the intercellular cytoskeleton on the one hand 10, and the inter-endothelial 
dimerization of VE-cadherin molecules from neighboring ECs on the other 
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hand, are thought to be crucial for maintaining stability and subsequently 
impermeability of endothelial adherent junctions 11.  
Permeability of the endothelial junction is achieved by phosphorylation 
of the cytoplasmic VE-cadherin residues. Upon phosphorylation, VE-cadherin 
dissociates from its co-factors, disconnects from the actin cytoskeleton, and is 
internalized. In contrast, de-phosphorylation by VE-protein tyrosine 
phosphatase (VE-PTP) 11-14 prevents the disruption of VE-cadherin complexes 
and VE-cadherin internalization.  
VE-cadherin has been identified as the main mediator of permeability, 
and blocking of VE-cadherin dimerization has been shown to increase fluidic 
permeability 9. Furthermore, several studies have shown an additional role of 
VE-cadherin in leukocyte extravasation 15-17. Mice treated with a VE-cadherin 
blocking antibody displayed a 70% increased neutrophil extravasation in a 
peritonitis model 15. These data on the effects of VE-cadherin, in combination 
with previous data from our group 2 led to the hypothesis that VE-cadherin 
may be involved in microvascular leakage in atherosclerosis, and that a VE-
cadherin-targeted intervention reduces microvascular leakage in plaque 
associated microvessels.  
Stabilization of the inter-endothelial VE-cadherin complex has been 
described in vivo by either use of a specific protein linker (tandem peptide) 18 
or by using transgenic mouse models 14, 19. The VE-cadherin protein linker is a 
peptide that links VE-cadherin molecules of two ECs leading to a more 
impermeable endothelial junction. Its application resulted in a 5-fold reduction 
of permeability in healthy hind limb vessels of rats challenged with tumor 
necrosis factor-α (TNFα) 18.  
Here, we investigated the effects of this VE-cadherin-linking tandem 
peptide to stabilize inter-endothelial junctions in vitro. In addition, we studied 
the effects of VE-cadherin disruption by a VE-cadherin blocking antibody to 
identify the role of VE-cadherin in the leaky phenotype in atherosclerotic 
plaque-associated vasa vasorum. To this end, we applied multiphoton laser 
scanning microscopy (MPLSM) to quantify microvascular permeability and 
leukocyte adhesion and transmigration in an in vivo setting.  
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Methods 
 
VE-cadherin stabilization 
 
Tandem peptide production  
VE-cadherin tandem peptide was produced by solid phase peptide synthesis 
(using Boc protecting groups) by the Department of Biochemistry, Maastricht 
University similar to previous publications 20. The peptide was fluorescently 
labeled with Oregon Green (OG488). Synthesized peptide was purified by high 
pressure liquid chromatography, identified using mass spectrometry, and was 
lyophilized before storage at -80°C.  
 
Testing of tandem peptide in vitro 
In vitro testing of the tandem peptide was performed at Sanquin, Amsterdam. 
The cellular location of the tandem peptide was detected by visualization of 
the OG488 label with confocal microscopy of human umbilical vein endothelial 
cells (HUVECs) confluent monolayers. HUVECs were treated with 20µM 
tandem peptide and challenged with human tumor necrosis factor-α (TNFα) 
prior to imaging. For better orientation, co-staining with an Alexa647-labeled 
VE-cadherin antibody (BD Pharmingen; 0.5mg/ml stock) was performed.     
Electric Cell-substrate Impedance Sensing (ECIS) was used to test 
permeability reducing properties of the tandem peptide, comparable to 
previous experiments 21. Shortly, a confluent monolayer of HUVEC was grown 
on fibronectin coated electrode arrays. Cells were incubated with 20µM 
tandem peptide or vehicle control when basal electrical resistance was 
reached. Short (8 hours) and long term (60 hours) changes in electrical 
resistance after challenge with human TNFα and after thrombin-induced 
permeability were measured on the ECIS-Model-100 Controller (BioPhysics). 
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VE-cadherin blocking 
 
Animals 
For in vivo experiments, 12-weeks old male LDLr-/- mice were placed on a high-
cholesterol diet (0.25% cholesterol, Special Diet Services) for 40 weeks (n=18) 
Young male LDLr-/- mice (16 weeks of age, normal chow; n=10) served as 
controls. Male C57Bl/6 mice (12 weeks of age, normal chow; n=14) served as 
donors for isolation of bone marrow derived cells from the tibia and femur. 
Mice were supplied by the institutional animal facility, and were housed in 
conventional cages. Experiments were approved by the local animal ethics 
committee and performed according to institutional guidelines.  
Four hours before in vivo imaging, mice were injected with 60 µl VE-
cadherin blocking antibody 15 (BD Pharmingen; 0.5 mg/ml stock) or control 
antibody (n=9/group for aged LDLr-/- mice, n=5/group for young LDLr-/- mice),  
125 µl 70 kDa dextran-tetramethylrhodamin (TMR; Invitrogen; 3 mg/ml stock), 
and 100 µl phosphate-buffered saline (PBS) intravenously via the tail vein. 
Mice then received an additional intravenous injection of 80µl CD31-FITC (BD 
Pharmingen; 0.5mg/ml stock) and 1x107 Syto44-labeled bone marrow derived 
cells in 200 µl PBS 30 minutes prior to imaging. Bone marrow derived cells 
were isolated from the tibia and femur from C57Bl/6 control mice, labeled 
with Syto44 5 μM (Invitrogen) for 30 min at 37°C, washed and kept on ice until 
further use.  
Mice were anaesthetized using a dorsal subcutaneous injection with 
ketamine (100 mg/kg body weight, Nematek) and xylazine (10 mg/kg body 
weight, Sedamun) through a catheter made from a 28  mm polyethylene tube 
fitted with a 30G needle. Body temperature was kept at 37°C by means of a 
heating pad. Every 30 minutes an additional dose of anaesthetics was 
administered to maintain anaesthesia. The carotid artery and the sternoyhoid 
muscle were exposed, and mice were imaged in vivo for up to 2 hours. After in 
vivo imaging, mice were sacrificed by intraperitoneal pentobarbital injection 
and in situ imaging was performed for 3D tissue analysis.  
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Multiphoton laser scanning microscopy 
MPLSM imaging was performed on a Leica SP5 imaging platform (Leica 
Microsystems, Wetzlar, Germany) that integrates two photon microscopy with 
fast resonant scanning, and uses a Compact Ultrafast Ti:Sapphire Laser 
(Chameleon, Coherent, USA). An excitation wavelength of 880nm was used in 
all experiments. Tissues were observed using a 20x water-dipping objective 
(HCX PL APO L 20x 1.0 water immersion objective, Leica Microsystems, 
Germany) with a numerical aperture of 1.00 and an integrated optical zoom 
mechanism allowing total magnification up to 60x. Photo-multiplier tubes 
(PMTs) were used to detect four spectral regions: 390-410 nm (SHG for 
imaging collagen fibrils), 420-470 nm (Syto44 for cell nuclei), 515-560 nm (FITC) 
and 570-600 nm (TMR).  
In vivo MPLSM imaging was performed at a frame size of 400 x 400 
pixels (pixel size: 1.0882 x 1.0882 μm), scanning at 8000 Hz for fast recording 
(20 frames/sec) and using a line average of 2 (10 frames/sec) for reduced noise 
scans. Per time series, a total of 500 frames was recorded. Field of view at 20x 
magnification is 434.2 x 434.2 µm. After in vivo imaging, the animal was 
sacrificed and additional in situ imaging performed to examine the carotid 
artery at higher resolution and an increased signal-to-noise ratio without the 
motion artifacts. In situ imaging was performed at a frame size of 512 x 512 
pixels (pixel size: 0.847 x 0.847 μm), scanning at 250 Hz and an interplanar 
distance of 1.00 μm.  
 
Data analysis 
All data analysis was performed using ImageJ (http://imagej.nih.gov/ij/). 3D 
rendering was performed using an ImageJ plugin for high level  
3D visualization 22. Microvessel diameter was assessed by measuring the 
maximum distance between the opposite sides of the microvessel wall at ten 
separate points per microvessel, from which the median diameter per 
microvessel was calculated.  
Leukocyte adhesion to the vessel wall was assessed by in vivo tracking 
of Syto44-labeled bone marrow derived cells that remained at the same point 
within the vessels for at least 250 frames. Adhesion and transmigration rates 
were normalized to the microvessel surface, which was derived from the 
microvessel length and microvessel diameter. The adjacent sternohyoid 
muscle capillaries served as control microvessels. Adhesion and transmigration 
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was assessed for all microvessels in 10 frames for plaque-associated vasa 
vasorum and in 5 frames for sternohyoid microvessels. 
Microvascular permeability was determined by calculating the ratio of 
the extraluminal/intraluminal fluorescence intensity of the 70 kDa dextran-
TMR, and corrected for intrinsic autofluorescence present in the tissue. 
Extraluminal tissue was defined as the area within 1.5x vessel diameter’s 
distance of the microvessel wall. Microvascular permeability was assessed in 
all microvessels in 10 frames for plaque-associated vasa vasorum and in 5 
frames for control sternohyoid microvessels.  
Mice were excluded from analysis in case of local bleeding during 
preparation or imaging (2/18 for atherosclerotic LDLr-/-; 1/10 for non-diseased 
LDLr-/-), or in absence of in vivo imaging data due to early death before imaging 
(2/18 for atherosclerotic LDLr-/-).  
 
Histology and fluorescence microscopy  
Subsequent to in situ imaging, mice were perfused with PBS and 1% 
paraformaldehyde, and carotid arteries and kidneys were isolated for 
histology, paraffin-embedded and cut into serial sections. Selected sections 
proximal to the bifurcation were stained in 0.3% Sudan black solution (in 70% 
ethanol, Sudan Black B) to reduce auto-fluorescence and pictures were made 
using a Leica DM5000b fluorescence microscope (Leica Microsystems) and 
analyzed with Leica Qwin (Leica Microsystems). The area of the intima, media 
and adventitia were defined by the autofluorescence in the OG488 channel 
(green) and the TMR positive area was detected by means of the TMR positive 
area in the N21 channel (red) (Supplemental Figure I). Adjacent paraffin-
embedded sections were stained immunohistochemically (IHC) for CD31 (BD 
Bioscience) to confirm MPLSM data on vasa vasorum presence. 
 
Statistics 
Data are presented as mean ± SEM, unless stated otherwise. The non-
parametric Mann-Whitney U test was used for statistical analysis. Results were 
considered statistically different when p < 0.05. 
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Results  
 
Old, WTD-fed LDLr-/- mice showed plaque-associated vasa vasorum 
First, we assessed presence and functionality of plaque-associated vasa 
vasorum in 52 weeks old atherosclerotic LDLr-/- mice and their younger 16 
weeks old controls. IHC staining for CD31 showed a clear presence of CD31+ 
plaque-associated VV in old, WTD-fed LDLr-/- mice (arrows, Figure 1A), but not 
in the adventitia of young LDLr-/- mice (Figure 1B). MPLSM confirmed that all 
old LDLr-/- mice exhibited a plaque-associated VV (Figure 1C), whereas those 
were absent in young LDLr-/- mice (Figure 1D). Median VV diameters were 15.5 
and 7.1 µm for 1st and 2nd order microvessels. Moreover, plaque-associated VV 
showed an increased baseline adhesion and transmigration compared to SH 
microvessels, whereas microvascular permeability was not increased  
(Figure 2).  
 
 
 
 
Figure 1. Plaque-associated VV in 52 weeks old LDLr-/- mice. IHC staining revealed microvessels 
in the adventitia (arrows) in old LDLr-/- mice (A; 10x magnification, inset: 40x magnification), but 
not in young LDLr-/- mice (B; 10x magnification, inset: 40x magnification). MPLSM also showed 
that plaque-associated VV (green) were present in the collagen-rich (blue) adventitia in old  
LDLr-/- mice (C), yet not in young LDLr-/- mice (D). Dotted line indicate outline of the arterial wall.  
A B 
C D 
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VE-cadherin tandem peptide was able to modestly stabilize VE-cadherin, yet 
did not prevent TNFα-induced permeability in vitro 
The VE-cadherin protein linker (tandem peptide) was clearly distributed along 
the endothelial junctions of HUVECs (Supplemental Figure II). Functional 
testing revealed that the tandem peptide increased endothelial resistance at 
short and long term (Figure 3A and 3B). The increase in endothelial resistance, 
although significant, was modest (Figure 3B). Remarkably, the tandem peptide 
failed to prevent TNFα-induced permeability as well as restoration of 
thrombin-induced permeability (Figure 3C). As such, the peptide was not a 
viable tool for stabilization of VE-cadherin dimerization in vivo. 
 
 
 
  
 
 
Figure 2. Baseline characteristics of SH (control) microvessels and plaque-associated VV. In old 
LDLr-/- mice, leukocyte adhesion (A) and transmigration (B) at baseline were increased 
compared to SH microvessels of similar diameter. Microvascular permeability (C) was not 
significantly different. 
A B 
C 
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VE-cadherin blocking increased leukocyte transmigration and microvascular 
permeability in sternohyoid microvasculature in vivo 
To assess efficacy of the VE-cadherin blocking antibody, we studied leukocyte 
adhesion, transmigration, and microvascular permeability in microvessels of 
the sternohyoid muscle as described previously 2. VE-cadherin blocking 
antibody did not alter microvessel diameter (Supplemental Figure III-A). Both 
in young and old LDLr-/- mice, we observed no differences in leukocyte 
adhesion upon VE-cadherin blocking (Figure 4A, 4B), while leukocyte 
transmigration and microvascular permeability for 70 kDa dextran-TMR were 
increased in old LDLr-/- mice (Figure 4C-4F; Supplemental Figure IV).  
 
   
 
 
Figure 3. VE-cadherin tandem peptide induced increased endothelial barrier function, but did 
not prevent TNFα-induced permeability or restoration of thrombin-induced permeability. 
Resistance measurements of HUVECs grown in monolayer were performed using ECIS. Tandem 
peptide was added to endothelial cells when baseline resistance was reached (A, time point 0). 
Follow-up of vascular resistance with time revealed an increased resistance for up to 30 hours 
after addition of the tandem peptide (B). Tandem peptide could not prevent TNFα-induced 
permeability (C, upper panel) or restoration of thrombin-induced permeability (C, lower panel). 
}
}
Tandem  
peptide 
Control 
A 
C B 
Control 
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Figure 4. Leukocyte transmigration and microvascular permeability in SH microvessels in old 
LDLr-/- mice was enhanced after VE-cadherin blocking antibody treatment. Adhesion of 
leukocytes is unaffected by VE-cadherin blockage both in young (A, p = 0.12) and old LDLr-/- mice 
(B, p = 0.15). In contrast, leukocyte transmigration is increased after treatment in young (C,  
p = 0.24) and old LDLr-/- mice (D, p < 0.05). In addition, microvascular permeability is significantly 
increased in young (E) and old (F) LDLr-/- mice (n=4/group for young LDLr-/- mice; n=7-8/group for 
old LDLr-/- mice). 
 
 
  
A B 
C D 
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No significant differences in baseline adhesion, transmigration and 
microvascular permeability were observed between microvessels of young, 
chow-fed and old, WTD-fed LDLr-/- mice in this sternohyoid microvascular bed. 
 
VE-cadherin blocking did not alter leukocyte adhesion, transmigration and 
microvascular permeability in plaque-associated vasa vasorum in vivo 
Given the efficacy of the VE-cadherin blocking antibody to increase 
permeability and transmigration in SH microvessels, we also investigated the 
effect of the VE-cadherin blocking antibody on plaque-associated VV. VE-
cadherin blocking antibody did not alter microvessel diameter (Supplemental 
Figure III-B), and microvascular permeability was not increased at baseline 
(Figure 2C). Similar to the SH microvessels, the antibody did not affect 
leukocyte adhesion (Figure 5A). In contrast to the SH microvasculature, we did 
 
 
Figure 5. VE-cadherin blocking antibody did not exacerbate the pre-existing leaky phenotype 
of plaque-associated VV. Plaque-associated VV in old LDLr-/- mice show a leaky phenotype with 
increased leukocyte adhesion, transmigration and microvascular permeability (A-C). Blocking VE-
cadherin dimerization did not further increase leukocyte adhesion (A), transmigration (B) or 
permeability (C) in vivo. 
 
 
A B 
C 
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not observe any changes in leukocyte transmigration (Figure 5B; Supplemental 
Figure V) or microvascular permeability (Figure 5C) after VE-cadherin blocking 
antibody treatment.  
Histological analysis showed an increase in 70 kDa dextran-TMR within 
the atherosclerotic lesions, confirming the efficacy of the VE-cadherin antibody 
on carotid luminal endothelium (Figure 6A). Yet, no increased TMR+ area was 
found in the media or the adventitia. Interestingly, in young LDLr-/- mice, a high 
baseline TMR+ area was observed, which increased after VE-cadherin blocking 
antibody treatment.  
  
 
Figure 6. Efficacy of VE-cadherin blocking antibody was confirmed by histological analysis. 
Dextran-TMR positive area was determined in the atherosclerotic plaque (intima), media and 
adventitia of old LDLr-/- mice (A). VE-cadherin blocking antibody treatment (black bars) led to an 
increase in intimal dextran-TMR compared to controls (white bars). Medial and adventitial 
dextran-TMR was unaltered. In young LDLr-/- mice, a high TMR+ area was observed in the media, 
and was significantly increased after VE-cadherin blocking antibody treatment (B). Adventitial 
dextran-TMR was unaltered. 
A B 
Old LDLr-/- Young LDLr-/- 
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Discussion 
 
Here, we studied the function of the junctional protein VE-cadherin in plaque-
associated vasa vasorum. Although a leaky phenotype was present in control 
microvessels after VE-cadherin blocking, the addition of the VE-cadherin 
blocking antibody did not cause an additional increase in leukocyte 
transmigration or microvascular permeability in plaque-associated vasa 
vasorum, suggesting that (i) VE-cadherin function may already be impaired in 
plaque-associated vasa vasorum or (ii) VE-cadherin is not involved in the leaky 
phenotype in plaque-associated vasa vasorum.  
The observed effects of the VE-cadherin blocking antibody in both 
control microvessels of old, WTD-fed LDLr-/- mice and in normal chow fed 
younger LDLr-/- mice are in line with previous findings that VE-cadherin is 
involved both in leukocyte transmigration and vascular permeability 15. In the 
sternohyoid microvessels, leukocyte transmigration was two to four times 
higher after VE-cadherin functional blocking, while microvascular permeability 
was increased by 50-70%. Leukocyte adhesion was not affected by VE-cadherin 
functional blocking. 
Efficacy of the VE-cadherin blocking antibody could also be confirmed 
by histological analysis, where we were able to detect a significant increase in 
70 kDa dextran-TMR within the atherosclerotic lesion, but not in the media or 
the adventitia. The luminal endothelium will also be affected by VE-cadherin 
blocking, and a concomitant increase in permeability will cause a rise in 
dextran-TMR in the underlying tissue, e.g. the atherosclerotic plaque. In young 
LDLr-/- mice we observed a significant increase in dextran-TMR in the medial 
layer, which was not present in the old LDLr-/- mice. The high baseline TMR+ 
area in the media and adventitia of young LDLr-/- mice were most likely due to 
diffusion of the probe over the endothelial layer, also at baseline. In the old 
LDLr-/- mice, the dextran-TMR leaked into the plaque itself, and did not reach 
the medial or adventitial layer. Taken together, the luminal endothelium may 
also influence fluorescence intensities adventitia. In the MPLSM study, we 
therefore stringently measured fluorescent intensities directly adjacent to the 
plaque-associated vasa vasorum, and corrected for background fluorescence 
which may be present as a result of luminal permeability. As such, it was 
possible to assess the local role of VE-cadherin, here in plaque-associated vasa 
vasorum. This approach is more sensitive and specific compared to the 
CHAPTER 5  
140 
5 
histological approach, which only is a measure of total vascular permeability, 
and not vascular permeability of the plaque-associated vasa vasorum. By 
confining histological analysis to the area around the plaque-associated vasa 
vasorum, it might be possible to also assess microvascular permeability by 
histology, although the sensitivity of this method remains unclear. 
Old, WTD-fed LDLr-/- showed a similar plaque-associated vasa vasorum 
as previously described in ApoE-/- mice. Microvessel diameters and parameters 
like leukocyte adhesion and transmigration levels were comparable 2. 
Recruitment numbers of leukocytes were slightly higher in the ApoE-/- model, 
which is in line with previous observations of heightened systemic 
inflammation compared to LDLr-/- mice 23. Although we could clearly observe a 
VE-cadherin-dependent increase in transmigration in control microvessels, and 
higher baseline transmigration in the plaque-associated vasa vasorum, it would 
be of interest to challenge the local microvasculature to determine if the 
inflammatory response and microvascular permeability were maximal or 
submaximal. Stimulation with histamine or TNFα 18 would yield insight into 
whether maximal permeability was indeed already achieved. If leukocyte 
transmigration and/or permeability could be increased, this would indicate 
that the inter-endothelial junctions can be disrupted beyond VE-cadherin 
blocking, suggestive of a limited or absent role for VE-cadherin in 
microvascular permeability in plaque-associated vasa vasorum.  
More importantly, it would be of great interest to assess the effect of 
VE-cadherin blocking antibody treatment on the plaque-associated vasa 
vasorum ultrastructurally using electron microscopy, and thus evaluate 
whether open inter-endothelial junctions can explain the increased leukocyte 
transmigration and microvascular permeability. A clear dissociation of 
neighboring microvascular ECs by blocking of VE-cadherin would thus explain 
the increased microvascular permeability by structural defects. Interestingly 
however, previous studies have shown that loss of VE-cadherin only resulted in 
minor ultrastructural changes in the endothelial junctions, although an 
increase in vascular permeability was found 24, 25. Data from our group also 
suggested no aberrant endothelial junctions in plaque-associated vasa 
vasorum of aged ApoE-/- mice 2, nor in LDLr-/- mice at different time points of 
WTD (unpublished observations). This would suggest a functional and not a 
structural defect in VE-cadherin to be causative for increased vascular 
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permeability, and would shed a new light on the role of VE-cadherin as a 
junctional molecule. 
To however prove that dysfunction or potential downregulation 26, 27 of 
VE-cadherin has a role in the leaky phenotype observed in plaque-associated 
microvessels, the experiments using the VE-cadherin tandem peptide in vivo to 
enhance endothelial barrier function are crucial. Not only will those 
experiments prove whether VE-cadherin is causal in microvascular 
permeability in plaque-associated vasa vasorum, but it may also confer a 
potential future target for interventions. 
Unfortunately, study of the tandem peptide and its effect on 
microvascular permeability and leukocyte recruitment in vivo were not yet 
possible.  The in vitro results of the VE-cadherin tandem peptide only showed a 
very limited effect on endothelial barrier function, and were in strong contrast 
to previous work from Heupel et al, who described a dramatic increase in 
resistance by addition of VE-cadherin tandem peptide in vitro and in vivo 18. 
Optimization of experimental conditions and/or improving the efficacy of the 
tandem peptide will be required before in vivo experiments are viable. 
Alternatively, an inducible VE-cadherin-VE-PTP complex mouse model would 
provide an interesting model to investigate the role of microvascular VE-
cadherin in atherosclerosis 14. In such a model, it will be possible to study the 
long term effects of VE-cadherin stabilization, and its impact on atherosclerosis 
development and progression in vivo.  
In conclusion, both microvascular permeability and leukocyte 
transmigration were increased in plaque-associated vasa vasorum, but could 
not be exacerbated by VE-cadherin blocking antibody treatment. This suggests 
that either VE-cadherin in plaque-associated vasa vasorum is already 
dysfunctional, and thus cannot be influenced by VE-cadherin blocking antibody 
treatment, or that VE-cadherin is not involved in the leaky phenotype of 
plaque-associated vasa vasorum. Enhancing VE-cadherin-mediated barrier 
function in vivo will be required to conclusively show whether there is a causal 
role for VE-cadherin in the leaky phenotype in plaque microvessels, and may 
provide a potential target for future intervention. 
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Supplemental Figures 
 
Supplemental Figure I. Quantification of the TMR positive area (A) in the intima (1), media (2) 
and adventitia (3) determined by autofluorescence in the OG488 channel (B) and TMR positivity 
in the N21 channel (C).  
 
 
 
Supplemental Figure II. Untreated HUVECS incubated with VE-cadherin tandem peptide. The 
OG488-labeled tandem peptide was located at the endothelial junction (VE-cadherin). 
 
 
 
 
 
Supplemental Figure III. Microvessel diameter in SH microvessels (A) and plaque-associated 
VV (B) was unaltered by treatment with VE-cadherin blocking antibody. 
A B C
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Supplemental Figure IV. Z-projection of sternohyoid muscle of old LDLr-/- mice showing collagen 
(blue) and microvessels (green). The number of transmigrated cells (arrows) was increased after 
treatment with the VE-cadherin blocking antibody (right) compared to controls (left).  
 
 
 
  
Supplemental Figure V. Stills from in vivo recordings from plaque-associated vasa vasorum 
showing of old LDLr-/- mice collagen (blue) and microvessels (green). The number of adhering 
cells (arrows) was not increased after treatment with the VE-cadherin blocking antibody (right) 
compared to controls (left). Dotted line indicated outline of the carotid artery. 
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Abstract 
 
During human atherosclerosis progression, plaque hypoxia and 
inflammation will induce a pro-angiogenic response which induces vasa 
vasorum expansion, the formation of intraplaque microvessels, and even 
lymph vessels. Although (lymph)angiogenesis has been well-characterized 
under physiological conditions, yet in atherosclerosis it is still poorly 
understood. In this study, we applied a genomics-based approach to dissect 
pathways and underlying regulatory cues in human plaque 
(lymph)angiogenesis. 
Human endarterectomy samples were collected during surgery of 24 
patients with plaques containing both a stable and a ruptured segment. 
Microvessel and lymph vessel density, relative angiogenic endothelium 
content, and microvessel pericyte coverage were assessed in stable and 
ruptured segments, showing a significant increase in microvessel density  (4.40 
± 0.78 vs. 7.47 ± 1.70 CD31+ vessels/mm2; p < 0.05), lymph vessel density (3.02 
± 1.72 vs. 16.56 ± 2.94 %D2-40+ area; p < 0.005), and percentage of angiogenic 
endothelium in unstable plaques (4.88 ± 2.16 vs. 12.00 ± 1.84 %CD105 of 
CD31+ vessels; p < 0.005). Pericyte coverage was similar in stable and ruptured 
segments. Microarray was performed on RNA isolated from parallel plaque 
tissue segments, after which expression data were correlated to histological 
features. Reversed engineered co-expression network analysis was performed 
and revealed gene modules which showed significant but essentially divergent 
correlations with microvessel and lymph vessel density, or percentage 
angiogenic endothelium. Gene modules associated with lymph vessel density 
and percentage angiogenic endothelium did not yield any genes for validation 
based on module centrality and gene significance. Gene module correlation 
with microvessel density exposed sixteen candidate genes for further analysis. 
Additionally, five miRNAs were predicted to regulate the gene module which 
correlated most highly with microvessel density. 
In conclusion, this study identified gene and miRNA candidates which 
may be involved in regulating the angiogenic response in progression from 
advanced to ruptured plaque segments. Further in vitro and in vivo 
characterization and validation of these genes and miRNAs may reveal a 
potential role in angiogenesis and yield prospective future targets for targeted 
intervention. 
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Introduction 
 
The development of atherosclerotic plaques in humans has been studied 
extensively over the last decades. An important characteristic of developing 
lesions is adventitial vasa vasorum expansion, accompanied by vascularization 
of the intimal lesion, by ingrowth of adventitial microvessels, through the 
medial layer into the lesion 1. Multiple human studies have shown a clear 
correlation between plaque stage and the extent of vascularization, as 
reviewed previously 2, 3. In addition, structural abnormalities are frequently 
occurring in these plaque microvessels 4, potentially facilitating influx of lipids, 
erythrocytes, and inflammatory cells 5. Beyond angiogenesis, recent studies 
also argue a role for lymphangiogenesis in atherosclerosis 6, 7, although its role 
is still poorly understood. 
Typical angiogenic responses, both physiological and pathological, 
have been well studied during embryogenesis and several disease processes, 
most notably tumorigenesis 8-11. This has led to a clear concept of the pathways 
involved in regulation of angiogenesis. The most well-known of these pathways 
is without question the Hypoxia Inducible Factor (HIF)-Vascular Endothelial 
Growth Factor (VEGF) axis 12-15. In short, the HIF-1 and HIF-2 proteins are able 
to detect tissue hypoxia, leading to an upregulation of several hypoxia 
response genes including the VEGF-family and it receptors. VEGF in its turn will 
allow sprouting of new endothelial buds, and further growth of new vessels 
towards the hypoxic region. Beyond this classic pathway, there is a myriad of 
genes and proteins involved in regulating angiogenic response, be it by 
endothelial activation and EC junction formation (e.g. CD105,  
VE-cadherin 16, 17), guidance of the angiogenic sprout (e.g. Dll-4, Notch, FGF, 
semaphorins, netrins 15, 18), perivascular matrix degradation (e.g. MMPs 19), 
(micro)vessel stabilization (e.g. TGF-β1, TIMPs 20), or (micro)vessel maturation 
and differentiation (e.g. ephrins, angiopoietins,PDGF 21). In recent years, 
several microRNAs (miRNAs or miRs) have been implicated as central 
regulators of angiogenesis, e.g. miR126 and miR27a/b 22, 23. Similar processes 
are involved in physiological and pathological lymphangiogenesis, which shows 
great homology to angiogenesis, and often involves family members of 
molecules involved in the angiogenic process, e.g. VEGFs, VEGFRs, and 
neuropilins (NRP) 24.  
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Many of the angiogenic factors mentioned have been studied in 
atherosclerosis 1, 2, 10, 25, 26. However, the majority are not viable as targets for 
(clinical) intervention, in view of adverse systemic side-effects 1, 11, 27. 
Obviously, genes specifically involved in the pathologic angiogenic process 
during atherosclerosis development and progression would represent a much 
more suitable clinical target. 
A genomics approach would be very suitable for identifying such novel, 
atherosclerosis specific targets. By correlating gene expression patterns to 
(lymph)angiogenesis certain traits, gene networks can be built revealing 
central hubs that are functionally related to these processes. Related 
approaches have already been employed in for instance oncology to discover 
new markers for tumor-derived endothelium 28, to detect expression 
signatures of miRNAs related to angiogenesis in tumors 29, to find biomarkers 
for endothelial cell proliferation in tumors 30, or to define response of tumor 
therapy by investigating expression profiles 31.  
Here, we used a method in which we combined data on plaque 
angiogenesis based on histology and immunohistochemistry with a microarray 
analysis on the same tissue. By this approach, we not only were able to 
demonstrate that angiogenesis, lymphangiogenesis and vessel maturation are 
associated with distinct regulatory gene modules, but also set forth to identify 
new genetic targets involved in the regulation of plaque angiogenesis and 
lymphangiogenesis in human atherosclerosis. 
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Methods 
 
Patient samples, histology and immunohistochemistry 
Human atherosclerotic plaque samples were obtained from carotid artery 
lesions from 24 patients undergoing endarterectomy (Department of Surgery, 
Orbis Medical Center, Sittard-Geleen, the Netherlands). The tissue was 
obtained from the Maastricht Pathology Tissue Collection (MPTC), and 
collection, storage, and use of tissue and patient data were performed in 
agreement with the Dutch Code for Proper Secondary Use of Human Tissue. 
Immediately after resection, the atherosclerotic tissue was divided into parallel 
segments of 5 mm. Snap frozen segments for RNA isolation were alternated by 
formalin-fixed segments for histology and were only included when both 
adjacent haematoxylin-eosin (HE) stained sections were classified as advanced 
stable or ruptured atherosclerotic lesions. Plaques were staged by histological 
analysis based on HE staining of adjacent slides according to Virmani et al, 
where thick fibrous cap atheroma (TkFCA) were classified as advanced stable, 
and intraplaque hemorrhage (IPH) as ruptured segments, respectively 32. 
Patients were selected for having an advanced stable and ruptured snap- 
frozen segment within the lesion (advanced stable (n=21) and ruptured (n=23) 
segments).  
Immunohistochemical (IHC) stainings were performed on consecutive 
paraffin sections for vascular endothelial marker CD31 (Dako), the angiogenic 
marker CD105 (Thermo Scientific), the smooth muscle cell/pericyte αSMA 
(Dako), the macrophage marker CD68 (Dako), the lymphatic endothelial 
marker D2-40 (Dako), and the lymphatic transcription factor Prox-1 (Prof. Dr. 
Alitalo, University of Helsinki, Finland).  
In all sections, the total amount of CD31+ microvessels, D2-40 lymph 
vessels and CD68+ macrophages in the plaque was counted by two observers 
and corrected for plaque size, yielding the microvessel density (MVD; 
vessels/mm2), lymph vessel density (LVD; %D2-40+ vessel area of plaque area), 
or lesional macrophage content (% of total plaque area).   
Double staining for CD31/CD105 to assess the percentage of 
angiogenic endothelium, was analyzed with the Nuance spectral imaging 
system (Caliper Life Science). Multispectral imaging (MSI) data sets were taken 
from 420-720 nm at 20nm intervals using a DM-5000 Leica microscope system 
at 20x (Plan Apo). Spectral libraries of single-red (Vector Red), single-blue 
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(Vector Blue), single-brown (DAB), and natural occurring iron pigments were 
obtained from the control slides. The resulting library was applied to the 
double stained slides to spectrally dissect/unmix them into individual 
component images using the Nuance™ 3.0 software 33. Pseudo-color images 
showing co-localization, as well as an exclusive image of co-localization, were 
generated with the Nuance 3.0 software. Quantitative assessment of co-
localization and pixel-based measurement of the individual markers per 
microscopic field was done with the same software. 
In addition, the amount of αSMA covered microvessels and the αSMA-
coverage per microvessel was quantified morphometrically using Leica QWin 
V3.0 (Leica).  
 
Statistical analysis of patient characteristics and immunohistochemistry 
All data on patient characteristics and immunohistochemistry are presented as 
mean ± SEM. Statistics were performed using Graphpad Prism 5.0. Groups 
were compared using a Mann-Whitney rank-sum test for continuous variables, 
and were considered statistically different when p < 0.05. 
 
RNA extraction & transcriptomics 
RNA isolation was performed by Guanidium Thiocyanate lysis followed by 
Cesium Chloride gradient centrifugation. Following extraction, the RNA was 
further purified using the Nucleospin RNAII kit (Macherey-Nagel GmbH & Co. 
KG). RNA concentration was measured using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies). The RNA quality and integrity 
was determined using Lab-on-Chip analysis on an Agilent 2100 Bioanalyzer 
(Agilent Technologies). The lowest RNA Integrity Number (RIN) was 5.6, the 
average RIN being 7.23 ± 0.48.  
Biotinylated cRNA was prepared using the Illumina TotalPrep RNA 
Amplification Kit (Ambion, Inc.) according to the manufacturer’s specifications 
starting with 100 ng total RNA. 750 ng of cRNA per sample was used for 
hybridization. Hybridization to Illumina Human Sentrix-8 V2.0 BeadChip® and 
washing were performed according to the Illumina standard assay procedure. 
Scanning was performed on the Illumina BeadStation 500 (Illumina Inc.), image 
analysis and extraction of raw expression data was performed with Illumina 
Beadstudio v3 Gene Expression software with default settings (no background 
subtraction) and no normalization. 
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Computational methods 
Analyses have been performed in the software module R 34. Raw expression 
data were imported using the package lumi 35, and its Variance Stabilizing 
Transform was used for background correction. Data were normalized by 
robust spline normalization, and a filter was imposed to exclude all those 
probes whose detection call resulted ambiguous (30 or more readings of one 
probe with a p-value higher than 0.01) (Supplemental Figure I). 
Expression of CD31, CD105, D2-40 and αSMA in the microarray data 
was consequently correlated to histological data. Reverse engineering of a co-
expression network was performed by taking advantage of the tools included 
in the package WGCNA 36. Softhreshold Power was set at 10. Modules, clusters 
of densely interconnected genes, were identified using the default method of 
hierarchical clustering 37 and the function ‘cutreeDynamic’ 38, with 
‘minModuleSize=30’ and ‘deepSplit=2’, to "cut" the branches of the tree. The 
function ‘moduleEigengenes’ was used to calculate modules Eigengene, and 
the function ‘mergeCloseModules’ to optimize the heuristics of modules by 
merging those who’s Eigengenes were highly correlated. 
For distinguishing between stable and ruptured sections of the same 
plaque, consensus modules, preserved across the two conditions, were 
identified by the function ‘blockwiseConsensusModule’. We assumed that 
consensus gene clusters would be reflective of biological processes underlying 
plaque progression towards instability. By contrast, modules only identified in 
ruptured samples would be reflective of the changes induced by rupture. 
Module-traits association was quantified by correlation and by 
univariate regression model of the Eigengene and quantitative trait, with a p-
value threshold ≤0.05. Within each module, genes with high module 
membership in modules related to traits were natural candidates for further 
investigation, as suggested by Langfelder and Horvath 39, 40. Hereafter, we 
exported the network data to Cytoscape for visualization and further  
analyses 41. The plugin ClueGO was used to enrich the modules of interest for 
over-represented Gene Ontology terms and Pathways 42. 
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Results  
 
Microvessel density was increased in ruptured segments and was associated 
with an increase in CD105, whereas αSMA coverage was unaltered 
To assess plaque and lipid core size, paraffin-embedded sections were HE 
stained and revealed an increased plaque (Figure 1A) and lipid core size (Figure 
1B) in ruptured segments compared to stable segments. Staining for the vessel 
marker CD31 showed both increased MVD (Figure 1C) and microvessel hotspot 
numbers (Figure 1D) within the plaque. Co-localization of the angiogenic 
marker CD105 and CD31 was assessed in stable and ruptured segments and 
analyzed using multispectral analysis (Figure 1E), showing an augmented 
percentage of angiogenic plaque microvessels (Figure 1F). Pericyte 
 
 
 
Figure 1. Ruptured segments showed an increase in microvessel density, angiogenically active 
endothelium, but no difference in pericyte coverage. Plaque area (A) and lipid core  
area (B) were quantified based on HE staining and were increased in ruptured segments. 
Concomitantly, MVD (C) and the number of intimal microvascular hot spots (D) were increased in 
ruptured segments. The percentage of CD105+ angiogenic endothelium was quantified by co-
localization analysis (yellow) using multispectral imaging (E), and showed a significant increase 
in ruptured segments (F). The pericyte coverage (G), as well as the aSMA-positive area per 
microvessel (H) was unchanged, although heterogeneity in aSMA-coverage (blue) between 
different CD31+ hotspots (red) was clearly visible (I). 
A B
C D
F G H
E 
I
IDENTIFYING REGULATORS OF PLAQUE (LYMPH)ANGIOGENESIS USING GENOMICS  
155 
6 
coverage defined as αSMA-covered microvessels (Figure 1G) and the amount 
of αSMA-positivity per microvessel (Figure 1H) were measured, and did not 
show differences between stable and ruptured segments, although a high 
heterogeneity could be observed within the segments. 
 
Extensive lymph vessel expansion was present in rupture segments 
Besides the expansion of plaque microvessels in human plaques, recent data 
suggested proliferation of D2-40+ lymph vessels in advanced stages of 
atherosclerosis 7. Accordingly, we performed D2-40 staining, targeting the 
specific lymphatic endothelial cell marker podoplanin, which revealed strong 
presence of D2-40 in our set of atherosclerotic lesions (Figure 2A), especially in 
the shoulder regions (Figure 2A, inset). When compared to stable segments, 
LVD was increased 5-fold in ruptured segments (Figure 2B). To confirm that the 
D2-40+ vessels indeed exclusively represented lymph vessels, a double staining 
with the lymphatic transcription factor Prox-1 was performed. D2-40/Prox-1 
double positive lymph vessels were specifically shown in control lymphoid 
tissue (Figure 2C) and within atherosclerotic lesions (Figure 2D), affirming that 
the vessel shaped D2-40+ structures were in fact lymph vessels. 
 
 
 
 
 
 
 
Figure 2. Expression of the lymphatic marker D2-40 in stable and ruptured segments. D2-40+ 
lymph vessels (A, brown) are abundantly present in ruptured segments in comparison to stable 
segments (B). Specificity of D2-40 (brown) was determined by double staining with the lymphatic 
transcription factor Prox-1 (blue) in control tonsil tissue (C) and in atherosclerotic lesions (D). 
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Plaque vascularization and lymph vascularization were regulated by 
independent gene clusters 
Quantified histological phenotypes were correlated to microarray data, 
allowing normalization for the histological traits. Correlation analysis of 
histologic traits was performed, to exclude co-linearity between traits which 
would influence later module-phenotype correlations, and showed no co-
linearity, except for the expected co-linearity between MVD and microvessels 
numbers (not shown). In addition, patient samples were clustered 
hierarchically and a heatmap of histological traits was constructed to assess 
possible segregation of patients samples based on histological traits 
(Supplemental Figure II). None of the patients showed significant segregation 
from the study population.  
Subsequently, a weighted co-expression network was constructed by 
implementing a gene co-expression similarity measure to relate every pairwise 
gene-gene relationship. To identify gene clusters, the network was partitioned 
into different modules whenever the number of connections of gene cluster to 
their immediate surroundings was higher than the number of connections 
shared with the center of the group (Supplemental Figure III). This approach 
resulted in the formation of network modules, consisting of groups of densely 
interconnected genes. Eventually, 38 gene modules could be distinguished and 
were subsequently correlated to the histological traits and visualized in a 
module-trait heatmap, to identify modules which are most significantly 
associated with a certain trait like MVD, LVD or angiogenic activity of lesional 
microvascular endothelium (Figure 3). MVD was highly correlated with module 
L (p = 1.0 x 10-4), LVD with module W (p = 1.0 x10-4), and angiogenic activity 
with module R (p = 0.004). Interestingly, MVD and lesion macrophage content 
showed a great, yet not significant overlap in upregulated modules. The 
modules which correlated most highly with specific phenotypic traits were 
investigated in more detail. 
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Figure 3. Heatmap of the module-trait correlations, showing upregulated (red) or 
downregulated (green) gene modules in relation to phenotypic traits in ruptured segments. A 
high overlap in genetic profile was found for MVD and lesional macrophage content  
(% Macrophages), while the percentage angiogenic endothelium (% CD105+ MV) showed a 
completely different expression profile. LVD showed some overlap with gene clusters associated 
with angiogenic endothelium, but was separated from e.g. MVD. Module W was especially 
enriched for LVD. αSMA parameters showed certain overlap with MVD, but failed to show highly 
enriched modules. Values of the Pearson's r coefficient and associated p-values (in parenthesis) 
are reported.  
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Analysis of the gene cluster highly correlating with MVD, but not with 
angiogenic activity, yielded potential target genes involved in plaque 
neovascularization   
To identify potential central genes involved in plaque neovascularization, the 
genes from module L were assessed with respect to the correlation  
between their centrality within module L and gene significance for MVD 
(Figure 4). By this approach, genes which are most likely to be functionally 
involved in determining MVD, in other words plaque neovascularization, 
displayed highest correlation to both centrality and gene significance. As a cut-
off for further gene selection, we applied a minimum value of 0.7 for centrality 
and gene significance to the module (Figure 4), reducing the number of genes 
for functional testing in vitro to 16 (Table 1).  
Identical analyses were performed for module R which was highly 
correlated to angiogenic activity of the microvascular endothelium in the 
lesion (p = 1.7 x 10-4). Module correlation was however low (25%) and none of 
the genes in this module met the criteria (cut-off values) proposed above 
(Supplemental Figure IV).  
 
 
Figure 4. Correlation of gene module centrality versus significance of association to the 
phenotypic parameter MVD. Genes which are most likely to be functionally involved in 
determining MVD can be detected by exhibiting a high correlation to both centrality and gene 
significance. Cut-off value was 0.7 for both parameters (dotted lines).  
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Table 1. Genes showing high correlation for centrality within module L and great gene 
significance for CD31 
 
Gene 
symbol 
Entrez 
ID 
Significance 
for MVD 
P-value Gene 
Significance 
Centrality in 
Module L 
P-value Module 
Centrality 
ABCA9 10350 0.86 2.86e-08 0.84 1.61e-07 
CNTNAP3 79937 0.81 9.16e-07 0.68 1.96e-04 
CASK 8573 0.79 3.32e-06 0.84 1.91e-07 
ZEB1 6935 0.78 4.13e-06 0.90 1.34e-09 
PFN2 5217 0.75 1.44e-05 0.82 4.64e-07 
PPP2CB 5516 0.74 2.06e-05 0.89 3.75e-09 
RPL32 6161 0.74 2.29e-05 0.91 2.45e-10 
ACSL3 2181 0.74 2.40e-05 0.87 2.06e-08 
CAV2 858 0.74 2.43e-05 0.94 4.54e-12 
TMEM98 26022 0.72 4.95e-05 0.95 7.82e-13 
RNF11 26994 0.72 5.10e-05 0.88 7.50e-09 
ECM2 1842 0.72 5.33e-05 0.88 1.01e-08 
PPAP2A 8611 0.72 5.86e-05 0.92 5.26e-11 
ARMCX6 54470 0.71 6.54e-05 0.78 4.11e-06 
TGFB2 7042 0.71 6.93e-05 0.86 3.27e-08 
CNPY4 245812 0.71 7.62e-05 0.81 7.23e-07 
 
 
Analysis of gene cluster highly correlating with LVD, did not reveal genes 
potentially relevant for plaque lymphangiogenesis  
Similar to the approach we applied for the genes from module L, we assessed 
the correlation between the centrality within module W and gene significance 
for LVD for genes of module W (Supplemental Figure V). Unexpectedly, this 
module was only comprised of a relatively small number of genes, and none 
of the genes met the criteria for centrality and gene significance. Also two 
additional modules with high correlation to LVD, modules T and AL, showed 
identical results. 
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Reverse network engineering predicted putative miRNAs involved in gene 
regulation within the module associated with MVD 
In addition to the previous analyses, the connectivity matrix representing 
module L was transferred in Cytoscape, where the network architecture was 
investigated and an enrichment analysis for regulatory mechanisms was 
performed on the basis of the gene-gene interactions. Interestingly, this 
approach revealed five miRNAs (miR302d, miR488*, miR582-3, miR606 and 
miR1284) which were predicted to be centrally present within the gene 
network, and which could potentially be of importance for regulation of the 
genes linked to MVD (Figure 5). 
 
 
 
Figure 5. Gene clustering of module L. Network analysis predicted five miRNAs (miR302d, 
miR488*, miR582-3, miR606 and miR1284) to be centrally present (arrows) within the gene 
network, potentially involved in the regulation of genes linked to MVD.  
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Discussion 
 
In this study, we identified genes, transcription factors, and miRNAs which are 
specifically regulated in plaque angiogenesis and lymphangiogenesis, and may 
thus be indirectly involved in plaque rupture and intraplaque hemorrhage. We 
correlated quantified histological data with expression data from a microarray 
performed on stable and ruptured atherosclerotic tissue segments, and 
attempted to dissect regulatory pathways that control or are affected by 
plaque (lymph)angiogenesis. We were able to distil a number of genes which 
may be involved in the (lymph)angiogenic process in atherosclerosis, as well as  
miRNAs which thus far are unknown both in atherosclerosis and angiogenesis. 
In the current study, we first assessed phenotypical traits based on 
histology and immunohistochemistry. Histological analysis showed an increase 
in plaque and lipid core size in ruptured segments. Concurrently, and in line 
with literature 3, 7, we found an increased microvascular density, lymph vessel 
density, and increased angiogenic activity in ruptured segments compared to 
stable segments. As expected, pericyte coverage was low, yet surprisingly not 
differential between the stable and ruptured segments, and showed a highly 
heterogeneous pattern of pericyte coverage. Low pericyte coverage has been 
described in tumor vasculature 43, but was until now not extensively 
investigated in plaque neovasculature. An important conclusion is that absence 
of pericytes is a common feature in advanced atherosclerotic lesions, and that 
an immature microvascular phenotype is already present prior to progression 
towards a ruptured or vulnerable plaque stage. This also suggests that newly 
formed microvessels in plaques do not undergo vessel maturation, and that 
the low pericyte coverage is not due to pericyte loss during plaque 
progression. To verify this however, pericyte coverage should be thoroughly 
quantified in several, also earlier, plaque development stages. 
From the histological analysis, data was correlated with expression 
data from a microarray. The large amount of genes found in the CD31 
correlation analysis required us to include further criteria for gene selection for 
validation. Implementing a strict cut-off value for correlation with the gene of 
interest with the module (Gene Significance) and a central position within the 
module (Module Membership) resulted in a great reduction in the number of 
genes. Although the cut-off value is in part arbitrary, we consider a high 
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correlation with both factors important, since this would reflect genes which 
likely have a central role in regulation of plaque neovascularization in vivo.  
Several of the genes we identified within module L (Table 1) could 
already represent interesting targets based on their previously described 
functions. Examples hereof are PFN2, CNTNAP3, or CASK, which have been 
linked to neuronal growth, neuronal guidance, or response to hypoxia 44-46. 
Specifically for finding new potential angiogenesis-related genes, genes which 
have already been described in neuronal growth could be of special interest, 
since it has been shown that there is a great homology between genes 
involved in neuronal growth and angiogenesis 47. Therefore, it is conceivable 
that genes described in this process may also be involved in plaque 
angiogenesis. Additionally, several known angiogenesis-related genes, e.g. 
FGF-2, were expressed in module L, although their module centrality and gene 
significance were below the cut-off values applied for gene selection. 
Interestingly, the modules correlating with analysis of the gene cluster 
which highly correlated with angiogenic endothelium did not reveal any 
relevant targets. This was unexpected, as one may expect that selection based 
on a marker which is regarded as a marker of angiogenesis yields specific 
angiogenic targets. One explanation may be that CD105, although it is known 
to be expressed on activated endothelium, can also be found on endothelial 
cells, activated macrophages, fibroblasts, and smooth muscle  
cells 48. Even though we specifically analyzed CD105 expression on CD31+ 
endothelium, whole tissue expression of CD105 in the atherosclerotic tissue 
may have obscured its function in angiogenesis in the microarray.  
Not only correlation with CD105 expression yielded poor results.  Also 
the amount of genes correlating with the lymphatic marker D2-40 was 
relatively low. Module W, most highly correlating with LVD, only consisted of 
few genes, none of which met the criteria (cut-off values) set for inclusion for 
further validation. Including alternative markers for lymphangiogenesis for 
correlation to the microarray data, or defining slightly less stringent cut-off 
values for gene inclusion may be options for future analysis. 
The module correlating to CD31 expression is also strongly correlated 
to the expression of the macrophage marker CD68. It is known that 
macrophages can produce high levels of angiogenic and potentially 
lymphangiogenic factors, especially under inflammatory conditions. In 
addition, macrophages produce a multitude of factors required for the 
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angiogenic process, e.g. proteases or guidance molecules 49, 50. Therefore, the 
fact that the same module is strongly correlating with both endothelial cells 
and macrophages is not surprising, and may reflect the interplay between 
microvessels and macrophages in plaque angiogenesis. Some of the genes 
described in Table 1 may also reflect the contribution of macrophages, as e.g. 
ABCA9 has been previously linked to lipid uptake by macrophages 51. The 
overlap in gene expression profile, however, substantiates the need for proper 
gene selection for validation, as mentioned earlier e.g. by looking at cell type 
specific expression. These studies are currently underway.  
Of great interest is our finding of novel miRNAs which may be involved 
in plaque angiogenesis. These miRNAs, non-coding, single-stranded RNAs 
which are important regulators of gene expression, have received a lot of 
attention in the last few years. Consequently, several miRNAs have been 
implicated in angiogenesis, or in related processes like migration, as recently 
reviewed by Chen et al 52. The miRNAs we found have thus far not been linked 
to angiogenesis, and except for miRNA606, which was detected in a miRNA 
screening in colorectal cancer 53, no function has been attributed to these 
miRNAs. This makes these miRNAs valuable targets for further validation.  
An imperative next step definitively will be validation of these genes 
and miRNAs, both in vitro and in vivo. A first step in this would be to 
characterize expression of these genes and miRNAs in endothelial cells (and 
macrophages). Additionally, the genes and miRNAs may be further studied 
functionally by inhibiting gene or miRNA expression. For endothelial cells, a 
number of functional parameters could be studied, e.g. adhesion, proliferation 
and migration capacity, the ability of the endothelial cells of form vessels in a 
tube formation assay, or the assessment of endothelial barrier function, 
investigating a potential role in the leaky phenotype of vessels. Viable 
candidates, which show a disturbed function after knock-out, may additionally 
be tested in vivo, e.g. in a zebrafish system 54, 55. This will allow validating in 
vitro data and would be a high-throughput system for selecting the most 
promising candidate for testing in a murine atherosclerosis setting.  
In conclusion, we present several genes and five miRNAs which may 
have a role in control of, or are affected by plaque (lymph)angiogenesis. 
Validation of the genes and miRNAs will be necessary to determine whether 
these genes are indeed involved in these processes and may potentially yield 
future targets for specific intervention. 
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Supplemental Figures 
 
Supplemental Figure I. Density histogram of raw log-intensities from patient samples before 
(upper panel) or after (lower panel) preprocessing. The overlap of samples after normalization 
confirms that batch effect has been eradicated and that all the signals share the same scale. 
 
 
 
Supplemental Figure II. Sample dendrogram and trait heatmap, showing homogeneous 
distribution of patients, with no outliers, and revealing the homogeneity of the impact of each 
included sample on the value distributions of the quantified phenotypes  
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Supplemental Figure III. Cluster dendrogram showing clustering of gene networks into modules. 
Whenever the number of connections of gene cluster to their immediate surroundings was 
higher than the number of connections shared with the center of the group, this network  
was classified as a module. 
 
 
Supplemental Figure IV. Module Membership for Module R versus Gene Significance for CD105. 
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Supplemental Figure V. Module Membership for Module R versus Gene Significance for D2-40. 
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Abstract 
 
During plaque progression, the adventitia has shown to be progressively 
enriched in inflammatory cells like T and B cells, mast cells and dendritic cells, 
cytokines and chemokines, as well as vasa vasorum and lymphatic capillaries. 
Lymphatic capillaries play an important role in lymphocyte and dendritic cell 
trafficking as well as analyte communication between inflammatory sites and 
draining lymph nodes. The observation that the adventitia of human 
atherosclerotic vessels is enriched not only in T cells but also in lymphatic 
capillaries has inspired us to address the role of these lymphatic capillaries in 
regulating T cell influx to, and efflux from the adventitia of atherosclerotic 
lesions of ApoE‐/‐ mice.  
Intravenous administration of CD3+ T cells resulted in a CXCR3 
dependent accumulation of CD3+ T cells in the adventitia of the atherosclerotic 
vessel wall, at which T cell presence displayed an overt gradient from 
adventitia (high) to intima (scarce). Second, we showed that, as in humans, the 
lymphatic capillary density in adventitia expanded during murine plaque 
development. Removal of the draining lymph node and its efferent lymphatic 
vessel resulted in an increase in plaque volume, accompanied by increased 
plaque and adventitial CD3+ T cell numbers. Inhibition of lymphangiogenesis 
using an AAV‐hVEGFR3‐Ig construct also resulted in CD3+ T cells enrichment in 
both plaque and adventitia.  
Taken together, this study showed that local lymph capillaries in the 
adventitia of atherosclerotic plaques may be involved in the dynamics of local 
T cell efflux and may affect plaque phenotype. 
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Introduction 
 
One of the key processes in atherosclerosis development, both in humans and 
experimental atherosclerosis models, is the local inflammatory response which 
drives disease progression. A myriad of immune cell types, e.g. macrophages, T 
and B cells, dendritic cells (DCs), have been described to be involved in plaque 
development and/or progression 1‐5. Although the inflammatory response in 
atherosclerosis is to a large part confined to the lesion itself, there is growing 
evidence for a crucial role of the adventitia in vascular inflammation and 
plaque development reviewed in 6. 
The adventitia is the outer layer of the vessel wall and is a highly 
organized tissue characterized by stromal tissue, vasculature and the presence 
of several leukocyte subsets. The adventitia is enriched in B cells, which were 
shown to exert both pro‐ and anti‐atherogenic effects 7‐9. Moreover, adventitial 
tissue is a major site of T cell accumulation in mouse atherosclerotic  
vessels 10, 11. Regulatory T cells and mast cells are scarcely present in the 
intima, but more abundant in the adventitia 12, 13. The overt presence of DCs in 
clusters near T cells in the adventitia, suggest a role for the adventitia as a 
platform for antigen presentation 9, 14. In addition, the adventitia is a highly 
vascularized tissue. Vasa vasorum in fact expand with atherosclerosis 
progression both in human atherosclerosis and murine atherosclerosis models, 
and is regarded to have an important function in trafficking of inflammatory 
cells 15, 16.  
The adventitia is therefore increasingly viewed as an important 
gateway for leukocytes to the plaque, a notion referred to as the “outside‐in” 
hypothesis 17. Findings by Ley and co‐workers support the notion that T cells 
can enter atherosclerotic lesions via the adventitia 11. In addition, Eriksson et al 
further substantiated this finding by demonstrating that leukocytes invade the 
plaque in an L‐ and P‐selectin dependent manner via microvessels sprouting 
from the adventitia 15. Previous work from our group has already shown that 
the extravasation of inflammatory cells from the vasa vasorum in mice is 
substantial 18. Next to vasa vasorum expansion, presence of lymphatic 
capillaries has recently been demonstrated in the adventitia of human 
atherosclerotic vessels 19, 20, and the number of adventitial lymphatic capillaries 
has been shown to increase with severity of atherosclerosis in humans 22, 23. 
The lymphatic system is also well known for its role in cell trafficking in and out 
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of tissues 21‐23. Although a functional role of adventitial lymphatic capillaries in 
atherosclerosis has not yet been documented, they conceivably are involved in 
the regulation of inflammation, by draining (i) antigen‐presenting cells from 
the site of inflammation to the draining lymph node, where lymphocytes will 
be sensitized and activated to participate in the ongoing inflammatory 
response; (ii) excess inflammatory cells in general; and/or (iii) secreted growth 
factors, cytokines, and built‐up interstitial fluid.  
In this study, we addressed the role of adventitial lymphatic capillaries 
in a murine model of atherosclerosis by a loss‐of‐function approach. Our 
results suggest that the lymphatic capillaries are responsible for drainage of T 
cells from the atherosclerotic lesion. 
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Methods 
 
Analysis of adventitial lymphatic capillaries and CD3+ T cells  
Male ApoE‐/‐ mice (n=21), backcrossed at least 11 times to C57Bl/6 and 
obtained from The Jackson Laboratory, were placed on western type diet 
(WTD) containing 0.25% cholesterol and 15% cacao butter (Special Diets 
Services, Witham, Essex, UK). Atherosclerotic lesions were induced in the 
carotid artery by bilateral placement of semi‐constrictive collars 24. To study 
the expression of lymphatic capillaries and CD3+ T cells in the adventitia of 
early lesions, mice (n=9) were sacrificed 4 weeks after collar placement. The 
expression of lymphatic capillaries and CD3+ T cells in the adventitia of 
advanced lesions was studied in mice (n=6), sacrificed 8 weeks after collar 
placement. ApoE‐/‐ mice without collar placement (n=6) served as control. All 
animal experiments were approved by the local animal ethics committee and 
performed according to institutional guidelines. 
 
T cell trafficking experiments 
For T cell trafficking studies, CD3+ T cells were isolated from spleen of wild‐type 
and CXCR3‐/‐ 24 mice using a CD3 isolation kit (BD Biosciences) and were pre‐
stimulated with 1 ng/mL IL‐2 (Sigma‐Aldrich). Male ApoE‐/‐ mice (n=8) were 
placed on western type diet and received a semi‐constrictive collar to induce 
plaque formation. Additionally, these mice received an intravenous injection 
containing a 1:1 mixture of CMFDA labeled WT (107 cells) and CMTPX labeled 
CXCR3‐/‐ (107 cells) T cells 4 weeks after collar placement; controls received WT 
T cells only. Twenty‐four hours later, mice were sacrificed and perfused with 
phosphate buffered saline (PBS). The right carotid artery was removed, 
embedded in Tissue Tek (Miles Inc) and snap‐frozen at ‐196°C. Frozen sections 
(5 µm) were cut over a segment covering the entire plaque and nuclei were 
counterstained with DAPI (Sigma‐Aldrich). Overlay images were acquired using 
a Leica DM5000B fluorescence microscope, using a DAPI filter (DAPI), a FITC 
filter (CMFDA) and a Tx2 filter (CMTPX). Analysis was performed in a blinded 
manner. The number of T cells present in the adventitia was expressed per  
10 µm segment plaque.  
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Lymph node and vessel dissection in mice 
Male ApoE‐/‐ mice (n=27) were placed on western type diet and semi‐
constrictive collars were placed around the carotid arteries to induce 
atherosclerosis development 24. To address the contribution of the deep 
cervical lymph node to leukocyte influx into, and efflux from the adjacent 
plaque, the lymph node and efferent lymph vessel were removed immediately 
after collar placement (n=14). Mock treated mice (n=13) served as control. At 
sacrifice, mice from the lymph node dissection group did not show any signs of 
edema in the neck region. In a separate study, we investigated whether lymph 
node and vessel dissection per se could induce an inflammatory response, 
which could impact lesion formation indirectly. We studied effects of the 
above intervention in normolipidemic wild‐type mice (n=5‐6). In both 
experiments mice were sacrificed 4 weeks after collar placement. 
 
Inhibition of lymphangiogenesis in mice  
Male ApoE‐/‐ mice (n=34) were placed on western type diet and semi‐
constrictive collars were placed around the carotid arteries to induce 
atherosclerosis development 24. To inhibit VEGFR3‐dependent adventitial 
lymphangiogenesis during plaque development, adeno‐associated virus (AAV) 
encoding a soluble hVEGFR3‐Ig (AAV‐hVEGFR3‐Ig, 1011 virus particles per 
mouse 25) or control virus (AAV‐hVEGFR3(D4‐7)‐Ig) was administered 
systemically by intravenous injection at the time of collar placement (n=17 
hVEGFR3‐Ig vs. n=17 control). Mice were sacrificed 4 weeks after collar 
placement. 
A subgroup of mice (n= 5 per group) also received a subcutaneous 
VEGF‐C supplemented matrigel plug (BD Bioscience), as a positive control for 
inhibition of lymphangiogenesis by the hVEGFR3‐Ig construct. In addition, 
serum from mice was isolated 4 weeks after collar placement by centrifugation 
of whole blood (10 min, 2100 rpm, 4°C), and transgene expression was 
assessed by ELISA and western blot. 
 
Histology of mouse atherosclerotic lesions 
Mice were euthanized by an overdose pentobarbital (115mg/kg) and perfused 
through the left cardiac ventricle with PBS (NaCl/Na2HPO4/KH2PO4, pH 7.4) 
containing sodium nitroprusside (0.1 mg/ml, Sigma) and 1% paraformaldehyde 
(PFA). The right carotid artery was removed, fixed overnight in 1% PFA and 
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paraffin‐embedded sections (4 µm) were cut. To determine plaque volume in 
the carotid artery, sections were stained with haematoxylin and eosin (HE) and 
plaque area was measured for consecutive cross sections at 100 µm intervals 
over a carotid artery segment that covered the entire plaque. Slides were 
analyzed in a blinded manner using a Leica DM3000 light microscope (Leica 
Microsystems) coupled to computerized morphometry (Leica Qwin 3.5.1) 26.  
 
Immunohistochemistry 
Immunohistochemical (IHC) staining on mouse paraffin carotid artery sections 
was performed for the lymph vessel markers podoplanin (R&D systems),  
LYVE‐1 (Abcam), and Prox‐1 (Prof. Dr. Alitalo, University of Helsinki, Finland), 
for T cells using CD3 (DAKO), for macrophages using Mac‐3 (BD), and for CXCR3 
(Sanbio/MBL) and for its ligand IP‐10 (R&D systems). Lyve‐1+ lymphatic 
capillary content was expressed as percentage of adventitial area. Adventitial 
area was defined as the tissue within the outer elastic lamina and twice the 
smallest intima‐media thickness. The number of CD3+, CXCR3+ and Mac‐3+ cells 
was expressed as percentage of total plaque or adventitial cells. IHC staining 
for podoplanin (R&D systems) was also performed on paraffin embedded 
matrigel plugs from the AAV‐hVEGFR3‐Ig study (n=5/group). Lymph vessel 
number per plug area was determined in three slides per matrigel plug. All 
slides were analyzed blindly using Leica Qwin software. 
 
Flow cytometry and plasma cholesterol measurements 
Blood, spleen and lymph nodes were removed before perfusion (n=10/group) 
and used for flow cytometry of monocytes (CD11bhigh Ly6G‐, BD), granulocytes 
(CD11bhigh Ly6Ghigh, BD), T helper cells (CD4+, BD), effector T cells (CD8a+,BD) 
and activated T cells (CD44high, eBioscience). Briefly spleen and lymph nodes 
were homogenized, filtered through a 70 µm mesh, and subjected to red blood 
cell lysis. All cells were stained in flow cytometry buffer (1x PBS, 0.5% BSA, 
0.01% NaN3). Staining for blood count analyses was conducted using 
antibodies to CD45, CD115, Gr1, CD19, and CD3 (all eBiosciences) in Hank's 
Balanced Salt Solution (HBSS) with 0.3 mM EDTA and 0.1 % BSA. Blood was 
subjected to red blood cell lysis. Cell counts were estimated utilizing 
CountBrightTM absolute counting beads (Invitrogen). All flow cytometry 
analysis was performed on a FACS CANTO II (BD Bioscience).  
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Plasma cholesterol levels were measured using a colorimetric assay (CHOD‐
PAP, Roche, Mannheim, Germany). Disposables were purchased from Greiner 
Bio One. 
 
Multiphoton laser scanning microscopy (MPLSM) 
For MPLSM of adventitial lymphatics, ApoE‐/‐ mice (n=6) were anaesthetized by 
dorsal subcutaneous injection with ketamin (100 mg/kg body weight, 
Nematek) and xylazin (10 mg/kg body weight, Sedamun). Hereafter, mice were 
injected with the fluorescently labelled ligands directly into the deep cervical 
lymph node or intracutaneously above the clavicula (as indicated) and after 10 
minutes mice were sacrificed. The lumen of the vasculature was flushed with 
0.9% NaCl by intracardial perfusion, and carotid arteries were exposed and in 
situ imaging was performed. 
 For imaging, the following probes were used: biotinylated podoplanin 
(R&D systems) conjugated to Dylight594 (ThermoScientific) for staining the 
lymphatic endothelial cells, Syto 41 (blue, Invitrogen) for staining all nuclei, a 
FITC‐labelled cABD probe 27 (green) for tracking lymph vessels in the adventitia, 
and CMTPX labeled (red, 107 cells) T cells. MPLSM imaging was performed on a 
Leica SP5 imaging platform (Leica Microsystems, Germany) that integrates 
multiphoton microscopy with fast resonant scanning, and uses a Compact 
Ultrafast femtosecond‐pulsed Ti:Sapphire Laser (Chameleon, Coherent, USA). 
An excitation wavelength of 880nm was used in all experiments. Tissues were 
observed using a 20x 1.0 water immersion objective (HCX PL APO L, Leica 
Microsystems, Germany) with a numerical aperture of 1.00 and integrated 
optical zoom allowing magnification up to 60x. Photo‐multiplier tubes were 
used to detect two spectral regions: 515‐560 nm (FITC, Syto13) and 570‐ 
600 nm (Dylight594, CMTPX). Image acquisition was performed at a frame size 
of 512x512 pixels (pixel size: 1.44 x 1.44 μm), scanning at 100Hz and a frame 
average filter of 2 was used to reduce noise. In‐depth scans were performed at 
200Hz with a frame average of 2. Consecutive images had an interplanar 
distance of 1.00 μm. 
 
Statistical analysis 
Data are expressed as mean ± SEM and Mann‐Whitney U test was used to 
compare individual groups of animals. Statistics were performed using 
Graphpad Prism 5.0. Data were considered statistically significant at p < 0.05. 
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Results 
 
Lymphatic capillaries were present in the adventitia of mouse atherosclerotic 
lesions and their presence increased with plaque progression 
First, we investigated the presence of lymphatic capillaries in the adventitia of 
mouse atherosclerotic lesions. In the adventitia, both vasa vasorum and 
lymphatic capillaries were present (Figure 1A).  Concordant with observations 
in human atherosclerotic lesions 19, 20, we observed that lymphatic capillary 
numbers in the adventitia were already significantly increased early in plaque 
development (Figure 1B). However, we did not observe any further expansion 
of the adventitial lymphatic vessel bed at later stages of plaque development, 
suggesting that lymphatic expansion occurs already early in plaque 
development. 
 
 
 
Figure 1. The presence of lymphatic capillaries in the adventitia of atherosclerotic lesions.  
Immunohistochemistry for LYVE-1+ lymphatic capillaries (purple) and CD31+ vasa vasorum (blue) 
in mouse carotid atherosclerotic lesions (A). Continuous line indicates the outer border of the 
media; the area between the continuous and dotted line indicates the adventitial area used for 
quantification. Perivascular fat was excluded from analysis (A). The percentage of LYVE-1+ 
lymphatic capillaries per adventitia area of healthy (n=6) versus early (n=9) and advanced (n=6) 
mouse carotid atherosclerotic lesions (B). ***p < 0.05 
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CD3+ T cells were abundant in the adventitia of mouse atherosclerotic lesions 
and entered the vessel wall via the adventitia in a CXCR3 dependent manner 
Adventitial T cell accumulation started during plaque initiation and decreased 
with plaque progression (Figure 2A). This observation suggests that CD3+ T cells 
may invade the vessel wall via the adventitia to contribute to early 
atherosclerosis development. To address this question, CMFDA (green) labeled 
CD3+ T cells were administered via intravenous injection in western type diet 
fed ApoE‐/‐ mice four weeks after collar placement, when early lesion had 
formed. 
 
 
 
 
Figure 2. Expression and migration of CD3+ T cells in the adventitia. The percentage of CD3+ T 
cells per adventitia area of healthy vessels (n=6) versus early (n=9) and advanced (n=6) mouse 
carotid atherosclerotic lesions showed a clear increase during plaque development, especially in 
early lesions (A). A CD3+ T cells homing experiment showed a gradient of T cells from the 
adventitia, via media to the plaque within 24 hours after injection, reflective of adventitia to 
intima T cell flux (B). Immunohistochemistry for IP-10, the main chemokine for attracting 
activated T cells, on mouse carotid atherosclerotic lesions revealed high IP-10 expression in the 
adventitia, most notably by vasa vasorum and scattered leukocytes (C). Arrows indicate the 
expression of the CXCR3 ligand IP-10 by the vasa vasorum. Injection of CXCR3-/- CD3+ T cells 
showed an abrogated homing of T cells to the adventitia within 24 hours compared to wild-type 
CD3+ T cells (D), arguing for IP-10/CXCR3-dependent T cell homing. *p < 0.05, **p < 0.01. 
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Histological analysis revealed a clear‐cut gradient in CD3+ T cell density from 
the adventitia (high numbers), via the media (intermediate numbers) to the 
intima (low numbers) (Figure 2B). In search of chemokines that might be 
responsible for adventitial T cell accumulation, we focused on Interferon 
Inducing Protein‐10 (IP‐10), which was highly expressed in the adventitia, 
especially around the vasa vasorum (Figure 2C, arrows) and is known to 
interact with CXCR3 as a major mediator of T cell chemotaxis 28. To investigate 
whether T cell migration towards the adventitia occurred in a CXCR3 
dependent manner, we administered a mixture of CMFDA (green) labeled wild‐
type and CMTPX (red) labeled CXCR3‐/‐ CD3+ T cells via intravenous injection 
into western type diet fed ApoE‐/‐ mice, four weeks after collar placement. In 
contrast to wild‐type T cells, which were prominently recruited, CXCR3‐/‐ T cell 
migration towards the adventitia was almost ablated (Figure 2D), indicating 
that adventitial T cell accumulation is largely CXCR3 dependent.   
 
 
Figure 3. Detection of lymph vessels and capillaries ex vivo and in situ. Dissected lymph node 
and efferent lymph vessel from lymph node dissection experiments (A). Lymph node and efferent 
lymph vessels could be stained for podoplanin (red) ex vivo (B, nuclei in green). A lymph-residing 
FITC-labelled cABD probe allowed staining of adventitial lymph capillaries in situ, and showed 
close proximity of CMTPX (red) labeled CD3+ T cells to lymph capillaries in ApoE-/- mice (C). Bar 
indicates 25 µm. 
 
To address the association between T cells and the adventitial lymph 
capillaries, MPLSM was used to visualize the lymphatic system. Intranodal 
injection of a podoplanin antibody into the draining lymph node before 
dissection (Figure 3A) visualized the lymph node and efferent lymph vessel 
(Figure 3B, red), but not the lymph capillaries in the adventitia (not shown). 
Moreover, by concomitant intracutaneous injection of a lymph‐residing cABD 
probe, to visualize lymph capillaries 27, and intravenous injection of CMTPX 
labeled CD3+ T cells, we were able to detect CD3+ T cells (Figure 3C, red) in 
close proximity of the adventitial lymph capillaries (Figure 3C, green).  
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Lymph node and lymph vessel dissection deteriorated atherosclerosis 
development in ApoE-/- mice by promoting T cell accumulation inside the 
lesion and adventitia 
The proximity of T cells to the adventitial lymph capillaries, together with the 
fact that lymph vessels have been implicated in regulation of  
inflammation 29, 30, argue a potential role for lymph capillaries in the 
inflammatory process in atherosclerotic arteries. To elucidate the role of 
adventitial lymph capillaries, we studied the effect of dissection of the draining 
lymph vessels and lymph node. The deep cervical lymph node is proximal to 
the carotid artery bifurcation. An efferent lymphatic vessel is originating from 
this lymph node, running upstream parallel to the carotid artery. To address 
whether adventitial lymph capillaries are involved in leukocyte accumulation 
and plaque development, the deep cervical lymph node and its efferent vessel 
were removed during collar placement in ApoE‐/‐ mice (Figure 4A).  
First, lymph node dissection by itself did not induce local inflammation 
in the adventitia, as judged the equal CD45+ leukocyte content between mice 
that had undergone lymph node dissection (Figure 4B). In addition, circulating 
monocyte numbers (Figure 4C) and spleen and peripheral lymph node CD3+ T 
cell content (Figure 4D, 4E) were unchanged as well, and lymph node 
dissection did not impact body weight (29.23 ± 0.48 g and 27.64 ± 0.52 g in 
control versus lymph node dissected mice, respectively). Interestingly, lymph 
node dissection aggravated atherosclerotic plaque development (Figure 4F, 
4G) and plaques displayed increased adventitial (Figure 4H) and intimal CD3+ T 
cell content (Figure 4I). Plaque macrophage content remained unaltered 
(Figure 4J). Remarkably, we did not observe any effects of draining lymph node 
removal on lymphatic capillary bed density, in the adventitia (Figure 4K) at end 
point (four weeks after lymph node dissection), although origin and 
functionality of these newly formed capillaries remained unclear. Altogether, 
these data point to a role of adventitial lymphatic capillaries in draining T cells 
and/or T cell activating chemokines and cytokines from the plaque, translating 
in reduced T cell but not macrophage accumulation in the plaque. This in turn 
may dampen inflammation and plaque development. 
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Figure 4. Lymph node dissection results in an aggravation of plaque development in mice, 
characterized by an accumulation of CD3+ T cells within the vessel wall. Draining lymph node and 
efferent vessel were excised in the lymph node dissection group (A). Lymph node dissection by 
itself did not induce inflammation in the vessel wall. Represented is the percentage of CD45+ 
leukocytes in the adventitia of control (n=6) and lymph node dissected (n=5) WT mice (B). Flow 
cytometry analysis for CD11bhigh monocytes in blood (C), as well as CD3+ T cells in spleen (D) and 
peripheral lymph nodes (E) revealed no changes. Lymph node dissection resulted in bigger plaques 
as observed by HE staining (F). Quantification of plaque volume confirmed the increase in plaque 
volume in the lymph node dissection group (G). Lymph node dissection increased the percentage of 
CD3+ T cells in the adventitia (H) and within the plaque (I), while plaque Mac-3+ macrophage 
presence was unaltered (J). The percentage of LYVE-1+ lymphatic capillary area in the adventitia 
also was unchanged. *p < 0.05.  
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Inhibition of lymphangiogenesis using an AAV-hVEGFR3-Ig construct did not 
change plaque burden, yet increased lesional T cell content 
The lymph node dissection study suggested that the efferent lymph vessel that 
parallels the carotid artery is not accountable for plaque initiation associated 
adventitial lymph vessel expansion. Therefore, we sought to address the effect 
of systemic interference in lymphangiogenesis by AAV overexpression of IgG 
fused soluble human VEGFR3 (AAV‐hVEGFR3‐Ig 25). Gene therapy led to 
persistent 3‐fold overexpression of soluble hVEGR3 in serum of treated mice, 
but not controls as assessed by western blotting (Figure 5A) and ELISA (Figure 
5B). The achieved sVEGFR3 levels were sufficient to halt, the lymphangiogenic 
response in an in vivo VEGF‐C supplemented matrigel plug assay, as illustrated 
by the sharp reduction in lymph vessel ingrowth (Figure 5C). AAV gene therapy 
showed a borderline reduction in body weight (Supplemental Figure I‐A;  
p = 0.053), but did not alter plasma cholesterol levels (Supplemental Figure I‐
B), nor did it affect leukocyte subset counts and distribution in blood, spleen, 
and lymph nodes, except for a tendency towards decreased numbers of 
CD4+Ly6Chigh effector‐memory T helper cells in the draining deep cervical 
lymph node, accompanied by an increase in CD4+Ly6Clow naïve T cells (not 
shown). 
Plaque volume (Figure 5D) and lipid core volume (Supplemental Figure 
I‐C) were not significantly affected. However, plaques of AAV‐hVEGFR3‐Ig 
treated mice showed a more inflammatory phenotype, with increased 
adventitial and intimal CD3+ T cell content (Figure 5E). Much to our surprise, 
while halting systemic lymphangiogenesis in the matrigel plug assay, hVEGFR3 
overexpression failed to inhibit adventitial lymphatic capillary expansion 
(Figure 5F). Moreover, in advanced inflammatory plaques, we observed an 
increase of lymph capillaries inside the plaque (Figure 5G, 5H).  
Collectively, in both the systemic lymphangiogenesis intervention 
study and the LN dissection study, we observed a striking increment in lesional 
T cell content, pointing to a role of plaque associated lymph vessels in 
regulating local T cell content.  
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Figure 5. Soluble hVEGFR3 gene therapy led to effective inhibition of systemic but not plaque-
associated lymphangiogenesis, yet induced an increase in plaque T cell content.  
Lymphangiogenesis was inhibited by intravenous AAV-hVEGFR3-Ig gene transfer resulting in a 
persistent, clear expression of soluble hVEGFR3, detected by western blotting (A), and an 
increase in total soluble hVEGFR3 (ELISA) in plasma (B). AAV-hVEGFR3-Ig gene transfer reduced 
lymph vessel formation and ingrowth in an in vivo matrigel plug assay (C, n=5 mice/group) four 
weeks after s.c. administration. While plaque volume was not affected by AAV-hVEGFR3 
treatment (D), it did significantly increase adventitial and plaque T cell content (E). Remarkably, 
the lymph vessel density was unaltered in the adventitia at point of sacrifice (F), and an increased 
lymph vessel density was observed within the plaque (G), as visualized by LYVE-1+ staining (H, 
arrow).  *p < 0.05, ***p < 0.005 
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Discussion 
In this study, we are the first to describe a role for adventitial lymphatic 
capillaries in plaque inflammation and atherosclerosis in mice. We show that 
the adventitial lymphatic capillary bed is expanded early on in the atherogenic 
process, concomitantly with the increase in plaque CD3+ T cell content. CD3+ T 
cells were found to enter the atherosclerotic vessel wall in a CXCR3 dependent 
manner, mainly via the adventitia. Combined dissection of the plaque draining 
lymph node and its efferent lymphatic vessel prior to the atherogenic stimulus 
resulted in an aggravation of atherosclerosis development, in which lesions 
were characterized by increased T cell accumulation in plaque and adventitia. 
Augmented accumulation of T cells was also found after systemic inhibition of 
VEGFR3 dependent lymphangiogenesis. Paradoxically, both interventions did 
not impact the lymph capillary bed density in adventitia and plaque, suggesting 
that atherosclerosis‐related interstitial pressure build‐up and/or inflammation 
may be the driving forces in plaque lymphangiogenesis.  
An intriguing finding was that during atherosclerosis in ApoE‐/‐ mice the 
adventitial lymphatic capillary bed is expanded, already at early stages of 
disease development. These data correspond with previous findings in humans 
in which the lymphatic capillary content of carotid artery plaques was seen to 
increase with severity of atherosclerosis 19, 20. Although the exact trigger for 
adventitial lymphangiogenesis during atherosclerosis remains to be 
established, it is conceivable that it is related to the augmented production of 
growth factors such as VEGFs and pro‐lymphangiogenic cytokines/chemokines 
in the inflamed plaque and adventitia 31. VEGF expression in the atherosclerotic 
vessel wall has been documented in several studies and its overexpression was 
shown to accelerate atherosclerosis by inducing monocyte activation, adhesion 
and migration and by enhancing vascular permeability 32‐34. In addition to 
VEGFs, various chemokines have been shown to regulate lymphangiogenesis. 
CCL21, which is expressed in the adventitia, and its receptor CCR7 were both 
reported to be involved in the induction of lymphangiogenesis 35, 36. A similar 
regulatory role in lymphangiogenesis and lymph vessel homeostasis was 
proposed for the CXCL13/CXCR5 axis and the CXCL12/CXCR4 axis 37‐39. 
Altogether, these data show a link between adventitial lymphangiogenesis and 
inflammation.  
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Our data showed that, concordant with previous observations 11, 17, the 
adventitia of mouse atherosclerotic lesions expresses high numbers of CD3+ T 
cells, where the adventitia contains much more T cells than the intima. In fact, 
adoptively transferred T cells migrate primarily to the adventitia, then to the 
media and to a lesser extent to the intima, suggestive adventitial to intimal 
flux. T cell influx into the adventitia is CXCR3 dependent. The main chemokine 
to activate CXCR3 and attract activated T cells is IP‐10. It is secreted by 
activated T cells, fibroblasts and endothelial cells 28, 40, 41, and is as we show 
highly expressed in the adventitia of atherosclerotic vessels.  
Given the (putative) role of lymphatic vessels in dendritic cell 
trafficking to the draining lymph node to activate T cells 29, we hypothesized 
that interruption of lymph draining by lymph node and efferent vessel 
dissection would result in impaired T cell activation and consequently reduced 
plaque inflammation. Surprisingly, removal of the plaque draining lymph node 
located proximal to the carotid artery bifurcation, resulted in aggravation of 
atherosclerosis, featured by pronounced CD3+ T cell accumulation in plaque 
and adventitia. Taken together with the close proximity of T cells to the 
adventitial lymph capillaries, our data suggest that the perivascular lymphatic 
bed in the adventitia may well be involved in drainage of T cells, and thus may 
play a role in the regulation of inflammation in the vessel wall. In addition to T 
cells, adventitial lymphatic capillaries could also help to prevent edema, 
inflicted by the leaky plaque vasa vasorum, drain plaque cytokines and in this 
way regulate inflammatory responses, and mediate efflux of lipid particles 42. 
Further study is required to dissect the contribution of these factors. 
Interestingly, inhibition of lymphangiogenesis did, in contrast to lymph 
node and efferent lymph vessel dissection, not affect atherosclerotic burden, 
although it was also seen to increase adventitial and plaque CD3+ T cell 
content. The exact mechanisms of T cell accumulation remain elusive, but 
could be attributable to initial impairment of T cell drainage from the plaque, 
after systemic hVEGFR3‐dependent lymphangiogenesis blockage. The resulting 
reduced draining capacity may elicit an alternative VEGF‐C and ‐D independent 
lymphangiogenesis axis in plaque tissue, such as the mechano‐induced integrin 
pathway recently described by Planas‐Paz et al 43, or the CXCL12‐CXCR4 
pathway, which earlier was shown to confer atheroprotection 38, 44. 
Unpublished work from our group has demonstrated high CXCR4 expression in 
atherosclerotic lesions, representing/harboring lymphangiogenic potential. 
CHAPTER 7 
188 
7 
Such alternative VEGFR3‐independent pathways may explain the unimpeded 
lymph vessel density in the adventitia and overt presence of lymph vessels in 
the atherosclerotic lesion itself observed after hVEGFR3 intervention. Future 
studies could interrogate this notion by measuring the interstitial pressure in 
the plaque and intraplaque β1‐integrin activation as a measure of mechano‐
induced lymphangiogenesis, or by co‐inhibition of the CXCL12‐CXCR4 axis. 
The interpretation of our findings is further complicated by the 
reciprocal interaction between lymph vessels and T cells. Besides the effect 
lymph vessels have on T cell trafficking, as illustrated in this study, T cells were 
vice versa also reported to inhibit lymphangiogenesis. Our current explorative 
study does not address the relevance of cross‐interaction under pathologic 
conditions and further studies will be needed to gain further insight into the 
interactions between the two. Of special interest would in this regard be the 
role of the T cell subset polarization, since e.g. Th1 and Th2 cells are associated 
with expression of different cytokine and inflammatory mediator repertoires45. 
In conclusion, this study shows that adventitial lymphatic vessels 
increased at an early stage of plaque development. Draining lymph node 
dissection and inhibition of lymphangiogenesis resulted in aggravation of 
atherosclerosis after lymph node dissection, accompanied by increased plaque 
and adventitial T cell content, probably due to disturbed drainage of T cells. 
Further studies are needed to give additional insights into the precise role and 
actual mechanisms of adventitial lymphatic capillary formation in 
atherosclerosis.  
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Supplemental Figures  
 
 
 
Supplemental Figure I. AAV-hVEGFR3-Ig treatment resulted in a slightly reduced body weight, as 
was described previously 25 (A). Plasma cholesterol levels were unaltered by AAV-hVEGFR3-Ig 
treatment (B). In parallel to the unchanged plaque volume, lipid core volume was not different 
from control mice after AAV-hVEGFR3-Ig treatment (C).  
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Atherosclerosis is at present one of the leading causes of mortality and 
morbidity in the world and is expected to remain so in the coming decades 1, 2. 
This fact alone clearly shows that a good understanding of disease 
development and progression is needed. One of the processes in lesion 
progression which has increasingly gained interest is the involvement of new 
vessel formation (neovascularization) in atherosclerosis. It has been 
hypothesized that newly formed plaque microvessels, similar to new vessels in 
tumors 3, show an aberrant, dysfunctional phenotype 4, 5. Nevertheless, 
evidence showing a causal link between vascularization state and lesion 
progression in vivo has been lacking so far. Moreover, not only microvessels, 
but also lymphatic microvessels have recently been linked to atherosclerosis 
progression 6, 7, although their role therein has not yet been established.  
The hypothesis underlying this thesis was that both angiogenesis and 
lymphangiogenesis are of key importance to atherosclerosis, and that the 
aberrant function of blood vessels and lymph vessels under inflammatory 
conditions promote atherosclerosis progression. Therefore, we aimed (I) to 
gain a better understanding of plaque neovascularization in vivo, (II) to assess 
whether specific targets for (lymph)angiogenesis in atherosclerotic lesions can 
be identified via a genomics-based approach, and (III) to gain more insights 
into the role of lymph vessel expansion in atherosclerosis. The main findings of 
this thesis are that: 
 
1. Murine models of atherosclerosis exhibit adventitial neovessels and 
present a suitable model of human plaque neovascularization 
 
2. Plaque-associated vasa vasorum in mice show a dysfunctional, pro-
atherogenic characteristics 
 
3. Aberrant expression and/or function of endothelial junction molecules 
is related to a leaky endothelial phenotype in murine atherosclerosis 
models 
 
4. Genomics-based methods identify potential novel targets involved in 
human plaque angiogenesis 
 
5. Plaque lymphangiogenesis, contrary to plaque angiogenesis, is 
beneficial for murine plaque development by reducing local 
inflammation 
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Murine models of atherosclerosis for studying plaque neovascularization  
A long-standing debate in literature has focused on the suitability of murine 
models for studying plaque neovascularization. This debate has been part of a 
broader discussions on the suitability of murine models of atherosclerosis in 
general, and has been reviewed extensively 8-10. Generally, murine models for 
atherosclerosis can mimic human atherosclerotic lesion development to a 
large extent. Both the ApoE-/- and the LDLr-/- model are used very frequently 
and have been extensively characterized. Though the ApoE-/- model is regarded 
as being slightly more inflammatory 11, both models in many aspects resemble 
human atherosclerosis. Both models exhibit early and advanced lesions, and 
their cellular composition is very similar to human lesions. A major difference 
between the murine models and human lesion development, however, is the 
rare occurrence of plaque rupture and atherothrombosis in murine models, 
even after aggressive pharmacological, biomechanical or genetic  
interventions 12-14. Recent data from Campbell et al suggests that differences  
in mechanical stress on the atherosclerotic lesion are an important reason for 
the lack of rupture in murine models of atherosclerosis 15. In fact, they showed 
that in human atherosclerosis, biomechanical stresses are highest at the 
thinning cap, while in murine models these are highest in the media and 
adventitia distal from the atherosclerotic plaque.  
In contrast, intraplaque hemorrhage (IPH) has been described more 
frequently in ApoE-/- and LDLr-/-, but is also present in several interventional 
models (Table 1) 16-34. An important contributor to occurrence of IPH has been 
suggested to be the location of the atherosclerotic lesion, as Johnson 
described a location-specific prevalence of IPH in aged ApoE-/- mice, with the 
brachiocephalic artery showing the highest prevalence 17. Indeed, Table 1 
confirms this finding, although other models (collar placement, specific 
interventions) also reveal the occurrence of IPH on other locations throughout 
the arterial tree. Interestingly, although IPH is regarded to be a consequence of 
leaky plaque microvessels in human lesions, most of the studies describing IPH 
in murine models did not investigate plaque vascularization, were unable to 
detect plaque microvessels adequately, or were unable to conclusively link 
plaque neovascularization to IPH. This illustrates the need for studies which 
consequently investigate plaque neovascularization, its contribution in the 
atherosclerotic process, and its link to intraplaque hemorrhage.        
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In the last few years, studies have been focusing more on determining the 
functional characteristics of plaque neovasculature, especially plaque-
associated vasa vasorum, with one of the most recent contribution being a 
study of Eriksson 19. Not only did this study establish the presence of a plaque-
specific vasa vasorum it was the first to establish increased adhesion of 
leukocytes to the vasa vasorum in vivo. This is in line with data from chapter 3, 
where we showed a clear presence of a plaque-associated vasa vasorum in 
aged ApoE-/- mice with advanced atherosclerotic lesion. These vasa vasorum 
showed distinct functional features compared to normal microvascular beds, 
e.g. reduced blood flow, increased permeability, leukocyte adhesion, and 
leukocyte transmigration. Moreover, the presence of plaque-associated vasa 
vasorum was also shown in atherosclerotic LDLr-/- mice exhibiting advanced 
lesions after 40 weeks of diet (chapter 5). In summary, the studies in Table 1, 
as well as our studies showed that formation of plaque-specific vasa vasorum 
is a common event in murine models of atherosclerosis. 
It however remains intriguing that plaque neovascularization in murine 
models seems to be limited to the adventitia, as the plaque-associated vasa 
vasorum did not traverse the medial layer, not in ApoE-/- mice nor in  
LDLr-/- mice (chapters 3 and 5). This exposes an essential limitation of murine 
models, i.e. the general lack of intraplaque plaque angiogenesis in mice. In 
chapters 3 and 5 we were unable to not discern functional microvessels within 
the atherosclerotic lesions, and in chapter 3 we only showed occurrence of 
sprouts derived from the luminal endothelium. The latter brings up the issue of 
functionality of these sprouts and involvement in the atherosclerotic process. 
As Table 1 shows, the occurrence of intraplaque microvessels seems to be 
model-specific, and its link to intraplaque hemorrhage is weak. Several of these 
studies indicate the challenge of detecting intraplaque microvessels, which 
however does not necessarily mean that these microvessels are absent. 
Advances in staining techniques, as well as novel applications of imaging 
techniques as presented in this thesis (chapter 3) will aid in determining 
(functional characteristics of) intraplaque vessels in future studies.  
Presently, the plaque-associated vasa vasorum can serve as a model 
for human plaque neovascularization. As shown by Langheinrich et al, there is 
a correlation between plaque vascularization and intraplaque hemorrhage 24. 
Additionally, studying the plaque-associated vasa vasorum is able to give 
insights into functional properties of plaque microvessels, and allows 
CHAPTER 8 
200 
8 
assessment of the effect of interventions on plaque vascularization 19. This will 
be aided by the use of other models which frequently show plaque 
vascularization, e.g. a collar-induced atherosclerosis model in the carotid 
artery of mice (Table 1). 
 
Causes and consequences of dysfunctional, leaky plaque microvasculature 
The angiogenic response occurring in human atherosclerosis is most likely a 
consequence of the hypoxic conditions present within the lesion. This is not 
only due to the increased distance from the lumen, exceeding the diffusion 
distance of oxygen, but also the increased oxygen demand in specific cell 
types, e.g. macrophages, under the inflammatory conditions. The latter aspect 
would also explain the presence of plaque hypoxia in murine lesions, even 
though the diffusion distance of oxygen probably is not limiting 35. Although 
relieving tissue hypoxia in itself is suggested to be a beneficial consequence of 
plaque vascularization, the pathologic angiogenic response which is elicited, 
induces formation of dysfunctional microvessels. This dysfunctional phenotype 
can have a myriad of causes, one of which is aberrations of the endothelial 
junctions. 
 In chapters 4 and 5 we examined two junctional molecules, and their 
role in atherosclerosis. On the one hand, JAM-A is an endothelial junction 
molecule which previously was associated with leukocyte adhesion 36, but 
which is also expressed on other cell types and has various cell-type specific 
functions. By looking specifically to macrovascular endothelial JAM-A in the 
(atherosclerotic) carotid artery, we elucidated its role in leukocyte adhesion 
and transmigration, but not in vascular permeability. Under atherosclerotic 
conditions or disturbed flow, macrovascular JAM-A is redistributed, leading to 
enhanced leukocyte adhesion and transmigration. On the other hand, VE-
cadherin, another endothelial junction molecule, is mostly involved in 
leukocyte transmigration and vascular permeability, not leukocyte adhesion 37. 
Importantly, on plaque-associated vasa vasorum, blocking of VE-cadherin did 
not result in additional leukocyte transmigration or vascular permeability, 
revealing a potential defect of VE-cadherin function in these microvessels, or a 
lack of involvement of VE-cadherin in plaque-associated vasa vasorum.  
 These two junctional molecules are good illustrations of the complexity 
of the endothelial barrier, in which one molecule (JAM-A) is upregulated in the 
microvasculature under atherosclerotic conditions and elicits pro-atherogenic 
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properties, while another molecule (VE-cadherin) potentially is dysfunctional 
and may cause pro-atherogenic properties. Concomitantly, to achieve a 
comprehensive view of the endothelial barrier in plaque microvessels, it would 
be of great interest to investigate the function of other endothelial junction 
molecules, e.g. claudins or occludins 38 in plaque-associated vasa vasorum. 
Alternatively, it would be interesting to assess which process is most 
prevalently contributing to plaque progression, i.e. leukocyte adhesion and 
transmigration (leukocyte recruitment), or general microvascular permeability. 
More insights into these mechanisms, their relative contributions, and the 
most important molecular mediators (specific junctional molecules) may then 
help guide the search for specific therapeutic targets. 
 It should be noted that micro- and even macrovascular function is not 
solely determined by the integrity of endothelial junctions (Figure 1). As we 
showed in chapter 3, ultrastructural analysis of plaque-associated vasa 
vasorum did not reveal any gross structural defects in the endothelial 
junctions, yet microvascular permeability was increased. This might be linked 
to alterations in the endothelial glycocalyx distribution. Changes in glycocalyx 
composition, distribution or thickness are already linked to several diseases, 
most importantly type II diabetes 39-41, and show changes in vascular 
permeability (Figure 1). As such, the glycocalyx should not be neglected when 
studying microvascular function in plaque neovascularization.  
 Additionally, pericytes, which surround blood vessels, and are 
important for vessel maturation and stability, are involved in (micro)vascular 
function. Ablation of pericytes has been shown to increase vascular 
permeability (Figure 1) 42-44. Incomplete or absent pericyte coverage has been 
shown in plaque microvasculature in human atherosclerotic lesions (chapter 6) 
and may thus contribute to the leaky phenotype, although we did not observe 
any difference in pericyte coverage between stable and ruptured lesions. 
Pericyte coverage has not been addressed in our experimental animal studies 
in this thesis, but the effect of aberrant or absent pericyte coverage should be 
studied functionally in vivo to assess pericyte contribution to microvascular 
permeability. A useful model for such studies would be transgenic mice 
expressing platelet-derived growth factor beta (PDGF-β), a growth factor 
involved in the recruitment and function of pericytes, lacking the proteoglycan 
binding domain (PDGF-βret/ret) resulting in a partial loss of function 45.  
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Figure 1. Schematic representation of mechanisms involved in vascular permeability. Under 
physiological conditions (upper panel), mature microvessels consist of a continuous endothelial 
layer, with stable endothelial barrier function. Glycocalyx is expressed on the endothelium and 
forms a barrier between the cells in the blood and the endothelial surface. Abluminally, the 
microvessel is covered by pericytes. Under inflammatory conditions or pathological angiogenesis, 
several processes can cause increased vascular permeability. The first process (bottom left panel) 
is disturbed endothelial barrier function, e.g. by loosening of the endothelial junctions. The 
second process (bottom middle panel) is aberrations in glycocalyx thickness, composition or 
distribution. A third process (bottom right panel) is abnormal or absent pericyte coverage leading 
to an immature vessel phenotype. In reality, a combination of the mechanisms mentioned in this 
figure will determine vascular permeability in vivo.  
 
Novel players of pathologic (lymph)angiogenesis in atherosclerosis 
Clearly, the variety of contributors to (micro)vascular function, and the myriad 
of potential molecular mediators thereof, make it difficult to dissect the 
regulatory pathways that are exclusively involved in plaque 
(lymph)angiogenesis, or eventually even determine potential targets for 
imaging or intervention, as discussed later. In chapter 6, we therefore applied 
a genomics-based approach to identify genes involved in plaque 
(lymph)angiogenesis. By correlating microarray analysis data with defined 
phenotypical traits, we established gene modules which correlated with 
plaque vascularization. From this, we could select highly correlating genes, as 
EC junction loosening Glycocalyx aberrations Aberrant pericyte coverage 
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well as a five miRNAs which may be involved in regulation of plaque 
neovascularization. Moreover, these genes and miRNAs were predicted to 
have a central role in the gene module associated with plaque angiogenesis. 
The next step would be to validate the genes and miRNAs for 
expression in endothelial cells, and establish their function in vitro and in vivo.  
In vitro tests could establish a role of the genes and miRNAs in endothelial cell 
proliferation, migration, tube formation capacity or endothelial barrier 
function. From there, genes of interest could be studied in vivo, first in 
angiogenic responses in vivo in e.g. a zebrafish model 46, 47, and later with a 
focus on microvascular function in atherosclerosis, following the methods 
described in chapters 3-5. Such an approach will reveal insights into 
contributions of these genes in (pathological) plaque angiogenesis. 
An additional goal could be determining novel targets which could 
serve as a molecular marker for detection of patients at risk of plaque rupture, 
or which could be used for targeted intervention. The development of 
molecular markers for non-invasive imaging (e.g. magnetic resonance imaging 
(MRI) or positron emission tomography (PET) 48-51) based on plaque 
angiogenesis markers, e.g. αVβ3-integrin, has been studied in animal models 
over the last years, and has shown promising results 52-54. First clinical trials are 
ongoing, but depending on their outcome, development of new markers for 
(lymph)angiogenesis may be required.  
Aside from molecular markers for detection of plaque 
(lymph)angiogenesis, targeted therapy could be a further goal. At present, no 
targeted interventions focused on plaque (lymph)angiogenesis have been 
described in human atherosclerosis. Use of statins has been correlated with 
decreased plaque vascularization 55, 56, although the pleitropic effects of statins 
make it nearly impossible do discern if it concerns a direct effect on 
angiogenesis, or whether it is attributable to the overall beneficial properties 
of statins on atherosclerosis 57. Targeted anti-angiogenic interventions in 
humans have been conducted especially in cancer therapy (e.g. VEGF-
depleting antibodies or VEGF-based gene therapy) reviewed in 58-60, but clinical 
studies for anti-angiogenic interventions in atherosclerosis are virtually lacking. 
Only one study investigated the effect of bevacizumab-eluting stents in 
restenosis 61, and showed encouraging results, with reduced neointimal 
hyperplasia after stenting. Except for this study and several ongoing clinical 
trials, however, anti-angiogenic therapy in atherosclerosis is absent. 
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The lack of studies investigating anti-angiogenic therapy in human 
atherosclerosis will in part due to the fact that angiogenesis is an essential 
process in physiology, e.g. growth and wound healing. Therefore, angiogenesis 
cannot be simply inhibited over long periods of time, without causing serious 
deleterious effects. Local delivery of anti-angiogenic might be an option, 
although this would require procedures like stenting 61. Identifying potential 
targets is complicated by the great molecular overlap between angiogenesis 
and lymphangiogenesis, and between angiogenesis and neurogenesis 62, 63. 
Evidently, intervention should not interfere with neurogenesis, physiological 
angiogenesis or lymphangiogenesis. An optimal therapeutic target for plaque 
angiogenesis would moreover not be directed against inhibition of the 
angiogenic process itself, but ideally should be directed towards normalizing 
microvascular function, preventing microvascular leakage and increased 
leukocyte recruitment. Vessel normalization has previously been described to 
be effective in treatment of e.g. tumors 64 or hereditary hemorrhagic 
telangiectasia 65, but currently involve non-targeted treatment. Genomics-
based approaches can aid in determining novel targets, taking into account 
their involvement in a certain phenotype and their connections to various 
pathways.  
 
Lymphangiogenesis is beneficial in atherosclerosis progression by reducing 
local inflammation 
The role of the lymphatic system in atherosclerosis, and possible options for 
targeted intervention, also requires extensive study. In chapter 7, we showed 
that lymphangiogenesis acts beneficial in atherosclerosis, by reducing local  
T cell content. This role of lymphangiogenesis is in sharp contrast to that of the 
angiogenic response. Since leukocyte recruitment is increased in 
atherosclerosis, and lymph vessels are able to remove cells from the 
atherosclerotic lesion, stimulating lymph vessel expansion may be a novel 
approach to alleviate atherosclerosis progression. Such an approach may be 
regarded counterintuitive at first, since lymphangiogenesis has been shown 
not to be beneficial at all in other diseases. Indeed, in tumorigenesis, 
lymphangiogenesis is upregulated, but is an important contributor to tumor 
metastasis 66, 67. Also in e.g. inflammatory bowel disease, the role of 
lymphangiogenesis is not clear, but has been regarded as being detrimental 68. 
Nevertheless, initial studies in mice have described pro-lymphangiogenic 
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therapy for instance in relieving edema formation 69, but may also be beneficial 
in atherosclerosis. Future studies however need to more firmly establish the 
role of lymph vessels in atherosclerosis. 
Interestingly, lymph vessel density (D2-40+ area) in human lesions 
showed a clear segregation between stable and ruptured segments (chapter 
6). As such, lymph vessel expansion in atherosclerotic lesions may present a 
promising molecular marker for screening of patients at risk for plaque 
rupture, and should be investigated in more detail. 
 
 
 
 
 
 
Figure 2. Schematic representation of adventitial plaque microvessels and lymph vessels 
function in murine atherosclerosis. This thesis established that plaque-associated vasa vasorum 
in mice showed a dysfunctional, pro-atherogenic phenotype, characterized by increased 
microvascular permeability and enhanced leukocyte adhesion and transmigration. This pro-
atherogenic phenotype may in part be due to aberrant glycocalyx distribution, or altered 
expression/function of the endothelial barrier. Alternatively, although not studied in this thesis, 
absence of pericytes may also contribute to the increase in permeability. Adventitial lymph 
vessels are beneficial for plaque development by reducing local T cell content. In addition, 
although not studied in this thesis, adventitial lymph vessels may drain the, potentially cytokine- 
and chemokine-rich, fluid exudate from the adventitia.     
 
 
  
JAM-A?
VE-cadherin? 
?
Glycocalyx aberrations 
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Concluding remarks and future perspectives 
In this thesis we addressed the role of angiogenesis and lymphangiogenesis in 
atherosclerosis. We confirmed a pro-atherogenic role of plaque angiogenesis, 
with a dysfunctional phenotype of plaque microvessels in vivo (Figure 2). This 
phenotype (in part) may be due to the altered distribution and function of 
endothelial junction molecules like JAM-A and VE-cadherin (Figure 2). In 
contrast, lymphangiogenesis showed a protective effect in atherosclerosis by 
draining inflammatory cells from the lesion (Figure 2). 
 The pathological angiogenic and lymphangiogenic response are 
however not yet completely understood. To further unravel the regulatory 
pathways involved herein, we used a genomics-based approach, by which we 
identified genes and regulatory miRNAs involved in plaque angiogenesis. After 
in vitro and in vivo validation, this approach will shed new light into the 
regulation of plaque (lymph)angiogenesis, and could in future potentially aid in   
establishing markers for molecular imaging or targets for interventions in 
atherosclerosis.  
Future studies will need to establish a comprehensive model of plaque 
angiogenesis and lymphangiogenesis, and the contribution of lesional and 
adventitial microvessels and lymph vessels to atherosclerosis. 
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Cardiovascular diseases are the leading cause of mortality worldwide, 
accounting for about 17 million deaths globally every year. The most prevalent 
cardiovascular diseases are acute myocardial infarction and stroke, which are 
mostly caused by occlusion of arteries as a result of rupture of advanced 
atherosclerotic plaques.  
Atherosclerosis is a progressive, chronic inflammatory disease, 
characterized by accumulation of lipids, and cellular and fibrous constituents in 
the arterial tree at sites of disturbed flow. At these sites, LDL cholesterol enters 
the vessel wall, is modified, and elicits recruitment of monocytes to the vessel 
wall. These monocytes differentiate into macrophages, which take up the 
oxidized LDL, develop into foam cells, are rendered immobile, and as a result 
accumulate in the vessel wall. This causes a persistent inflammatory response 
in the vessel wall and, with time, the development of advanced atherosclerotic 
lesions with a necrotic and lipid-rich core which is covered by a fibrous cap. 
Production of several types of proteases, as well as cell death, and erosion will 
destabilize the fibrous cap, allowing the plaque to evolve to a rupture-prone 
plaque phenotype. Upon plaque rupture, the pro-thrombotic constituents of 
the necrotic core will come into contact with the blood, thus causing thrombus 
formation, and potentially causing acute myocardial infarction or stroke.  
 Angiogenesis, the development of new blood vessels, is also an 
important factor in atherosclerosis. In human atherosclerotic lesions, there is a 
clear association between expansion of microvessels and plaque progression, 
both in the adventitia and the intima. Plaque microvasculature has been 
attributed both beneficial and detrimental contributions to atherosclerosis 
progression. On the one hand, plaque microvasculature has been suggested to 
be a means of efflux of lipids and inflammatory cells. On the other hand, 
plaque microvessels have been linked to influx of lipids and inflammatory cells, 
and show a clear association with a more instable plaque phenotype. Yet, the 
exact role of plaque microvasculature in vivo is not completely understood. 
Recently, also lymph vessels have been implicated in atherosclerosis 
development, and were shown to be increased in later stages of plaque 
progression. The role of plaque lymph vessels, however, is still elusive.   
Therefore, the hypothesis of this thesis is that both angiogenesis and 
lymphangiogenesis are of key importance to atherosclerosis, and that the 
aberrant function of blood vessels and lymph vessels under inflammatory 
conditions promote atherosclerosis progression.  
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Our first studies (chapters 2-5) were focused on establishing functional 
characteristics of atherosclerotic plaque microvasculature using an in vivo 
multiphoton laser scanning microscopy (MPLSM) approach. Chapter 2 
reviewed the current state of in vivo cardiovascular imaging using MPLSM, and 
discussed the benefits and shortcomings of the technique.  
In chapter 3, plaque microvasculature was studied in an ApoE-/- mouse 
model, where it was shown that plaque neovascularization was present in the 
outer layer of atherosclerotic blood vessels. Furthermore, it was found that 
only aged ApoE-/- mice showed these microvessels, and that these were not 
present in non-atherosclerotic C57Bl/6 mice or young atherosclerotic ApoE-/- 
mice. It was also shown that the adventitial microvessels exhibited active 
angiogenesis, low blood flow, increased permeability, and leukocyte adhesion 
and extravasation. These functional features can generally be considered pro-
atherogenic features.  
In order to explore possible causes of this leaky phenotype, we studied 
the function of two important endothelial junction molecules, JAM-A and VE-
cadherin. In chapter 4, the role of the adhesion molecule JAM-A on endothelial 
permeability and leukocyte adhesion was investigated. It was shown that in 
arteries, JAM-A was important for adhesion and transmigration of leukocytes, 
and that alteration in the distribution of endothelial JAM-A induced increased 
leukocyte recruitment, while there was no effect on vascular permeability. 
Another endothelial junction molecule involved in endothelial barrier function, 
VE-cadherin, was studied in chapter 5. In this study, the effect of acute 
deterioration of the endothelial barrier function in plaque microvessels was 
examined. We could show that blocking VE-cadherin dimerization induced an 
increase in microvascular permeability and leukocyte transmigration in control 
microvessels. These parameters were however unchanged in plaque 
microvessels after VE-cadherin blocking. These findings suggested that either 
VE-cadherin may already be dysfunctional in adventitial microvessels and 
hence cannot be disrupted additionally, or alternatively are not involved in 
microvascular permeability in adventitial microvessels at all.   
In a subsequent study in chapter 6, we sought to identify novel genetic 
targets involved in plaque angiogenesis and lymphangiogenesis using a 
genomics-based study in human atherosclerotic lesions samples. To this end, 
we correlated microarray data from stable and ruptured atherosclerotic plaque 
segments to microvessel and lymph vessel density. A set of sixteen genes and 
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five miRNAs were linked to plaque angiogenesis, while initial analyses were 
unable to uncover novel genes associated with plaque lymphangiogenesis.   
With the role of lymphangiogenesis being poorly understood, we 
performed several intervention studies in atherosclerotic ApoE-/- mice to gain a 
better understanding of the role of the lymphatic system in atherosclerosis. In 
chapter 7, we showed that removal of the lymph node draining the 
(atherosclerotic) carotid artery had an adverse effect on plaque progression, 
resulting in increased plaque size and induction of a more inflammatory 
phenotype with significantly increased T cell numbers. Similarly, systemic 
inhibition of lymphangiogenesis induced an enhanced T cell content in 
atherosclerotic lesions. Taken together, these data suggested a beneficial role 
of adventitial lymph vessels during plaque progression. 
In chapter 8, the results described in this thesis and potential 
implications hereof were discussed and put in perspective. Also, future 
directions were given for further study of angiogenesis and lymphangiogenesis 
in atherosclerosis. In conclusion, this thesis provides new insights into the 
contribution of plaque angiogenesis and lymphangiogenesis to atherosclerosis 
progression. 
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Hart- en vaatziekten zijn, met circa 17 miljoen sterfgevallen per jaar, één van 
de belangrijkste oorzaken van sterfte wereldwijd. De meest voorkomende 
hart- en vaatziekten zijn hartinfarcten en beroertes, die voor het overgrote 
deel veroorzaakt worden door het scheuren van atherosclerotische laesies. 
Atherosclerose, in de volksmond beter bekend onder de naam 
aderverkalking, is een aandoening gekenmerkt door een chronische 
ontstekingsreactie in de vaatwand van de slagaders op plaatsen met een 
turbulent bloedstroomprofiel. Deze ontstekingsreactie ontstaat door het 
binnendringen van LDL cholesterol in de vaatwand doorheen de laag 
endotheelcellen, die de vaatwand bekleed. Na processen als oxidatie van het 
LDL cholesterol worden vervolgens signalen afgegeven waardoor monocyten 
worden aangetrokken tot de vaatwand. Na het binnendringen in de vaatwand 
differentiëren de monocyten tot macrofagen in een poging het geoxideerde 
LDL cholesterol te verwijderen uit de vaatwand. Echter, de opname van grote 
hoeveelheden geoxideerd LDL cholesterol door macrofagen zal ervoor zorgen 
dat deze veranderen in schuimcellen, die niet langer in staat zijn het LDL 
cholesterol af te breken. Daardoor vindt er een opstapeling plaats van 
schuimcellen en geoxideerd LDL cholesterol in de vaatwand. Dit is de stimulans 
voor een chronische ontstekingsreactie waarbij verschillende 
ontstekingscellen, zoals T-cellen, een rol spelen. Na verloop van tijd 
ontwikkelen de bovengenoemde, schuimcelrijke vroege laesies zich verder 
naar geavanceerde laesies. Deze laesies worden gekenmerkt door een grote 
kern gevuld met onder andere cholesterol en resten van dode 
ontstekingscellen (necrotische resten). Deze kern is omgeven door een kapsel 
van gladde spiercellen en bindweefsel, dat de kern gescheiden houdt van de 
bloedstroom. Dit kapsel is echter gevoelig voor afbraak, en zal na verloop van 
tijd dunner worden hetgeen leidt tot een instabiele atherosclerotische laesie. 
Uiteindelijk kan dit kapsel dan ook scheuren, waarbij de inhoud van de 
necrotische en vetrijke kern in contact komt met het bloed. Hierdoor zal er een 
bloedstolsel ontstaan dat een bloedvat gedeeltelijk of volledig kan afsluiten. 
Wanneer dit gebeurt in de kransslagaders of de halsslagaders kan dit leiden tot 
respectievelijk een hartinfarct of beroerte.  
Tijdens de ontwikkeling van atherosclerotische laesies worden ook 
nieuwe kleine bloedvaatjes (microvaten) gevormd in en rond de laesie via een 
proces dat bekend staat als angiogenese. Het is bekend dat er in humane 
atherosclerotische laesies een duidelijke correlatie is tussen het 
SAMENVATTING 
221 
 
ontwikkelingsstadium waarin een laesie zich bevindt en de expansie van de 
microvaten in de buitenste laag van het bloedvat (de adventitia) als ook in de 
laesie zelf. Aan deze microvaten in en rond de laesies is zowel een positieve als 
negatieve rol toegeschreven. Aan de ene kant wordt gesuggereerd dat de 
microvaten een rol zouden kunnen spelen in het verwijderen van cholesterol 
en ontstekingscellen uit de laesie. Aan de andere kant zijn microvaten in de 
laesie juist geassocieerd met een toename van cholesterol en 
ontstekingscellen in de laesie. Recent is verder ook aangetoond dat 
lymfevaatjes in en rond de atherosclerotische laesie expanderen in verder 
gevorderde stadia van laesie ontwikkeling als gevolg van het proces genaamd 
lymfevat-angiogenese. De rol die deze lymfevaatjes spelen is nochtans 
onduidelijk. 
Daarom hebben we in dit proefschrift getracht meer duidelijkheid te 
krijgen over de rol die microvaten en lymfevaatjes spelen in de ontwikkeling 
van atherosclerotische laesies. De hypothese behorende bij dit proefschrift is 
dat angiogenese en lymfevat-angiogenese een belangrijke rol hebben in de 
ontwikkeling van atherosclerotische laesies, en dat afwijkende functie van 
microvaten en lymfevaten in en rondom de laesies bijdraagt aan verdere 
ontwikkeling hiervan. 
De eerste studies in deze thesis (hoofdstukken 2-5) zijn gefocust op het 
bepalen van de functionele karakteristieken van microvaten rondom 
atherosclerotische laesies in levende dieren (in vivo). Hierbij hebben we 
gebruik gemaakt van multifoton microscopie, een op fluorescentie gebaseerde 
techniek waarmee het mogelijk is in vivo door weefsel te scannen. Hoofdstuk 2 
geeft een overzicht van de huidige status van in vivo beeldvorming met behulp 
van multifoton microscopie, en bediscussieert de baten en tekortkomingen 
van deze techniek. 
In hoofdstuk 3 is deze techniek vervolgens toegepast om microvaten 
rondom atherosclerotische laesies in een muismodel voor atherosclerose, de 
ApoE-deficiënte muis, te onderzoeken. Met behulp van deze techniek konden 
we microvaten rondom atherosclerotische laesies in beeld brengen en hieruit 
bleek dat deze microvaten in dit model specifiek voorkomen in muizen met 
vergevorderde laesies, maar niet in dieren zonder laesies of met vroege 
laesies. Rondom de atherosclerotische leasies kon actieve vorming van nieuwe 
microvaten (angiogenese) worden aangetoond, en deze microvaten 
vertoonden een verlaagde bloedstroomsnelheid, een verhoogde permeabiliteit 
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(doorlaatbaarheid) en een versterkte rekrutering van ontstekingscellen in 
vergelijk met controle-microvaten. Deze functionele kenmerken kunnen gezien 
worden als bevorderend voor verdere ontwikkeling van atherosclerotische 
laesies.  
Om een beter inzicht te krijgen in de mogelijke oorzaken van de 
bovengenoemde functionele kenmerken, werden hierna twee belangrijke 
adhesiemoleculen, die de endotheelcellen onder normale omstandigheden 
met elkaar verbinden, bestudeerd. In hoofdstuk 4 is gekeken naar de rol van 
het adhesiemolecuul JAM-A op permeabiliteit van de vaatwand en de 
rekrutering van ontstekingscellen. De resultaten lieten zien dat JAM-A, in ieder 
geval op de vaatwand van de slagaders zelf, van belang is voor adhesie van 
ontstekingscellen aan, en transmigratie door de vaatwand. Veranderde 
distributie van deze moleculen op de endotheelcellaag, zoals in 
atherosclerotische laesies, zorgt voor een versterkte rekrutering van 
ontstekingscellen. Er was geen effect op de permeabiliteit van de 
endotheelcellaag. In hoofdstuk 5 is vervolgens specifiek in de microvaten 
rondom de atherosclerotische laesies gekeken naar het molecuul VE-
cadherine. Wanneer de binding van VE-cadherine tussen de endotheelcellen 
werd verstoord met behulp van een specifiek antilichaam, werd in controle-
microvaten een versterkte permeabiliteit gemeten, als ook een versterkte 
transmigratie van ontstekingscellen door de vaatwand heen. Daarentegen was 
dit effect niet waarneembaar in microvaten rondom de atherosclerotische 
laesies. Deze bevindingen suggereren dat hetzij VE-cadherine al dysfunctioneel 
is in microvaten rondom atherosclerotische laesies en dus niet verder 
verstoord kan worden, hetzij VE-cadherine geen rol speelt in microvaten 
rondom atherosclerotische laesies. 
In hoofdstuk 6 is vervolgens gekeken naar expressie van genen in 
humane atherosclerotische laesies in relatie tot de vorming van nieuwe 
microvaten en lymfevaten in de laesies. Hierbij is rekening gehouden met de 
veranderde expressie van genen tussen stabiele en instabiele geavanceerde 
laesies. Op basis van deze methode konden zestien genen en vijf micro-RNAs, 
betrokken bij genregulatie, gecorreleerd worden met de toename van 
microvaten in instabiele atherosclerotische laesies. Voor lymfevat-angiogenese 
konden in de eerste analyses geen genen gecorreleerd worden aan de 
toename van lymfevaten in instabiele atherosclerotische laesies. 
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Aangezien de rol van lymfevat-angiogenese in de verdere ontwikkeling van 
atherosclerose niet bekend is, is in hoofdstuk 7 de rol van lymfevaten in 
atherosclerose in het ApoE-deficiënte muismodel bestudeerd. Na het 
verwijderen van de lymfeknopen die verbonden zijn met de lokale lymfevaten 
rondom atherosclerotische laesies, kon een versterkte laesie-ontwikkeling 
worden waargenomen, waarbij de grootte van de laesie toenam en er een 
groter aantal T-lymfocyten in en rond de laesie aanwezig was. Vergelijkbare 
resultaten, met een toename in het aantal T-cellen rondom de laesie, werden 
verkregen nadat specifiek de lymfevat-angiogenese werd geremd. Deze data 
suggereren dat lymfevat-angiogenese in latere stadia van de ontwikkeling van 
atherosclerotische laesies een mogelijk remmende werking heeft. 
Tot slot werden in hoofdstuk 8 de resultaten beschreven in dit 
proefschrift en de implicaties hiervan bediscussieerd en in perspectief 
geplaatst en werden opties gegeven voor verder onderzoek. Concluderend, dit 
proefschrift geeft nieuwe inzichten in de rol van angiogenese en lymfevat-
angiogenese in de ontwikkeling van atherosclerose. 
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AAV Adeno-associated virus 
AMI Acute myocardial infarction 
Ang Angiopoietin 
ANOVA Analysis of variance 
ApoE Apolipoprotein-E 
αSMA Alpha smooth muscle actin 
CCD Charge-coupled device 
CCL CC chemokine ligand 
CCR CC chemokine receptor 
CD Cluster of differentiation 
CEUS Contrast-enhanced ultrasound 
CFSE Carboxyfluorescein succinimidyl ester 
Col18 Collagen type XVIII 
CT Computed tomography 
CVD Cardiovascular disease 
CXCR Chemokine (C-X-C motif) receptor 
DAB 3,3'-Diaminobenzidine 
DC Dendritic cell 
EC Endothelial cell 
ECIS Electric cell-substrate impedance sensing 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EM Electron microscopy 
EVG Elastica van Gieson 
FACS Fluorescence-activated cell sorting 
FAD Flavin adenine dinucleotide 
FGF Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
FLIM Fluorescence-lifetime imaging microscopy 
FMT Fluorescence molecular tomography 
Fox-C2 Forkhead box protein C2 
fps Frames per second 
HAoEC Human aortic endothelial cells 
HBSS Hank's balanced salt solution 
HDL High density lipoprotein 
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HE Haemotoxylin and eosin 
HIF Hypoxia inducible factor  
HUVEC Human umbilical vein endothelial cell 
i.p. Intraperitoneal 
i.v. Intravenous 
ICAM Intercellular adhesion molecule 
IFN Interferon 
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IL Interleukin 
IMT Intima-media thickness 
IP-10 Interferon gamma-induced protein 10 
IPH Intraplaque hemorrhage 
JAM-A Junctional adhesion molecule A 
kDa  Kilodalton 
KLF Kruppel-like factor 
LDL Low density lipoprotein 
LDLr Low density lipoprotein receptor 
LEC Lymphatic endothelial cell 
LFA Lymphocyte function-associated antigen 
LN Lymph node 
LVD Lymph vessel density 
LYVE-1 Lymphatic vessel endothelial hyaluronic acid receptor 1 
miRNA / miR microRNA 
MMP Matrix metalloproteinase 
MPLSM Multiphoton laser scanning microscopy 
MPTC Maastricht Pathology Tissue Collection 
MRI Magnetic resonance imaging 
mRNA Messenger RNA 
MVD Microvessel density 
NAD(P)H Nicotinamide adenine dinucleotide phosphate 
NF-κB Nuclear factor κB 
NIR Near-infrared 
NO Nitric oxide 
NRP Neuropilin 
OCT Optical coherence tomography 
OPO Optical parametric oscillator 
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ORO Oil red O 
oxLDL Oxidized low density lipoprotein 
PAT Photoacoustic tomography 
PBS Phosphate buffered saline 
PDGF Platelet-derived growth factor 
PDT Photodynamic therapy 
PE Phycoerythrin 
PECAM Platelet endothelial cell adhesion molecule 
PET Positron emission tomography 
PFA Paraformaldehyde 
PI Propidium iodide 
PlGF Placental growth factor 
PMT Photo-multiplier tube 
Prox-1 Prospero homeobox 1 
PTT Photothermal therapy 
QD Quantum dot 
RNA Ribonucleic acid 
s.c. Subcutaneous 
SEM Standard Error of the Mean 
SH Sternohyoid 
SHG Second harmonic generation 
SPECT Single-photon emission computed tomography 
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THG Third harmonic generation 
TkFCA Thick fibrous cap atheroma 
TLO Tertiary lymphoid organ 
TLR Toll-like receptor 
TMR Tetramethylrhodamine 
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TP Two-photon 
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VCAM Vascular cell adhesion protein 
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VE-PTP Vascular endothelial protein tyrosine phosphatase 
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VSMC Vascular smooth muscle cell 
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En na 233 pagina’s (er komen nogal wat pagina’s bij, dus ga er even voor 
zitten), volgt nu het misschien wel belangrijkste en in elk geval meest gelezen 
deel van het proefschrift: het dankwoord. Terecht een belangrijk deel, want 
ruim 4 jaar promoveren doe je uiteraard niet alleen. Op de eerste plaats ben ik 
heel veel dank verschuldigd aan mijn promotie-team! 
 
Prof. Dr. Biessen, beste Erik. Ik herinner me nog als de dag van gisteren onze 
eerste werkbespreking: ik kwam helemaal murw van alle nieuwe termen en 
ideeën je kantoor uitgelopen, en realiseerde me dat er nog tientallen van deze 
besprekingen zouden volgen. Hoe langer ik bezig was, hoe gemakkelijker het 
werd om je ideeën te kunnen volgen, maar tot mijn verbazing bleef de vrijwel 
eindeloze stroom aan ideeën constant. Ik kan alleen maar ontzettend veel 
waardering uitspreken hiervoor, want er waren meer dan genoeg ideeën waar 
geen normaal mens op zou komen. Erik, ik wil je in ieder geval heel hartelijk 
bedanken voor de afgelopen 4,5 jaar. Ondanks je soms chaotische aard (die 
ook wel eens botste met mijn minder chaotische aard), heb ik veel dingen van 
je kunnen leren, dingen waar ik in de toekomst ook zeker profijt van zal 
hebben. Ik kijk er in ieder geval naar uit om nog invulling te kunnen geven aan 
afronding van een aantal van de studie uit dit proefschrift. 
 
Prof. Dr. van Zandvoort, beste Marc. Jij was de imaging-man van het promotie-
team! Met een onuitputtelijk optimisme verkondigde je 4,5 jaar geleden dat 
tweefoton-microscopie zo moeilijk niet was, en dat die plaquevaatjes vinden 
gewoon een kwestie was van aan wat knopjes en schuifjes zitten en goed 
zoeken (althans, dat heb ik ervan onthouden). Nu zou ik het toch niet als 
eenvoudig betitelen (zie ook stelling 6), maar het is uiteindelijk toch een erg 
succesvolle onderneming gebleken. Je optimistische houding was in elk geval 
een welkome afwisseling op de donkere en onheilspellende krochten van de 
tweefotonruimte, en zeker ook richting het einde van mijn promotie heb ik dat 
optimisme erg gewaardeerd. Het is jammer dat er op het moment geen 
imaging-avonturen in het verschiet liggen, maar wie weet wat de toekomst 
gaat brengen. Ik zal in elk geval nog geregeld bij MCB komen langswandelen 
voor een praatje. 
 
(Bijna Prof.) Dr. Heeneman, beste Sylvia. Het rustpunt van het promotie-team 
en degene die een goede hulp was in het in goede banen leiden van de soms 
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wilde ideeën van de heren promotores. Daarnaast ben je natuurlijk EVP’s DEC-
specialist en dé persoon die volhardend mijn manuscripten corrigeert 
corrigeerde; mijn schrijfstijl zal nooit meer dezelfde zijn ;-). Het meest 
gedenkwaardig waren echter de niet-proefschrift-gerelateerde discussies. Wat 
meestal (semi-)serieus begon, eindigde meer dan eens met één van je gevatte 
en soms licht-dubieuze opmerkingen. Ik ben in elk geval blij dat ik nog even 
blijf plakken bij de pathologie en me nog mag verheugen op meer van dit soort 
discussies. Heel erg bedankt voor alle hulp! 
 
Dr. Sluimer, beste Judith. Voordat ik overga tot het bedanken van alle anderen, 
verdien jij een extra bedankje. Want hoewel je niet officieel deel uitmaakte 
van mijn promotie-team, was je op zijn minst mijn co-co-promotor, en ik ben je 
dan ook erg dankbaar dat je je na je terugkeer uit New York aan hebt gesloten 
bij het angiogenese-clubje. Jouw expertise op dit gebied was een perfecte 
aanvulling op het promotie-team, en jouw proefschrift is ook vaak een goed 
naslagwerk voor mij geweest. Ik vond het ook erg leuk om samen met jou en 
Thomas te kunnen werken aan het VE-cadherine-stuk, waar we het komende 
jaar zeker nog een mooie publicatie uit gaan halen! Ik wens je alle goeds voor 
de toekomst, zowel professioneel, als ook met Steven en Sophie. 
 
Naast een promotie-team, kan niemand zonder zijn paranifmen. Herr Doktor 
Engel, lieber David, was soll ich hier jetzt noch schreiben. Ich würde sagen, 
dass vieles schon mal gesagt wurde in den letzten Jahren. Ich kann nur sagen, 
dass jeder einen besten Freund wie dich haben sollte! Du bist immer da wenn 
es mal nötig sein sollte und hast fast immer gute Laune (auch wenn man 
urteilend nach deinem Gefluche im Büro manchmal anders behaupten würde). 
Ich bin dann wirklich sehr erfreut, dass wir 4 Jahre zusammen arbeiten 
konnten, und sogar Nachbarn waren im Büro. Außerhalb der Arbeit hatten wir 
wirklich ne Menge Spaß in Maastricht, Aachen, Ede, Hamburg, Biezenmortel (ja 
genau, noch immer weiß keiner wo das liegt), Stockholm, Noordwijkerhout, 
Florida oder Bonn. Ich bin jedenfalls froh, dass wir uns in Stockholm schon mal 
entschieden hatten gegenseitig Paranimfen zu sein, und ich freue mich, dass 
du mit dabei bist zur Promotion. Ich bin mir sicher, dass wir uns auch nach 
meiner Promotion immerhin noch oft sehen werden in Bonn oder Maastricht, 
und hoffe wir können in Zukunft auch noch mal einige witzige Sachen 
unternehmen (der Rekord von 25 Achterbahnfahrten war ja nur ein guter 
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Anfang). Ich wünsche dir alles Gute für deine Zeit im Kreis Bonn (und Köln ;-)) 
und bis demnächst! 
  
Beste Jeroen, wij kennen elkaar inmiddels bijna 10 jaar, met dank aan de 
introductiedag van MLW (jij was net als ik één van de enthousiastelingen die 
natuurlijk véél te vroeg aanwezig was). We zijn toen eigenlijk wel vanaf de 
eerste dag goede vrienden geworden, en naast de studie hebben we samen 
ook een aantal bestuursjaren bij Helix en Xist erop zitten. Na een kort uitstapje 
als CSI-trainee Otten, ben je toen toch weer teruggekomen naar het zuiden en 
kwam je na een tip van mij terecht bij EVP (sorry, je had inderdaad een veel 
normaler leven kunnen hebben ;-)). In de 4 jaren sindsdien heb ik altijd graag 
met je samengewerkt. Verder waren er ook de nog veel leukere dingen, zoals 
bezoeken van congressen (met als hoogtepunt het exotische Humlebӕk en 
omgeving), of buiten werk bijvoorbeeld je bruiloft (of beter nog, het 
vrijgezellenfeest ;-)). Inmiddels zit voor jou het promotietraject er ook bijna 
helemaal op. Ik wil je bij dezen heel veel succes wensen bij het afronden van je 
eigen boekje en het zoeken van een nieuwe baan, en uiteraard heel veel geluk 
samen met Stefanie en Finn! 
 
Zo, hiermee zijn we aangekomen bij de rest van de EVP’ers. Liebe Anette, wir 
haben fast zur gleichen Zeit angefangen und du bist mittlerweile auch mit 
deinem Buch fertig. Ich freu mich jedenfalls schon mal auf deiner Promotion, 
die wird sicher super, wie auch die Party nachher. Weil, wie ich schon mal 
gesagt habe, du bist ja heimlich ne richtige Party-Tigerin ;-). Es war deswegen 
dann auch extrem witzig als wir mit der deutsche Truppe unterwegs waren in 
Maastricht oder Aachen. Ich wünsch dir für jetzt viel Erfolg und Glück in die 
Staaten. Bis bald! 
 
Beste Karen, ook jij bent er inmiddels al een paar jaartjes bij. Ooit hier 
begonnen als onderdeel van pathologie’s eigen K3 (ja, lang geleden, en ik zou 
er eigenlijk niks meer over zeggen geloof ik, oeps), en vervolgens hier gebleven 
om te promoveren. Jij bent toch ook wel één van de schoolvoorbeelden van de 
(te?) lieve Belgische meisjes. Ik heb in ieder geval graag met je samengewerkt, 
en erg leuk ook dat je door je Kootstra nu nog wat langer hier kunt blijven. Jij 
ook succes met het afronden van je promotie, nog een feestje waar we 
binnenkort naar uit kunnen kijken, en heel veel geluk samen met Wim. 
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Beste Lieve (ofwel lieve dr. Lieve), sinds een jaartje of 2 maak je ook deel uit 
van de groep. De altijd drukke maar toch immer vrolijke Belg die terugkwam 
vanuit Italië. Ik denk dat je je gelijk wel thuis hebt gevoeld in de groep, en je 
was (samen met Lucas :D) ook direct altijd van de partij als er weer iets te 
vieren viel. Dit heeft in ieder geval ook een erg geslaagde patho-bingo-borrel 
bij jou thuis opgeleverd. Ik hoop dat je nog een tijd bij de EVP'ers zult blijven, 
want je kritische blik en goede ideeën zijn een erg waardevolle toevoeging. Ik 
wens je heel veel succes met al je projecten en veel geluk thuis met Pieter, 
Lucas, en ... :-). 
 
Ine, na je transfer vanuit Molgen ben je ook op de AIO-kamer van de EVP 
terechtgekomen. Niet altijd zonder ergernis geloof ik, maar we zijn nu eenmaal 
fan van muziek en het nodige geklets op onze kamer ;-). Ik hoop dat je een 
leuke tijd hebt gehad bij die rare EVP'ers, je paste in ieder geval prima bij . Jij 
ook succes met de laatste loodjes van je promotie, de feestjes-teller staat dus 
op 4. 
 
Thomas, sinds iets meer dan een jaar mijn patho-partner in crime bij de 
tweefoton. Ik ben blij dat ik in ieder geval iemand ook heb weten te 
enthousiasmeren voor het doen van in vivo proeven op de tweefoton. Dat 
heeft de nodige lange dagen opgeleverd, maar we hebben er toch mooie data 
uit kunnen slepen. Heel veel succes met je projecten, ik ben heel erg benieuwd 
wat er allemaal uit gaat komen. Verder ook heel veel succes met alle borrels 
die je in de komende jaren nog van plan bent te organiseren (toch?) en 
groetjes aan Anna! 
 
Bart, net als ik ben je na een stage weer teruggekomen bij de pathologie als 
AIO. Altijd vroeg op werk, en altijd vriendelijk, en altijd hulpbeleid. Helaas heb 
je dan toch meer interesse in DCs dan vaatjes, maar goed, ieder z’n hobby ;-)... 
Heel veel succes de komende 2 jaar en veel geluk samen met Noor! 
 
Elke, je bent de Benjamina van de groep, maar een goede aanvulling op de 
Deutsche Truppe. Je bent meestal erg duidelijk aanwezig (toch misschien al die 
koffie? ;-)), maar daarmee ben je ook een erg gezellig nieuwe buurvrouw op de 
kamer. En ik ben in ieder geval blij dat ik het zo vertrouwde Duitse gevloek 
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naast me (ja herr Dr. Engel) niet meer hoef te missen. Heel veel succes in de 
komende jaren, ik weet zeker dat je wat moois weet te maken van je project! 
 
Wat ben je verder op een lab, als je niet kunt rekenen op de hulp van een team 
ervaren en bovenal gezellige en praatgrage analisten. Anique, onze immuno-
vraagbaak (en bedreven cupcake-bakster ). Hoe vaak hebben we in de 
afgelopen jaren niet het een of andere protocol bediscussieerd, of de kwaliteit 
van…. de cupcakes inderdaad. Ik houd me in elk geval aanbevolen voor als je 
nieuwe recepten gaat testen ;-).  
 
Clairy, jouw hulp bij genotyperingen, het doen van kleuringen en het werk voor 
de plaque-database van de EVP zijn van groot belang voor de groep. Bedankt 
voor je hulp de afgelopen jaren. 
 
Erwin, de FACS-goeroe. Gezien mijn relatieve 'gebrek' aan FACS-experimenten 
hebben we op dat punt niet heel veel samengewerkt, maar je bent altijd in 
voor een borrel of feestje. Met je jarenlange ervaring en je grote interesse in 
nieuwe ontwikkeling op het gebied van flow cytometrie. ben je uitermate goed 
op de hoogte van allerlei manieren om de meest gekke dingen te FACSen. Ik 
heb nog wel wat FACS-plannen voor de toekomst, dus ik zal je nog wel een 
aantal keren komen lastigvallen. Groetjes ook aan Linda! 
 
Mat, je hulp op het gebied van kweken en de moleculaire technieken was erg 
waardevol. Alhoewel ik de afgelopen jaren maar relatief weinig met je heb 
samengewerkt op dat gebied, heb ik ook hier nog wel wat plannen, en ik kijk er 
dan ook naar uit om in de toekomst meer samen te kunnen werken. 
 
Zo, nog een paar EVP’ers te gaan. Jack, mijn overbuurman op de afdeling. Wat 
zouden we moeten doen zonder je quantimet-programma’s. Bedankt voor al je 
hulp en de vele discussies over  microscopie, onderwijs, de patho-website, en 
het recept voor "hemelse modder”.  
 
Beste Marion, dank voor al je hulp bij de lastige histologische gevallen. Zeker 
op het collageen-XVIII project heb je me goed daarbij geholpen, jammer 
genoeg heeft dit project het niet tot het boekje gered.  
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Danielle, jou heb ik toch wel oneindig vaak lastiggevallen met het inplannen 
van de zoveelste (verschoven) afspraak met mijn promotie-team of wat dan 
ook. Dank voor al je hulp in het oerwoud van afspraken plannen, en natuurlijk 
de gezellige praatjes op het secretariaat samen met Ingrid en Audrey. 
 
Marjo, Nadine en Emiel. Hoewel jullie technisch gezien misschien maar half-
EVPers zijn, horen jullie ook zeker bij de groep. Marjo, op de een of andere 
manier blijf je met je ADAMs-family toch telkens weer terugkomen bij de 
pathologie. Bedankt voor je goede suggesties en interesse in mijn project. Voor 
de toekomst waren er wel al wat leuke ideetjes, maar eens zien of we daar 
verder mee kunnen gaan. 
 
Nadine, mijn maatje uit het angiogenese-portfolio, we hebben in die 4 jaar 
toch wel leuke data weten te verzamelen over angiogenese. Behalve de 
gezamenlijke interesse in angiogenese, zal je bij mij altijd bekend staan om je 
geweldig gevoel voor humor. Ik kan me genoeg melige momenten herinneren. 
Heel veel succes met het afronden van je eigen boekje, en het vinden van een 
nieuwe baan! 
 
Emiel, jou ken ik natuurlijk met name van I’MCARIM, waar ik met veel plezier 
met je hebt samengewerkt. Je hebt verder een leuk (en soms verwarrend) 
project, maar daar weet je zeker wat van te maken! 
 
Beste Carine, Floor en Petra. Jullie ben ik uiteraard niet vergeten, maar een 
apart stukje was wel op zijn plaats. Carine, bij jou is mijn verblijf bij de 
pathologie begonnen. Lang lang geleden kwam ik in de bachelor voor een 
korte stage bij jou bij de pathologie. Na niet al te lange tijd kwam ik alweer 
terug voor mijn afstudeerstage, en ben sindsdien ook niet meer weggegaan. Ik 
ben je in ieder geval erg dankbaar voor de goede indruk die je van de 
pathologie en onderzoek doen hebt achtergelaten en je interesse in mijn 
projecten gedurende de jaren. Het is in ieder geval erg leuk dat we het project 
dat we ooit gestart zijn al die jaren geleden nu alsnog kunnen afmaken en ik 
hoop dat dat slechts het begin is van vele andere projecten naar afwijkende 
microvaatjes in de nier. 
 
 242 
 
Beste Floor, ook jij bent inmiddels al jaren een bekend gezicht bij de 
pathologie. Je combinatie van geneeskunde afmaken en tegelijk onderzoek 
doen en promoveren was niet altijd even makkelijk, en je hebt dan ook de 
nodige erg lange dagen met SPSS gehad. Je bent een erg gezellige en leuke 
collega, en gelukkig zijn we het laatste jaar toch weer kamergenoten 
geworden. Hoewel het in dit dankwoord langzaamaan wel cliché begint te 
worden, wens ik ook jou heel veel succes met de afronding van je promotie. Je 
hebt genoeg mooie hoofdstukken, dus op naar promotiefeest nummer 6. Heel 
veel succes alvast bij je specialisatie en veel geluk samen met Bas. 
 
Petra, na mijn terugkomst bij de "niergroep", hebben we redelijk intensief 
samengewerkt de laatste maanden. Zonder jou waren we met de verschillende 
projecten nooit zo ver geweest, ook al levert al dat PCR en vaatjes tellen wel 
eens de nodige frustratie op . Bedankt voor de prettige en gezellige 
samenwerking.  
 
Verder een bedankje voor alle andere (oud)-EVP'ers voor hun praktische hulp, 
ideeën, handige suggesties, en/of gewoon gezelligheid en collegialiteit. Jasper, 
Kitty, Anjana, Marco, Sofia, Isabelle, Lili, Cora, Mathijs, Matthijs, Wouter, Dirk, 
Indira, Beatriz, Brenda, Marjorie, Veronica, Chantal, Barry, Jeffrey en Mirte, 
thank you all very much! 
 
Een aantal oud-EVPers heeft tussendoor de overstap gemaakt naar 
Amsterdam, maar mogen zeker niet vergeten worden. Beste Linda, ik hoop dat 
je je wel eens hebt gerealiseerd, wat je vertrek heeft aangericht? Alle onze 
muisexperimenten liepen opeens totaal in de soep en er waren geen brownies 
en chocolate cookies meer! Nou is het misschien een heel klein beetje 
overdreven, en heeft het ons allen wel van onze (door jou geïnduceerde?) 
verslaving voor brownies en chocolate cookies geholpen, maar jij was toch wel 
degene bij wie iedereen te pas en te onpas kwam om iets te vragen of gewoon 
voor een praatje. Ik ben in ieder geval blij dat je het in Amsterdam/Vleuten 
goed naar je zin hebt, maar ik hoop dat je binnenkort weer eens in Maastricht 
langskomt! Heel erg bedankt voor alles, heel veel geluk in de toekomst en 
groetjes aan Lauran en Ella. 
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Tom, toekomstig dr. dokter Seijkens. Je was altijd op het lab, en dan bedoel ik 
dus ook letterlijk altijd, tenzij je in de kliniek was. Je was een erg leuke collega, 
en ik heb me meer dan eens helemaal krom gelachen over je briljante, 
bijzondere en/of bedenkelijke uitspraken. Heel veel succes met het afronden 
van je projecten, het kan niet anders dan een heel mooi proefschrift worden. 
 
Prof. Dr. Lutgens, beste Esther, hoe doe je toch alles wat je op een dag doet? 
Zelfs nu dat je al een tijdje in Amsterdam zit, heb ik dit raadsel nog niet kunnen 
oplossen. Hoe dan ook, ik wil je heel erg bedanken voor je goede suggesties, 
en heel veel succes verder in Amsterdam.  
 
Prof. Dr. Daemen, beste Mat, bedankt voor je altijd kritische blik, maar zeker 
ook je blijvende interesse in het angiogenese-project. Zelfs na je vertrek naar 
Amsterdam bleef je graag op de hoogte over wat we aan het uitspoken waren 
in Maastricht, en je maakte dan ook elke keer dat ik eens in Amsterdam was 
tijd om ge-update te worden. Verder ook bedankt voor de prettige 
samenwerking bij CARIM gedurende de eerste jaren, en je steun bij de ideeën 
die we vanuit de AIO-vertegenwoordiging naar voren brachten. 
 
Verder hebben de laatste jaar ook de nodige studenten de revue gepasseerd. 
Judith, Jan-Jurre, Bart, Laura, Sanne, Bert, Marnix en Romy, bedankt voor jullie 
harde werk de afgelopen jaren op de verschillende projecten en de leuke tijd 
tijdens jullie stages! 
 
Daarmee zijn we aanbeland bij de rest van de pathologie, want de afdeling 
pathologie is meer dan EVP alleen. Ten eerste de "epi's". Beste Manon, Veerle, 
Hanneke, Joep, Karin, Kim W, Edith, Peter,  Jürgen, Kim S, Iris, Suzanne, Ingrid 
en oud-epi’s die ik zou zijn vergeten: bedankt voor de leuke discussies, 
gesprekken en soms ook samenwerkingen. Altijd leuk om weer eens over wat 
anders te praten dat athero ;-). Also the people from Axel’s group, thank you 
for the being nice colleagues! 
 
En dan is er nog “de kliniek”. Prof. Dr. Zur Hausen, beste Axel, dank voor de 
interesse in de projecten, ondanks dat deze mijlenver verwijderd zijn van virale 
oncologie. Cor & Elly, jullie deur heb ik ook platgelopen zo nu en dan. Bedankt 
voor alle hulp gedurende de laatste jaren, en de gezellige gesprekken die daar 
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meestal op volgden (ook als jullie daar geen tijd voor hadden). Dan een 
speciaal bedankje voor Unit IV, en dan met name Guido, Andrea, Jolanda en 
Margriet. Bij jullie werd ik zo’n 7 jaar geleden ondergebracht tijdens mijn 
eerste, en later ook tweede, stage. Bedankt voor de gezellige tijd daar op jullie 
lab en al jullie hulp tijdens de stages; de leuke tijd op jullie lab heeft er zeker 
aan bijgedragen dat ik wat langer ben blijven hangen bij de pathologie. Verder 
tot slot een bedankje aan de rest van de medewerkers van de afdeling die ik 
helaas niet allemaal bij naam kan gaan noemen. Heel erg bedankt allemaal 
voor de interesse, hulp en small talk in de wandelgangen; ik blijf met plezier 
nog wat langer plakken!  
 
Zo… Voor degenen die nog wakker zijn tegen de tijd dat ze hier zijn aanbeland, 
ga ik nu over van pathologie naar een andere groep die zeker niet vergeten 
mag worden, mijn derde thuis, de tweefoton-groep. Beste Kim, jij was degene 
die ooit een keer bedacht had om te proberen plaque-vaatjes te imagen met 
behulp van tweefoton-microscopie. Deze data hebben een belangrijke rol 
gehad, zeker in de beginfase van mijn promotie. Ik heb in die tijd ook 
waanzinnig veel gehad aan je praktische ervaring om mij te leren 
tweefotonnen. Ik ben in ieder geval ook heel blij dat we nog een lange tijd 
samen hebben kunnen werken, en je hulp bij het schrijven en submitten en 
herschrijven en hersubmitten en herschrijven en… (ja, je snapt hem wel), was 
geweldig. Dank dus voor alles, heel veel succes met je opleiding en groeten aan 
Douwe en Marelle! 
 
Beste Wim, hoe vaak is jouw naam niet over het tweefoton-lab geroepen als 
de apparatuur toch weer even niet deed wat het zou moeten doen? Jouw 
technische expertise was onontbeerlijk. Ik heb altijd met veel plezier met je 
samengewerkt, van de soms eindeloos durende practica, tot de 
borrelmomenten daarna bij Thembi. Geniet in ieder geval van je welverdiende 
pensioen, en laat maar weten als je weer eens komt buurten bij BME. 
 
Lenneke, ook jij was één van de originele tweefotonners. Ook jij hebt me in de 
beginperiode altijd goed op weg geholpen, en was altijd in voor een praatje. 
Bedankt ook voor de blijvende interesse in het project, zelfs nadat je je 
opleiding tot klinisch chemicus was gestart. Deze zit er inmiddels ook alweer 
bijna op, dus heel veel succes met de laatste loodjes! 
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Sietze, via een omweg is mijn project uiteindelijk ook een keer uitgekomen bij 
het kijken naar glycocalyx. Ik was dan ook erg blij dat we iemand hadden met 
ervaring op dat gebied, en je review heeft daarbij veel helderheid gebracht. 
Ondanks de combinatie van co-schappen en promoveren, maakte je altijd tijd 
om te helpen als dat nodig was. Bedankt en heel veel succes bij KNO! 
 
Remco, wij kenden elkaar al van voor mijn promotie-traject, als ik het me goed 
herinner van toen ik nog stage liep bij de groep van Johan. Ik ben blij dat we 
nog geregeld samen hebben kunnen werken, eerst vooral ook praktisch in 
Aken, maar naderhand na je verhuizing naar München met name ook aan het 
review, etc.. Bedankt voor je hulp en heel veel succes nog in München, ik 
beloof dat ik echt nog een keer kom kijken naar de TP-opstellingen daar ;-). 
 
Mitrajit, in the meantime you have already finished your project and are 
finishing your promotion as well. I’ve always been amazed by the way you kept 
on going with the NO project, I’m sure it would have driven me insane 
somewhere along the road. Thanks for the nice conversations and your kind 
nature, and good luck on the new job! 
 
Anneke, hoewel je in de afgelopen jaren wegens persoonlijke omstandigheden 
vaak ook afwezig was, was je een ontzettend leuke collega. We zijn er helaas 
nog niet aan toegekomen om een keer ervaringen uit te wisselen op het 
gebied van bakken, moeten we binnenkort toch echt maar eens doen! 
 
Jeroen (H.), onze nieuwe technische specialist voor de tweefoton. Wat ben ik 
blij dat we na het pensioen van Wim jou als nieuwe aanvulling op het TP-team 
kregen. Bedankt voor alle support, maar zeker ook de geslaagde practica en 
gezellige gesprekken! 
 
Door de vele tweefoton-uren was ik ook veel te vinden bij de vakgroep die ooit 
nog biofysica heette, maar nu bekend staat als BME. Tammo, Koen, Joost, 
Wilco, Yvette, Bart, Jort, Claire, en alle anderen, heel erg bedankt voor de 
filmavonden, en in het algemeen voor alle gezelligheid. Ondanks dat ik maar 
de helft van de tijd bij BME te vinden was, heb ik me daar ook altijd thuis 
gevoeld! 
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Wat recenter is er dan nog een extra vakgroep bijgekomen, de moleculaire 
celbiologie. Hoewel ik daar praktisch gezien niet gewerkt heb, was ik direct 
welkom om mee te doen met allerlei activiteiten. Bedankt allemaal! 
 
Vervolgens zijn er nog meer UM’ers die een bedankje verdienen. Mark Post, 
Miriam, Menno, Johan, bedankt voor jullie kritische blik binnen het 
angiogenese-portfolio, de projecten hebben er veel voordeel bij gehad. Tilman, 
bedankt voor je hulp bij de verschillende hoofdstukken. Viviane, bedankt voor 
alle nuttige tips voor het in vivo werk; zoals je ziet, heb ik er voor dit boekje 
genoeg gebruik van gemaakt. 
 
Marijke en Judith C, na mijn junior-stage ben ik nog vaak bij biochemie binnen 
komen vallen, gewoon voor een leuk gesprek (of omdat de tweefoton weer 
eens geen zin had). Leuk dat jullie altijd interesse zijn blijven houden, ik wandel 
binnenkort wel weer eens langs. Erik W, jammer dat je weer Down Under bent, 
maar bedankt voor de interessant discussies over data-analyse van de 
tweefoton-beelden; deze hebben veel inspiratie opgeleverd! 
 
Verder verdienen ook de medewerkers van het CPV een woord van dank. 
Allen, maar in het bijzonder Richard, Paulien, Rik, Clarice, Mandy, Sytske en 
Saskia, bedankt voor alle goede zorgen voor de dieren de afgelopen jaren en 
de prettige samenwerking. 
 
Over samenwerkingen gesproken, ook buiten de UM werd er met genoeg 
samengewerkt. Allard en Chris, bedankt voor jullie hulp in Amsterdam met de 
multi-spectraalanalyses. Ik ben altijd met veel plezier richting noorden gereisd.  
 
Martin, es freut mich, dass es mit der JAM-A Versuche doch noch funktioniert 
hat. War anfangs noch nicht mal so einfach, aber die Daten waren umso 
besser! Viel Glück beim Zusammenschreiben deines Buches! Rory, jij ook 
bedankt voor je hulp en de prettige samenwerking.  
 
Michael, Wu, and Adelina, thanks for the nice discussions about two-photon in 
Aachen. Wu, good luck with your project, I hope you’ll get some nice in vivo 
data! 
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David V. from Finland, thanks for the nice collaboration on the collagen-XV and 
-XVIII projects, the data look really promising. Good luck finishing up your own 
thesis!  
 
Dan is er ook nog een leven buiten het onderzoek (ja, echt). Beste mensen bij 
CARIM (Riet, Esther, Johanna, Saskia, Tara, Petra, Rob en de rest), heel erg 
bedankt voor de leuke tijd die ik bij jullie heb gehad tijdens mijn periode als 
AIO-vertegenwoordiger. Ook iedereen die bij I’MCARIM heeft gezeten 
(Mathijs, Auke, Kelly, Romy, Ellen, Emiel, Yvonne, Siamack) bedankt! 
 
Alle vrienden, oud-studiegenoten, en bekenden, heel erg bedankt voor de 
leuke tijd de afgelopen jaren, in het bijzonder Rianne, Roger, Ryanne, 
Marjolein, Jim, Dennis en Jo. Jennifer en Daniël; erg jammer dat jullie er niet bij 
kunnen zijn op de promotie, maar Canada is toch net ietsje te ver weg. Jen, 
zoals je zelf al refereerde, de reguliere koffiepauzes zijn wel een gemis. Heel 
veel succes en plezier daar en tot in oktober! 
 
With the list of people who I should thank growing larger and larger, I’m sure I 
will have inadvertently forgotten. So, also to these people: thank you for your 
practical help, suggestions, kind words, support and/or “gezelligheid” during 
the last years. 
 
Beste ooms en tantes, neven en nichten, hoewel we elkaar niet heel 
regelmatig zien, hebben jullie altijd de grootste interesse getoond in mijn 
studie en promotie. Ik wil jullie hiervoor dan ook heel erg bedanken en hoop 
dat in elk geval de Nederlandse samenvatting een beetje uitleg geeft van wat 
ik nu eigenlijk gedaan heb al die jaren! 
 
Cody en Artan, ik weet dat jullie dit zelf niet kunnen lezen, maar dat betekent 
niet dat jullie niet ook een klein bedankje hier verdienen. Want toegegeven, als 
er 2 hondjes zijn die iemand in een klap kunnen opvrolijken, dan zijn jullie 2 
het wel met jullie altijd vrolijke begroetingen en rare acties. Een hele dikke 
knuffel en aai over de bol voor jullie! 
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Beste Glenn, je was vooraf bang dat ik je zou overslaan in het dankwoord, en 
hoewel het op zich best een grap was geweest om je gelijk te bewijzen, weet je 
net zo goed dat ik je niet zou overslaan. Mijn “kleine” (maar wel een kop groter 
zijnde) broertje, heel erg bedankt voor de gezelligheid thuis, de flauwe 
opmerkingen over en weer, de game-avonturen, etc.. Grappig genoeg bleek al 
snel dat ook jij de biomedische richting wel interessant vond, dus wie weet dat 
ik over een paar jaar jouw proefschrift tegemoet mag zien. Heel veel succes in 
ieder geval eerst met het halen van je bachelor (en master ;-)). 
 
Beste pap en mam, zoals vaker wordt gezegd, bewaard men “the best for last”, 
en dat is in dit geval zeker zo. Daarmee is deze laatste alinea van het boekje 
dan ook direct de moeilijkste om te schrijven, want ik denk dat niemand hier 
echt zijn ouders genoeg kan bedanken. Ik weet dat jullie ook met spanning 
hebben uitgekeken naar het boekje en de verdediging. Hopelijk helpen zowel 
het boekje als de verdediging om duidelijk te maken wat ik nu eigenlijk heb 
uitgespookt de laatste 4,5 jaar. Jullie hebben me in elk geval altijd mijn gang 
laten gaan en me in alles gesteund. Daarentegen kan ik altijd bij jullie terecht 
als ik ergens mee zit, of gewoon voor een weekendje “Hotel pap & mam”, om 
even te relaxen. Heel, heel, heel erg bedankt voor de onvoorwaardelijke steun, 
hulp, interesse en liefde in de afgelopen 28 jaar! 
 
 
Timo 
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